FOR OFFICIAL USE ONLY

## **Official Transcript of Proceedings**

## NUCLEAR REGULATORY COMMISSION

Title:	Advisory Committee on the Medical Uses of
	Isotopes: OPEN SESSION

Docket Number: (not applicable)

Location: Rockville, Maryland

Date: Thursday, October 14, 2004

Work Order No.: NRC-024

Pages 1-287

NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers

FOR OFFICIAL USE ONLY

## FOR OFFICIAL USE ONLY

1323 Rhode Island Avenue, N.W. Washington, D.C. 20005 (202) 234-4433

FOR OFFICIAL USE ONLY

	3
1	UNITED STATES OF AMERICA
2	NUCLEAR REGULATORY COMMISSION
3	+ + + +
4	MEETING
5	ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES
6	(ACMUI)
7	+ + + +
8	OPEN SESSION
9	+ + + + +
10	THURSDAY
11	OCTOBER 14, 2004
12	+ + + + +
13	ROCKVILLE, MARYLAND
14	+ + + + +
15	The meeting came to order at 8:00 a.m. in
16	Room T-2B3 of Two White Flint North, Leon S. Malmud,
17	M.D., Chair, presiding.
18	COMMITTEE MEMBERS:
19	LEON S. MALMUD Chairman
20	EDGAR D. BAILEY Member
21	DAVID DIAMOND, M.D. Member
22	DOUGLAS F. EGGLI, M.D. Member
23	RALPH P. LIETO Member
24	SUBIR NAG, M.D. Member
25	SALLY W. SCHWARZ, RPh Member

		4
1	COMMITTEE MEMBERS: (CONT.)	
2	ORHAN H. SULEIMAN, Ph.D.	Member
3	WILLIAM VAN DECKER, M.D.	Member
4	RICHARD J. VETTER, Ph.D.	Member
5	JEFFREY WILLIAMSON, Ph.D.	Member
6	NRC STAFF PRESENT:	
7	THOMAS H. ESSIG	Designated
8		Federal Official
9	Linda M. Gersey	NMSS/IMNS
10	Patricia K. Holahan, Ph.D.	NMSS/IMNS
11	Merri Horn	NMSS/IMNS
12	John Jankovich	NMSS/IMNS
13	Charles L. Miller Ph.D.	NMSS/IMNS
14	John Szabo, Esq.	OGC
15	Sami Sherbini, Ph.D.	NMSS/IMNS
16	Sandra Wastler	NMSS/IMNS
17	Angela R. McIntosh	NMSS/IMNS
18	Ronald E. Zelac, Ph.D.	NMSS/IMNS
19		
20		
21		
22		
23		
24		
25		

	5
1	I-N-D-E-X
2	Agenda Item Page
3	Administrative Issues 5
4	Final Draft 10 CFR 35 T&E 8
5	Public Comment
6	Proposed Changes to the AO Criteria 174
7	ICRP recommendations
8	Action Items
9	New Modality Subcommittee
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

	6
1	PROCEEDINGS
2	(8:05 a.m.)
3	CHAIRMAN MALMUD: Good morning, ladies and
4	gentlemen. We would like to get started so that we
5	complete today's full agenda on time. There'll be a
6	slight change in the program, and Mr. Essig will begin
7	first with some administrative issues. Tom.
8	MR. ESSIG: Just a couple of follow-up
9	items from yesterday. One is, there was a question
10	asked on the ACMUI Member Handbook, and I believe it
11	was Ralph Lieto that had asked the question about
12	special government employees. We touched base with
13	John Szabo from our Office of General Counsel, and his
14	response is as follows; as to the member's question,
15	ACMUI members are considered special government
16	employees throughout their tenure and are subject to
17	federal laws and regulations for special government
18	employees. And then he goes on to say, which is, I
19	believe, what you thought was the answer anyway, so we
20	should clarify the handbook so that it just doesn't
21	read only when you're attending meetings and that sort
22	of thing. It's during the term of your appointment to
23	the committee.
24	And then he goes on to say what is
25	relevant is that when they are not performing services

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

for the ACMUI, the member should not use their ACMUI title or membership for any non-NRC purpose, unless 2 3 authorized; such as, using your ACMUI position to 4 benefit others. That was his response, and hopefully 5 that clarifies that matter. But I believe -- my thought was we kind of suspected that was going to be 6 7 his response anyway, but this clarifies the issue.

administrative 8 Α second matter was 9 yesterday when we were talking about the nuclear materials events database, and I believe Mr. Lieto 10 11 asked the broader question about searching of the 12 database and looking at these -- event information that wouldn't strictly be a medical event, but it 13 14 would be something that had a clear connection to a 15 medical event; such as, a leaking radiopharmaceutical package and that sort of thing. 16

17 My response would be yes, that would be worthy of also looking at those events. 18 I would remind the members that they all have access to NMED, 19 20 and I sensed from the discussion yesterday that if Mr. 21 Lieto, and perhaps others, would be interested in 22 doing some systematic searches of NMED to ferret out 23 information of that namely, type maybe а 24 transportation event or a leaking package and what might be the trends there, I think that information 25

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

(202) 234-4433

7

would be certainly valuable.

1

2 I have two of my staff here in the 3 audience, Michelle Burgess - if Michelle would wave 4 her hand. She is in the blue over there on the left. 5 She is the NMED Project Manager, and any questions that any of the members would have about either access 6 7 or how do I navigate once I get in NMED, she would be happy to sit down with you on the telephone and walk 8 9 you through NMED. Her extension is 5868, so that would be (301) 415-5868. And also, another member of 10 11 my staff who is knowledgeable in NMED is Ivelisse 12 Ivelisse, if you'd raise your hand. Cabrera. She's sitting next to Michelle, and her extension is 8152. 13 14 And so either one would be available to help any of 15 the members navigate through NMED.

I think we might even consider, 16 Mr. 17 Chairman, if you're agreeable, that since Mr. Lieto expressed an interest in NMED, if he might want to do 18 some sort of pilot searches, if you will, and use that 19 20 as maybe feedback to the committee, and it might help 21 structure some of the committee's review of the 22 to looking at some of these related medical events 23 events, and then maybe even looking at the medical 24 events that were included in your package. So with 25 your okay, I would suggest Mr. Lieto being --

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

8

1CHAIRMAN MALMUD: If he has some time2MR. ESSIG: I sensed the okay was already3given yesterday when he broached the subject, but I4didn't want to be too presumptuous.5And it seemed like there was a third6matter, but it will occur to me later, so I think that7takes care of the administrative items that I wanted.8I'm sorry. Charlie has one.9MR. MILLER: Yes. I had the occasion to10talk to Szabo this morning also. I ran into him, and11I specifically focused on the question that was raised12by you, Dave, concerning the travel. I think Tom's13answer with regard to the periods, during your whole14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. BROSEUS: Thank you all for having me.23DR. BROSEUS: Thank you all for having me.24I want to lead off very quickly, have as short as		9
<ul> <li>given yesterday when he broached the subject, but I</li> <li>didn't want to be too presumptuous.</li> <li>And it seemed like there was a third</li> <li>matter, but it will occur to me later, so I think that</li> <li>takes care of the administrative items that I wanted.</li> <li>I'm sorry. Charlie has one.</li> <li>MR. MILLER: Yes. I had the occasion to</li> <li>talk to Szabo this morning also. I ran into him, and</li> <li>I specifically focused on the question that was raised</li> <li>by you, Dave, concerning the travel. I think Tom's</li> <li>answer with regard to the periods, during your whole</li> <li>appointment period you're governed by that 24/7. He</li> <li>said he doesn't necessarily agree with the law, but</li> <li>we're bound to uphold it. So again, if you have any</li> <li>questions, feel free at any time to give any of us a</li> <li>call, or John Szabo directly. He's more than willing</li> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	1	CHAIRMAN MALMUD: If he has some time
<ul> <li>didn't want to be too presumptuous.</li> <li>And it seemed like there was a third</li> <li>matter, but it will occur to me later, so I think that</li> <li>takes care of the administrative items that I wanted.</li> <li>I'm sorry. Charlie has one.</li> <li>MR. MILLER: Yes. I had the occasion to</li> <li>talk to Szabo this morning also. I ran into him, and</li> <li>I specifically focused on the question that was raised</li> <li>by you, Dave, concerning the travel. I think Tom's</li> <li>answer with regard to the periods, during your whole</li> <li>appointment period you're governed by that 24/7. He</li> <li>said he doesn't necessarily agree with the law, but</li> <li>we're bound to uphold it. So again, if you have any</li> <li>questions, feel free at any time to give any of us a</li> <li>call, or John Szabo directly. He's more than willing</li> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	2	MR. ESSIG: I sensed the okay was already
5And it seemed like there was a third6matter, but it will occur to me later, so I think that7takes care of the administrative items that I wanted.8I'm sorry. Charlie has one.9MR. MILLER: Yes. I had the occasion to10talk to Szabo this morning also. I ran into him, and11I specifically focused on the question that was raised12by you, Dave, concerning the travel. I think Tom's13answer with regard to the periods, during your whole14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. EROSEUS: Thank you all for having me.	3	given yesterday when he broached the subject, but I
6matter, but it will occur to me later, so I think that7takes care of the administrative items that I wanted.8I'm sorry. Charlie has one.9MR. MILLER: Yes. I had the occasion to10talk to Szabo this morning also. I ran into him, and11I specifically focused on the question that was raised12by you, Dave, concerning the travel. I think Tom's13answer with regard to the periods, during your whole14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. BROSEUS: Thank you all for having me.	4	didn't want to be too presumptuous.
7takes care of the administrative items that I wanted.8I'm sorry. Charlie has one.9MR. MILLER: Yes. I had the occasion to10talk to Szabo this morning also. I ran into him, and11I specifically focused on the question that was raised12by you, Dave, concerning the travel. I think Tom's13answer with regard to the periods, during your whole14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. BROSEUS: Thank you all for having me.	5	And it seemed like there was a third
<ul> <li>8 I'm sorry. Charlie has one.</li> <li>9 MR. MILLER: Yes. I had the occasion to</li> <li>10 talk to Szabo this morning also. I ran into him, and</li> <li>11 I specifically focused on the question that was raised</li> <li>12 by you, Dave, concerning the travel. I think Tom's</li> <li>13 answer with regard to the periods, during your whole</li> <li>14 appointment period you're governed by that 24/7. He</li> <li>15 said he doesn't necessarily agree with the law, but</li> <li>16 we're bound to uphold it. So again, if you have any</li> <li>17 questions, feel free at any time to give any of us a</li> <li>18 call, or John Szabo directly. He's more than willing</li> <li>19 always to answer any kinds of calls of that nature.</li> <li>20 CHAIRMAN MALMUD: Thank you. And the next</li> <li>21 item on the agenda is the presentation of the final</li> <li>22 DR. BROSEUS: Thank you all for having me.</li> </ul>	6	matter, but it will occur to me later, so I think that
9MR. MILLER: Yes. I had the occasion to10talk to Szabo this morning also. I ran into him, and11I specifically focused on the question that was raised12by you, Dave, concerning the travel. I think Tom's13answer with regard to the periods, during your whole14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. BROSEUS: Thank you all for having me.	7	takes care of the administrative items that I wanted.
<ul> <li>talk to Szabo this morning also. I ran into him, and</li> <li>I specifically focused on the question that was raised</li> <li>by you, Dave, concerning the travel. I think Tom's</li> <li>answer with regard to the periods, during your whole</li> <li>appointment period you're governed by that 24/7. He</li> <li>said he doesn't necessarily agree with the law, but</li> <li>we're bound to uphold it. So again, if you have any</li> <li>questions, feel free at any time to give any of us a</li> <li>call, or John Szabo directly. He's more than willing</li> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	8	I'm sorry. Charlie has one.
<ul> <li>I specifically focused on the question that was raised</li> <li>by you, Dave, concerning the travel. I think Tom's</li> <li>answer with regard to the periods, during your whole</li> <li>appointment period you're governed by that 24/7. He</li> <li>said he doesn't necessarily agree with the law, but</li> <li>we're bound to uphold it. So again, if you have any</li> <li>questions, feel free at any time to give any of us a</li> <li>call, or John Szabo directly. He's more than willing</li> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	9	MR. MILLER: Yes. I had the occasion to
<ul> <li>by you, Dave, concerning the travel. I think Tom's answer with regard to the periods, during your whole appointment period you're governed by that 24/7. He said he doesn't necessarily agree with the law, but we're bound to uphold it. So again, if you have any questions, feel free at any time to give any of us a call, or John Szabo directly. He's more than willing always to answer any kinds of calls of that nature. CHAIRMAN MALMUD: Thank you. And the next item on the agenda is the presentation of the final draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	10	talk to Szabo this morning also. I ran into him, and
13 answer with regard to the periods, during your whole 14 appointment period you're governed by that 24/7. He 15 said he doesn't necessarily agree with the law, but 16 we're bound to uphold it. So again, if you have any 17 questions, feel free at any time to give any of us a 18 call, or John Szabo directly. He's more than willing 19 always to answer any kinds of calls of that nature. 20 CHAIRMAN MALMUD: Thank you. And the next 21 item on the agenda is the presentation of the final 22 draft 10 CFR 35 T&E by Dr. Broseus. 23 DR. BROSEUS: Thank you all for having me.	11	I specifically focused on the question that was raised
14appointment period you're governed by that 24/7. He15said he doesn't necessarily agree with the law, but16we're bound to uphold it. So again, if you have any17questions, feel free at any time to give any of us a18call, or John Szabo directly. He's more than willing19always to answer any kinds of calls of that nature.20CHAIRMAN MALMUD: Thank you. And the next21item on the agenda is the presentation of the final22DR. BROSEUS: Thank you all for having me.	12	by you, Dave, concerning the travel. I think Tom's
15 said he doesn't necessarily agree with the law, but we're bound to uphold it. So again, if you have any questions, feel free at any time to give any of us a call, or John Szabo directly. He's more than willing always to answer any kinds of calls of that nature. CHAIRMAN MALMUD: Thank you. And the next item on the agenda is the presentation of the final draft 10 CFR 35 T&E by Dr. Broseus. DR. BROSEUS: Thank you all for having me.	13	answer with regard to the periods, during your whole
<ul> <li>we're bound to uphold it. So again, if you have any</li> <li>questions, feel free at any time to give any of us a</li> <li>call, or John Szabo directly. He's more than willing</li> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	14	appointment period you're governed by that 24/7. He
17 questions, feel free at any time to give any of us a 18 call, or John Szabo directly. He's more than willing 19 always to answer any kinds of calls of that nature. 20 CHAIRMAN MALMUD: Thank you. And the next 21 item on the agenda is the presentation of the final 22 draft 10 CFR 35 T&E by Dr. Broseus. 23 DR. BROSEUS: Thank you all for having me.	15	said he doesn't necessarily agree with the law, but
<ul> <li>18 call, or John Szabo directly. He's more than willing</li> <li>19 always to answer any kinds of calls of that nature.</li> <li>20 CHAIRMAN MALMUD: Thank you. And the next</li> <li>21 item on the agenda is the presentation of the final</li> <li>22 draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>23 DR. BROSEUS: Thank you all for having me.</li> </ul>	16	we're bound to uphold it. So again, if you have any
<ul> <li>always to answer any kinds of calls of that nature.</li> <li>CHAIRMAN MALMUD: Thank you. And the next</li> <li>item on the agenda is the presentation of the final</li> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	17	questions, feel free at any time to give any of us a
CHAIRMAN MALMUD: Thank you. And the next item on the agenda is the presentation of the final draft 10 CFR 35 T&E by Dr. Broseus. DR. BROSEUS: Thank you all for having me.	18	call, or John Szabo directly. He's more than willing
<ul> <li>21 item on the agenda is the presentation of the final</li> <li>22 draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>23 DR. BROSEUS: Thank you all for having me.</li> </ul>	19	always to answer any kinds of calls of that nature.
<ul> <li>draft 10 CFR 35 T&amp;E by Dr. Broseus.</li> <li>DR. BROSEUS: Thank you all for having me.</li> </ul>	20	CHAIRMAN MALMUD: Thank you. And the next
23 DR. BROSEUS: Thank you all for having me.	21	item on the agenda is the presentation of the final
	22	draft 10 CFR 35 T&E by Dr. Broseus.
24 I want to lead off very quickly, have as short as	23	DR. BROSEUS: Thank you all for having me.
	24	I want to lead off very quickly, have as short as
25 possible presentation so you all will have plenty of	25	possible presentation so you all will have plenty of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	10
1	time to discuss any issues that you might want to
2	bring to our attention with regard to rule making.
3	Let me just briefly go through the status of where
4	we're at.
5	The proposed rule, as you know, was
6	published on December 9 <sup>th</sup> for a 75-day comment period,
7	which ended on February 23 <sup>rd</sup> . Since that time, the
8	staff has been in the process to resolving comments
9	from the public, including the advisory committee, the
10	agreement states, and so on.
11	The draft final rule is now out for 30-day
12	comment by agreement states, and by the ACMUI. We're
13	doing this in parallel to keep things moving as
14	quickly as possible. The formal ending of the 30-day
15	comment period is October 18 <sup>th</sup> .
16	As I go through my presentation, I'd like
17	to emphasize that I'm discussing the staff's approach
18	to the rule making. The issues before us are staff
19	discussion, and approval of our final recommendation
20	with the Nuclear Regulatory Commission's
21	commissioners.
22	Very quickly, as most of you know, I just
23	want to remind you that Subpart J, which was due to
24	expire this October, the staff published on September
25	$16^{th}$ an extension of the effective date for Subpart J

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	11
1	to October 24 <sup>th</sup> , 2005. The reference to the Federal
2	Register announcement is in your slides, if you need
3	it. This is going to allow time for a board to apply
4	for recognition of board certifications under the
5	forthcoming revisions to Part 35.
б	Let me briefly go through some of the
7	examples of key comments that we have on the proposed
8	rule. This is not meant to be an exhaustive listing
9	of the comments, by the way, but to pull out some
10	examples. The handout materials that were provided in
11	advance, including the rule making package, has a
12	detailed summary of the comments.
13	The first one that I'd like to mention is
14	a preceptor's comment that they should not be required
15	to attest to a candidate passing a board administered
16	exam, and on the use of the word "attest" versus
17	"certify" in preceptor statements. The staff believes
18	that the second comment is a good one. I meant to say
19	to the first one, and we'll go back to that in a
20	moment. That our final draft rule substitutes attest
21	or attestation for certify and certification in the
22	requirements for preceptor statements.
23	We feel that the comments that we received
24	from ACMUI and the public are valid in that regard.
25	And also, removes a little bit of ambiguity about what

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	12
1	is certified versus attest. We have board
2	certifications and attestations as preceptors.
3	The next slide
4	MEMBER NAG: I have a question about the
5	first part.
6	DR. BROSEUS: Sure. Yes, I'm coming back
7	to that right now.
8	MEMBER NAG: Okay.
9	DR. BROSEUS: Okay. An example of the
10	first one was flagged by commentors in proposed rule
11	35.390C, in which it appeared to apply - in fact, the
12	words did say that a preceptor would be attesting to
13	all of the requirements for board certification,
14	including the examination. And the staff agrees that
15	it's inappropriate to ask a preceptor to attest to a
16	passing of an exam. That's part of what a
17	certification is about, and so our draft final rule,
18	which you all had distributed to you, had that
19	requirement removed and reworded that. We also sought
20	comments on that, not just from ACMUI, but other
21	members of the public.
22	There also was a comment by ACMUI and
23	members of the public to allow for the authorization
24	of radiation oncologists who complete residency
25	programs under 390. One of the big issues here, I

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

believe, for ACMUI and others was to make sure that oncologists who are now able to perform therapies for which a written directive is required, using material for which a written directive is required, continue to have that ability. They qualify under Subpart J, but many of them do not qualify under what we have in the proposed rule.

8 We took this into account and developed a 9 new Section 396, which provides for well-trained 10 oncologists to have an avenue to be approved for uses 11 under 390. A key requirement that we have in there is 12 to make sure that there's training and experience for 13 use of unsealed sources, unsealed byproduct material.

MEMBER NAG: May I?

DR. BROSEUS: Sure.

MEMBER NAG: You're saying the preceptor 16 17 should not be required to attest to candidate passing board exam would be fine; however, 18 this will 19 contradict your 396 because you are going to have 20 someone who became board certified, but may not have 21 had the 80 hours or may not have had a preceptor for the unsealed source, and may require a separate 22 23 unsealed source preceptor.

DR. BROSEUS: That's okay.

MEMBER NAG: But then you're saying

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

14

15

24

25

1 preceptor should not be allowed to attest candidate 2 passing board exam. Isn't that contradictory then? 3 DR. BROSEUS: The requirements -- there's 4 several conditions of 396, and I'd urge you to look 5 through them. But one of the key ones is that if an individual is certified by a board for the other 6 7 sections where therapy has been done, the sealed sources, brachytherapy or the high dose rate units -8 if they are board certified and have the T&E for 9 unsealed sources, then they may be approved. 10 11 We can go back and look and make sure that 12 we haven't built in something that isn't appropriate. If you have a particular observation, I'll make a 13 14 little note and get back to you. 15 MEMBER NAG: No. If you go back to your previous slide, and if you look at that, in 396 you 16 17 really need the preceptor to certify that three unsealed source, but here you are saying you are not 18 19 required to attest for a candidate passing board exam. 20 So if someone would pass board exam but needs an 21 additional attestation --22 DR. BROSEUS: I understand. 23 MEMBER NAG: So you need to be careful how 24 you word that sentence, because otherwise you are 25 going to contradict yourself.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

14

	15
1	DR. BROSEUS: So your comment is to make
2	sure that we're not requiring unnecessary attestation,
3	and just attestation to the training and experience
4	for unsealed sources. Is that correct?
5	MEMBER NAG: No. I think I'm trying to
6	say that the wording should be such that you don't
7	contradict yourself. I mean, your meaning is they
8	are well-meant, but the wording can be contradictory.
9	That's all I'm saying.
10	DR. BROSEUS: Okay. Thank you. We'll
11	note that.
12	CHAIRMAN MALMUD: WE also have a comment
13	from the public.
14	MS. FAIROBENT: Thank you, Dr. Malmud. My
15	name is Lynne Fairobent with the American Association
16	of Physicists. Dr. Nag, the origin of the comment
17	that generated I'm sure this first bullet on Roger's
18	behalf had to do with the fact that when a preceptor
19	is going to sign the preceptor statement, the
20	individual may actually have not completed the board
21	exam process. And, therefore, asking the preceptor to
22	attest that the individual has passed the exam was
23	premature, so that was the origin of that.
24	MEMBER NAG: I know the origin, but the
25	way it is put, it can become contradictory, and I'm

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	16
1	trying to say before it becomes contradictory, you
2	need a preventative measure. I know what the
3	objective is and what it is meant to say, but the
4	wording may not be what is really meant to say.
5	DR. BROSEUS: Okay. Thanks for the
б	observation. We'll go back and look at that again.
7	CHAIRMAN MALMUD: Roger.
8	DR. BROSEUS: Dr. Malmud, there's somebody
9	
10	CHAIRMAN MALMUD: Oh, Dr. Zelac.
11	DR. ZELAC: I'd just like to comment that
12	if my understanding of what 396 preceptor is attesting
13	to is simply the additional number of hours of
14	unsealed material training that the individual has
15	undergone, period. The individual who would be
16	applying for authorization would, in addition to that
17	preceptor statement, submit either a copy of their
18	board certification, for which no additional
19	attestation would be required. Is that correct,
20	Roger?
21	DR. BROSEUS: Yes. I'm re-reading our
22	draft right now, and I believe that the concern that
23	Dr. Nag expressed is not there. However, I would
24	encourage you that if you see something there that we
25	haven't seen, to annotate it and call it to our

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

17 1 attention because we want to have a rule that's out there that's clear and understandable, and is not 2 3 internally contradictory. Okay. So thank you for 4 looking at this very closely. 5 CHAIRMAN MALMUD: Roger, may I ask for a concrete example. Let's say that there is a radiation 6 7 oncologist, board certified, who now wishes to use unsealed sources, but did not have experience in 8 unsealed sources during his or her residency training. 9 How many hours of training does that individual 10 11 require be attested to? 12 Under 396, it's 80 hours. DR. BROSEUS: CHAIRMAN MALMUD: Eighty hours. 13 14 DR. BROSEUS: Yes. 15 CHAIRMAN MALMUD: Thank Dr. you. Williamson. 16 17 MEMBER WILLIAMSON: Yes, I have some questions too about the meaning of 396. This is meant 18 19 apply any radionuclide and form to for of administration other than oral. Is that the correct 20 21 \_ \_ 22 DR. BROSEUS: It's written for parenteral 23 administration. 24 MEMBER WILLIAMSON: Which means what in the NRC? 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	18
1	DR. BROSEUS: I'd go back and look at the
2	dictionary, but I believe it means administration by
3	injection. It's not oral.
4	MEMBER WILLIAMSON: So it would cover, for
5	example, installation of P-32 radiochromic
6	(Simultaneous speech.)
7	DR. BROSEUS: We didn't say
8	intravascularly. We didn't say venous or anything
9	like that. We used parenteral. My understanding
10	parenteral would include like
11	CHAIRMAN MALMUD: I believe parenteral is
12	anything except oral.
13	DR. BROSEUS: That's how I would interpret
14	it, yes.
15	MEMBER WILLIAMSON: And so if the is
16	this to be done on a radionuclide by radionuclide
17	basis, or if, for example, a radiation oncologist
18	qualifies for say P-32 intra abdominal installation,
19	and then subsequently wants to do Zevelin or something
20	else - is there a need for the individual to do
21	anything else, or is this actually
22	DR. BROSEUS: The rule doesn't say that.
23	The rule says it doesn't name a radionuclide, and
24	the intent in Part 35 now is to have more general
25	rules that cover broader aspects. You shouldn't have

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	19
1	to come in for a license amendment if somebody you
2	know, I could conceive of circumstances where that
3	might be, but that's not the intent of the rule. The
4	intent of the rule doesn't say for P-32 or abdominal
5	sitees or whatever. It isn't narrow, it's broad, for
6	which a written directive is required for parenteral
7	administration, period.
8	MEMBER WILLIAMSON: And I guess then that
9	a radiation oncologist then by complying with 396 and
10	getting 80 hours of training and experience, and then
11	doing what is it - 392 for thyroid radioiodine
12	treatment? Is it 392 or 394?
13	MEMBER EGGLI: Depending on whether you're
14	doing a benign or malignant 394 is malignant.
15	MEMBER WILLIAMSON: So then by or if
16	they wanted to do 392, as well, then three times 80
17	hours and they would be able to have the equivalent
18	authorization, authorized user privileges as
19	MEMBER EGGLI: It would be three times 80
20	hours.
21	MEMBER WILLIAMSON: Okay. That was going
22	to be my follow-up question, is that for multiple
23	how would you handle the case where a physician wanted
24	to do both radio Iodine and more general radionuclide
25	therapy - would you want just one 80-hour training?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	20
1	DR. BROSEUS: It sounds like it's coming
2	under
3	MEMBER WILLIAMSON: Yes.
4	DR. BROSEUS: now if it's really broad.
5	It depends upon what the particular application is.
6	I could foresee using material that would fall under
7	the requirements for 396, and if they wanted to do a
8	certain level of activity with I-131, they'd have to
9	meet 392 or 394.
10	MEMBER WILLIAMSON: Yes. So that would be
11	another 80 hours, or could the same 80 hours be used,
12	and effectively the additional requirement for the
13	radiation oncologist would be to have three supervised
14	radio Iodine treatments for thyroid carcinoma?
15	DR. BROSEUS: Well, the requirements for
16	case experience are in there, and so if a person
17	didn't have the case experience required for 392, they
18	would have to pick that up.
19	MEMBER WILLIAMSON: But they wouldn't need
20	an additional 80 hours of training and experience.
21	DR. BROSEUS: That's not the intent of the
22	working group.
23	MEMBER WILLIAMSON: What is the intent of
24	the in terms of trying to qualify for multiple
25	authorized user privileges.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	21
1	DR. BROSEUS: Well, I think the intent is
2	for an individual who is using byproduct material for
3	which a written directive is required, to have
4	experience with unsealed sources for which a written
5	directive is required. So they're aware of the safety
6	requirements, the hazards, the cautions associated
7	with these higher levels of activity, so if they have
8	a spill or whatever, that they could take care of it.
9	Think about this for a moment. Sometimes a physician
10	is his own radiation safety officer, or her own
11	radiation safety officer. It isn't to require 240
12	hours. It's to have an appropriate amount of training
13	and experience for the type of use you're going for.
14	And it doesn't say P-32 and 396. Okay.
15	CHAIRMAN MALMUD: Dr. Eggli.
16	MEMBER EGGLI: To qualify under 396, I
17	don't remember I don't have it in front of me. Do
18	you have to be a 400 or higher authorized user to
19	qualify for unsealed sources?
20	DR. BROSEUS: You don't have to be
21	authorized in the other types of uses.
22	MEMBER EGGLI: Okay. Because
23	DR. BROSEUS: What it does do is admit, if
24	a person is board certified for those types of uses,
25	they may use that board certification as evidence of

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	22
1	their T&E.
2	MEMBER EGGLI: But one of the issues
3	though is, there are only two kinds of administration,
4	basically. There's oral administration and parenteral
5	administration, and if I can come in under 394 and
6	396, I can do 80 hours of training, and I can bag the
7	700 hours in Part 300, so why the heck would I ever
8	want to worry about Part 300, because I can circumvent
9	Part 300 all together by doing 392, 394, and 396.
10	I've got everything available under Part 390.
11	MEMBER WILLIAMSON: May we should multiply
12	the 80 times
13	MEMBER EGGLI: No, I'm not trying to
14	suggest that. But I think there's a potential
15	inconsistency there. And if you limited 396 to those
16	who are certified at 400 or higher, then I have no
17	problem with 396.
18	DR. BROSEUS: I'm sorry. Would you repeat
19	what you just said.
20	MEMBER EGGLI: To qualify to use unsealed
21	sources under 396, if you have to be an authorized
22	user of 400 or 600, then I have no problem with 396.
23	But if anybody can go an 80-hour pathway and get into
24	396 without being an authorized user in 400 or 600,
25	then I have a problem.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	23
1	CHAIRMAN MALMUD: But you have to be board
2	certified.
3	MS. CHIDAKEL: If I could clarify; now
4	this is a technical discussion. I know this is a
5	technical discussion.
6	CHAIRMAN MALMUD: Would you please
7	introduce yourself.
8	MS. CHIDAKEL: I'm Susan Chidakel. I'm
9	the Office of General Counsel Senior Attorney. I
10	don't know if you all have the draft final rule in
11	front of you or not, but if you will look at the draft
12	final rule, it says that the licensee shall require an
13	authorized user for the administration requiring a
14	written directive to be a physician who is an
15	authorized user under 490, 690, or before October
16	$24^{th}$ , 2005, 940 or 960, or certified by a medical
17	specialty board whose certification process has been
18	recognized under 490, 690, or before October $24^{th}$ , 940
19	or 960. So I don't know if this answers your
20	question. And then in addition, has completed these
21	80 hours and so forth. I don't know if this resolves
22	your question or not.
23	MEMBER EGGLI: It does. Thank you.
24	DR. BROSEUS: I think we're covered here,
25	because there is not an alternate pathway also.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	24
1	MEMBER EGGLI: Okay. I'm happy with that.
2	DR. BROSEUS: Okay. Great. But thank you
3	for attending to that, because that's something I
4	don't believe we necessarily thought about in the
5	working group.
б	CHAIRMAN MALMUD: Dr. Williamson.
7	MEMBER WILLIAMSON: Well, I think it's an
8	excellent idea doing this 396, and resolves a lot of
9	the complexity and arguments that we've had over the
10	390. The only suggestion I would make to you to
11	consider is to fold into this a parallel definition of
12	acceptable board certification, on the assumption that
13	the American Board of Radiology will eventually adapt
14	and require the 80-hours and three cases as part of
15	the certification process in the future, so that then
16	the additional requirements
17	DR. BROSEUS: Well, if ABR has
18	certification recognized for the other uses and a
19	person comes in with 80 hours, they would meet the
20	requirements of 396, so I think there's sufficient
21	there now. Now they could add 80 hours and create a
22	new certification, but 396 does not need a new
23	certification. There's not a new certification.
24	MEMBER WILLIAMSON: Yes, I understand
25	that. I'm suggesting you could potentially structure

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	25
1	396 to be the same as the other rules, which would
2	have both an alternate pathway and a board
3	certification pathway, which would then, at that point
4	if and when American Board of Radiology adapts and
5	makes it clear that
6	MEMBER EGGLI: I think the American Board
7	of Radiology intends that it's diplomats should be
8	certifiable for all 390 uses.
9	MEMBER WILLIAMSON: That's my
10	understanding, as well.
11	CHAIRMAN MALMUD: May I suggest, in
12	listening to all these questions, that it might be
13	most useful if there were a spreadsheet which had
14	matrices in it, including certification by the
15	American Board of Radiology, the American Board of
16	Physicists in Medicine, the American Board of Nuclear
17	Medicine, the American Board of Radiation Oncology,
18	and the American Boards of other specialties in one
19	column, indicating what the requirements are for those
20	individuals to achieve satisfactory compliance with
21	NRC regulations for the performance of tests involving
22	unsealed sources, so that it would be very clear to
23	any user what his or her requirements are, because if
24	this committee, which has worked on it with you for
25	months, if not years, remains confused, the public-at-

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 large, particularly the users, are going to be 2 extraordinarily confused. And it doesn't seem to be 3 clear yet to us as а group, as to what the 4 requirements are going to be for individuals who will 5 have completed training by October, who will complete training after October, and what the additive numbers 6 7 are, though you've clarified an issue certainly for us 8 this morning. 9 think a spreadsheet would be most Ι useful, and that would be something that anyone could 10 11 look at and say well, this individual qualifies. I'm

12 not speaking about the credentialing process in the 13 hospital. That's separate. I'm talking about NRC, 14 satisfying NRC regulations.

15 DR. BROSEUS: I think I would refer that to our Material Safety and Inspection Branch for 16 consideration in developing guidance with the rule. 17 I think at the point we're at, to develop something at 18 19 this point, we're trying to get this rule out so these 20 things will be in place, but I think a potentially 21 good suggestion for explaining things and how the rule 22 works, and so I would expect the MSIB to take this 23 under advisement as a suggestion. There's been a hand 24 back here for guite some time.

CHAIRMAN MALMUD: Yes, I'm sorry. Could

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

(202) 234-4433

26

	27
1	you introduce yourself, please.
2	MR. MOORE: Yes, sir. Dr. Malmud, I'm
3	Scott Moore. I'm the Chief of the Rulemaking and
4	Guidance Branch. I'm Tom's counterpart. We can
5	certainly work towards getting such a spreadsheet, but
6	as Roger just noted, I don't think we would be able to
7	provide that within the time period that we're asking
8	for comments back from the ACMUI.
9	We put this item on the agenda primarily
10	so that the ACMUI can prepare comments back to us
11	within the time period that we need them, and have
12	asked you for them, which is October 18 $^{ m th}$ .
13	I just heard Dr. Williamson make a
14	suggestion to us with regard, I believe, to 396. What
15	we really need for the ACMUI to do is to make those
16	suggestions to us as a body in writing, and we have
17	another hour and a half for you all on the agenda to
18	prepare such comments in writing to us to work
19	together as a group, to decide what you want to make
20	in comments back to us, the agency, if you want to
21	make any such comments on the draft final rule.
22	Within our time frame, we're asking for
23	the agreement state comments back by the $18^{th}$ , and for
24	us to stay on schedule, we need the advisory committee
25	comments back also by the $18^{ ext{th}}$ . We can continue to

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	28
1	provide comments throughout the next hour and a half
2	and discuss the rule, but I do need to let you all
3	know that we need the ACMUI's comments to go forward,
4	and that's the time schedule that we're working
5	against.
6	CHAIRMAN MALMUD: So you need comments by
7	the end of today.
8	MR. MOORE: We need them back by the $18^{ ext{th}}$ ,
9	sir.
10	CHAIRMAN MALMUD: Dr. Diamond, I think you
11	were next, and then Mr. Lieto.
12	MEMBER DIAMOND: Ladies and gentlemen,
13	obviously what we have here are some very substantive
14	changes in the regulations, and in this pre-decisional
15	material, as you can clearly see, even we as very
16	experienced members who have been working with those
17	regulations, I've been involved for six years myself.
18	I think Dr. Williamson for nine years. There are very
19	important questions related to how the regulations are
20	being interpreted. There's absolutely now way it is
21	appropriate for us to come to a consensus opinion for
22	you by October the $18^{th}$ , absolutely no way whatsoever.
23	What ought to be done is that these pre-
24	decisional regulations ought to be released to the
25	stakeholders, to the public, at this time, so that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

everyone can take a look at them. Good guidance is not to supplant bad rulemaking, and I think we need to get this out to the stakeholders. These are very substantive changes.

My understanding, for example, is that a 5 radiation oncologist in practice who's currently not 6 7 licensed to, for example, use some of these materials, will not be grandfathered if he or she wishes to use, 8 9 let's say Zevelin radio immuno therapy in the future without going through a fairly proscriptive set of 10 tasks. And I think that in the grand scheme of 11 12 things, we have lost our main focus.

When this process started several years 13 14 ago, one of the key elements was that we all agreed 15 that board certification would be the default pathway to authorized user status. Now we're learning that 16 17 because of the way the hours are enumerated, that board certification in radiation oncology, 18 for 19 example, by the American Board of Radiology would not 20 necessarily accomplish that task because of how the 21 700 hours are accomplished.

We had Donna-Beth yesterday tell us that we needed 700 hours of classroom laboratory experience - to paraphrase - exclusively and specifically related to unsealed radio isotope material. My question to

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

	30
1	her is what are you going to talk about for 700 hours
2	in classroom laboratory exclusively related to that.
3	It makes no sense at all to me. And the point related
4	to that is it's a different interpretation of how
5	you're counting hours that now leads some members of
6	the staff to say that the ABR Boards in Radiation
7	Oncology or not satisfying the requirements and,
8	therefore, we need to create this new 396. So as you
9	see, gentlemen and ladies, I have some serious issues
10	with the substantive and interpretive changes that we
11	see before us. And I believe the correct approach is
12	to release this pre-decisional material to the public
13	for public comment. And after discussion, I'd be
14	happy to make a motion to that effect.
15	CHAIRMAN MALMUD: Thank you, Dr. Diamond.
16	Mr. Bailey. Excuse me. Mr. Lieto was waiting in
17	line.
18	MEMBER LIETO: I have two comments, one a
19	general question. At the teleconference, I believe
20	that one of the committee members had requested that
21	we have before us a version of the proposed rules
22	redlined, strikeout, underlined edition-type document
23	so that we could see where the changes were in
24	relationship to what had been proposed from last year.
25	Has that been made available, or is that available?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	31
1	MR. MOORE: I could address that. The
2	request at the teleconference was wherein the draft
3	rule was issued in final that a redlined strikeout be
4	prepared at that time.
5	MEMBER LIETO: No, that was not the
6	understanding I think at the teleconference. I'd be
7	glad if board members here
8	MR. MOORE: I disagree with you.
9	MEMBER LIETO: Well, I guess I'd like to
10	ask the committee members, because that's been one of
11	the biggest problems in coming before this group, is
12	that we get this document which is what's supposed to
13	go to the Federal Register, and we have repeatedly
14	said that it's very difficult to look at things out of
15	context with a specific rule, and that in order to
16	understand all the nuances that go into the changes
17	that the working group is recommending, especially
18	with these changes of 396 and some of these other
19	things regarding grandfathering and so forth, it's
20	very important for us to understand what the working
21	group is intending to put in there, and be sure that
22	our understanding is correct. It's just plain
23	difficult to look at it through this part, and just
24	like happened a little bit earlier. There was a
25	misunderstanding about what the working group was

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

intending or has put in there versus what the committee members have.

3 I've been on here through this T&E, and 4 this has been a request repeatedly from committee 5 members. And if I'm wrong, I'd like one of the committee members to let me know, but that's one of 6 7 the things that I think really would aid. I would 8 heartily support Dr. Diamond's statement about the 9 realization that we're going to go through all these changes in an hour and a half, come to a consensus for 10 11 the NRC working group, I think is really unrealistic. 12 And I think a lot of committee members that I've talked to didn't even recognize the October 18<sup>th</sup> 13 14 deadline. Okay. That that was going to be the 15 expectation, that we're going to spend less than two hours, come out with a consensus document over all 16 these changes, and then walk out of here with this is 17 what the ACMUI wants to do, I think is a little 18 19 unrealistic; especially not having a good working 20 document to work from. 21 Thank you, Mr. Lieto. CHAIRMAN MALMUD: 22 The next was Mr. Bailey.

23 MEMBER BAILEY: Yes. I'm not sure that 24 ACMUI is aware that the Organization of Agreement 25 States has petitioned the NRC on this very item, and

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

(202) 234-4433

32

	33
1	this petition has now been accepted. And it seems
2	that assuming that NRC will take the petition with
3	some seriousness, that were going to end up in another
4	rulemaking process almost immediately.
5	The agreement states, all of them signed
6	off that they wanted this petition, that they're not
7	happy with the way the current rule is written with
8	regard to T&E. It may not be the agreement states
9	may not agree with the physician members on T&E, but
10	at least we think it needs to be clear, and it needs
11	to be based on some sort of information, some value
12	judgments on really how many hours. It was asked, how
13	do you spend 700 hours? I personally do not know.
14	We have begun to look at what is the
15	rationale for the number of hours being required, and
16	for which groups? And I think maybe it's totally
17	premature to go forward with this rule at this time
18	until we have had more comment.
19	MS. CHIDAKEL: Excuse me, if I may
20	interject here.
21	CHAIRMAN MALMUD: This is Susan Chidakel.
22	MS. CHIDAKEL: Yes. I wanted to sort of
23	clarify and sort of focus on what we're doing here, if
24	I may, from my perspective.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

public, the proposed rule, with major changes went out for comment and was published in the Federal Register, and we have received the comments back, so the public did have an initial comment period to review the major changes of the T&E.

1

2

3

4

5

The main thing that is changing now with 6 7 our draft final rule is in response to the comment that we should have a breakdown of the hours, a 8 9 specification of division up of the, say for example, 700 hours between on the one hand classroom and 10 11 laboratory, on the other hand work experience. So 12 this is the main thing, and I do believe this is the main thing that we need ACMUI's input on right now, 13 14 because the other changes, while there have been 15 changes made in this draft final rule, I think the majority of the basis of the rule as it was, the 16 17 proposed rule basically was essentially very similar to what we are coming out with now with the draft 18 19 final rule, with the exception of this hour issue.

Now with regard to the hour issue, bear in mind that we not affecting the board certification pathway. We are not breaking down the hours between classroom and laboratory and work experience with regard to board certification. The proposal for the breakdown of the hours goes only to the alternate

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	35
1	pathway. And I think is what we - excuse me, I see
2	someone shaking his head. Do you disagree with what
3	I've said?
4	MEMBER NAG: Yes.
5	MS. CHIDAKEL: Please.
6	CHAIRMAN MALMUD: This is Dr. Nag.
7	MS. CHIDAKEL: Well, basically that was
8	the emphasis that I wanted to put on this, and we do
9	need ACMUI's input on that particular issue, in
10	particular. That is the whole point and the whole
11	focus, as I see it, of our discussion this morning, so
12	that I want to make sure that we're not going to go
13	into all other directions and not resolve this issue,
14	because the rest of the rule did go out, like I said,
15	for public comment with the exception of the 396.
16	This is true, that was added, and other changes that
17	I consider were relatively minor, but the main change,
18	and the main thing we need ACMUI to look at is the
19	division over the hours. And again, bear in mind the
20	division of the hours only goes to the alternate
21	pathway, does not go to the board certification.
22	CHAIRMAN MALMUD: If you'd remain at the
23	microphone.
24	MS. CHIDAKEL: Sure.
25	CHAIRMAN MALMUD: The issue that both Dr.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

36 1 Nag and Dr. Eggli are going to raise, I believe, is 2 this; board certification pathway is the not 3 independent of the alternate pathway since if an 4 individual does not pass his boards at first taking, that individual will have to have documented that the 5 individual received a certain number of hours of 6 7 training in the course of preparation for the board certification; that is, during the residency program. 8 Therefore, the residency program must include the 9 10 requirements of the alternate pathway, or the 11 individual physician will not be able to meet NRC 12 standards. MS. CHIDAKEL: The individual always, of 13 14 course, has the option to do the alternate pathway. 15 Let me just -- I don't want to be facetious. 16 CHAIRMAN MALMUD: Excuse me. You are 17 incorrect, if I may say so. The individual does not have the option of the alternate pathway when in the 18 19 course of his residency training, where he fully 20 expects to become certified within a year or so of 21 completing the residency, those requirements were not 22 met by the residency because though the current 23 regulations indicate that only the alternate pathway 24 must have the numerical requirements, the residency 25 will not have prepared the individual unless the

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	37
1	residency meets the alternate pathway requirements.
2	MS. CHIDAKEL: I understand. I understand
3	what you're saying. I did hear the same argument
4	during the telecon.
5	CHAIRMAN MALMUD: It's not argument, it's
6	a fact.
7	MS. CHIDAKEL: And I understand well,
8	forgive me, I'm sorry. We're talking about semantics
9	here. I understand the discussion. I understand the
10	point that you are making.
11	If I may, and I'm not trying to be
12	facetious or anything else on this issue - while I
13	understand the problem, this is not a problem that's
14	unique to the medical profession, frankly speaking.
15	I'm an attorney. I went all through law school. I
16	took four years, or 3-1/2 years, or three years of
17	whatever it was to go through law school and meet all
18	of these tough requirements and pass my law school
19	exam. If I don't pass my bar, I have the same
20	problem, so that this is - you're shaking your head,
21	but it's true. I cannot practice law really before a
22	court if I'm not bar certified, which is essentially
23	the same thing as being board certified.
24	MEMBER EGGLI: That's wrong. There are
25	boards who don't allow their candidates to take the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

exam until they've been in practice for more than a year.

3 MEMBER DIAMOND: Under the new 4 requirements for radiation oncology, radiation 5 oncology residents who graduate their programs, they will take their written boards in the fall after they 6 7 finish training. And if they pass that, they will take in the spring, following completion of training, 8 the oral boards; thus, for a person who has completed 9 training on schedule, has completed the examinations 10 11 and passed them sequentially, one will not be board 12 certified for essentially four years, so every single resident coming out of training will not be board 13 14 certified for a minimum of one year, and during the 15 first year of practice by default would have to fall 16 under the alternate pathway. MS. CHIDAKEL: I understand. 17 I see what 18 you're saying. 19 MEMBER DIAMOND: And because of the way we 20 are enumerating these hours with the 700 being

20 are enumerating these hours with the 700 being 21 specifically and exclusively devoted to the unsealed 22 radioisotopes which makes no sense to me, there's 23 going to be --

24 MS. CHIDAKEL: This problem -- this was 25 never -- I never heard this problem explained before.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

	39
1	What I heard in the telecon was the idea that people
2	would be failing their boards and, therefore, would be
3	out of luck. I never heard this discussion
4	MEMBER DIAMOND: The other issue, just for
5	your information again - this is not the world in
б	which you function - is the boards set failure rates
7	that unfortunately are probably artificially high, and
8	they do that for a number of reasons. The failure
9	rate for the Part 1 Written Boards is somewhere around
10	30 percent, so you have some very, very highly
11	educated well-trained people that are failing simply
12	to meet the criteria of the curves. The fail rates
13	for the orals - Subir, what do you think - they are
14	probably around the same?
15	MEMBER NAG: Thirty percent.
16	MEMBER DIAMOND: So you're talking about
17	large numbers of extremely qualified people who are
18	not passing on their first go-around. There's really
19	no stigma associated with it. It's kind of the way
20	the game is played.
21	MS. CHIDAKEL: Let me see if I can
22	understand your position then. Are you saying that
23	you don't feel there should be any change as far as
24	specification of hours, either in the alternate
25	pathway or the board certification path?

(202) 234-4433

	40
1	MEMBER DIAMOND: I think the main issues,
2	if I may, are that my sense is that the NRC staff
3	is interpreting the enumeration of hours differently.
4	And based upon that different interpretation, the
5	American Board of Radiology for Radiation Oncology
6	certification would not meet all the requirements that
7	are being enumerated and, therefore, we're falling
8	into this alternate pathway problem. That's number
9	one.
10	Number two, all of the residents coming
11	out of training now will not be board certified for at
12	least a year and, therefore, will all fall into the
13	alternate pathway matrix.
14	CHAIRMAN MALMUD: Dr. Nag.
15	MEMBER NAG: Okay. I do have a few
16	comments. Although this was out for public comments
17	a couple of weeks ago, this was not conveyed to the
18	ACMUI, so the ACMUI has not had a chance to look at it
19	in detail. One thing would have helped would have
20	been an email that this is being out and have that
21	sent to us. But one of the things is that next month,
22	I am giving on how do you get certified. And because
23	of that specific reason, I had to talk with NRC
24	officials to gain some of the insight and, therefore,
25	I do have a little insight because of that. But the

(202) 234-4433

ACMUI members have not had that chance for the interaction, so I do support Dr. Diamond's proposal that we be given more time to be able to analyze and understand this. We could do it, perhaps, as a subcommittee or any other way you need a two week notice, because otherwise you will not have a chance to discuss this among ourselves.

With this alternate pathway of 396, a 8 board certified radiation oncologist can become an 9 authorized user of the 390 requirement, but will 10 11 require 80 hours of unsealed sources extra. Now the 12 board at the moment is not requiring that 80 hours, but once it does, it will solve the problem. I think 13 14 one of the problems you are seeing right now of making 15 a spreadsheet is that the board requirements are changing, and they have not finalized what the exact 16 requirements are, because of this situation. The NRC 17 is making some of these requirements, and then the 18 19 board has now to see whether it can meet these 20 For, for example, right now the requirements. 21 American Board of Radiology does not require a 22 noted, although separate 80-hour as it may be 23 incorporated as part of the program in many of the 24 programs. Now the board has to make a separate decision whether they are going to make that 80-hours 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

(202) 234-4433

	42
1	incorporated within that training program. So at the
2	moment, we can't even make a spreadsheet. So I think
3	with all of the confusion going on, I do support Dr.
4	Diamond's proposal.
5	MR. MOORE: Dr. Malmud.
6	CHAIRMAN MALMUD: Who just said Dr.
7	Malmud?
8	MR. MOORE: I did.
9	CHAIRMAN MALMUD: Okay.
10	MR. MOORE: This is Scott Moore. Dr. Nag
11	just recommended that an email would have helped. I'd
12	like to point out that Sandy Wastler did send an
13	email. We have a 30-day comment period for agreement
14	states and ACMUI built into the rulemaking process to
15	comment on rules. We have a very tight deadline for
16	complex rules, and this is certainly one of them.
17	Sandy sent out an email to all members of
18	the ACMUI at the start of the 30-day comment period.
19	The 30-day comment period ends on October $18^{th}$ , and it
20	was sent to agreement states at the same time. Each
21	of you received an email from Sandy at the start of
22	the 30-day comment period, and we asked for comments
23	back from the ACMUI at the end of the 30-days, which
24	is October 18 <sup>th</sup> . So in response to what Dr. Nag just
25	brought up, we did send the email.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

43 1 CHAIRMAN MALMUD: I think Dr. Broseus was 2 next. BROSEUS: have 3 DR. Ι а couple of 4 observations. One of them is sort of parallel to 5 Scott's, but not quite the same. The working group feels a tug both ways, but we feel it's very important 6 7 to get this rule out as soon as possible. And if the rule were reopened for public comments, that would 8 9 cause quite a lengthy delay in getting this rule on the books, and getting stability into the regulation 10 11 in this particular area. The second observation is that I believe 12 if we come back and focus on some of the key elements 13 14 here, that it is possible to move forward 15 396, if it were in redline, productively. in a redline strikeout, will all be redlined because it's 16 new. And I have a copy here which I can circulate to 17 people - in fact, I'll pass it around. Dr. Nag asked 18 19 for this yesterday, but if you could bring questions 20 you have to me about these particular areas, I think 21 we could focus on them. One of the comments that Dr. Diamond made 22 23 related to the interpretation of the 700 hours, and 24 differing messages that you received from the staff. 25 I've tousled with those very issues when we were

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

44 1 developing guidance in 2002 before the current rule 2 was issued, and so my own personal opinion is that a 3 comment coming back from ACMUI that recognizes that 4 and calls that to our attention, we can go back and 5 look at it in the supplementary information how to address these differing views and clarify them because 6 7 the steady message has been from the NRC, and the people developing the rule and the guidance that are 8 9 guiding this forward is to have reasonable rule, have it clear, and not have different interpretations that 10 cause problems. 11 12 So once again, I would just say anything that we can come out of this meeting with about 13 October 18<sup>th</sup> that would move this forward is important 14 15 because it may be the Commission would not grant us the privilege of extending the rule if that were a 16 recommendation in order to go forward. 17 Thank you. CHAIRMAN MALMUD: I think Dr. Williamson 18 19 was next. 20 MEMBER WILLIAMSON: I think maybe with

regard to Dr. Diamond's suggestion, we need to think through the different parts of the rule, 100, 200, 300, 400, and 600, and ask the question for radiation oncology and other boards potentially, too, if the number of hours of training and experience in the

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

alternate pathway is a problem. So if one looks at the 490, the alternate pathway for brachytherapy, manual brachytherapy requires 200 hours of classroom and laboratory, and 500 hours of supervised experience which I think the word is involves, it doesn't say exclusively devoted to, but involves the handling and preparation of sources.

Do Dr. Diamond and Dr. Nag think that the 8 current four year residency complies would allow an 9 10 applicant to satisfy that requirement for the 11 alternate pathway for manual brachytherapy?

12 MEMBER DIAMOND: This is Dr. Diamond. То answer your question, Jeff, I believe that many of the 13 14 programs currently satisfy all of those requirements, 15 and for those programs that do not, relatively minor additive changes would satisfy that requirement. 16

17 MEMBER WILLIAMSON: Okay. Let's qo to Do Dr. Diamond and Dr. Nag think that the 18 600 now. 19 rule as written, which again the alternative pathway 20 requires 200 hours of classroom and laboratory, plus 21 500 hours involving, and then again a slightly 22 modified laundry list of technical tasks associated 23 with high dose rate and teletherapy. Do you think an 24 individual that has successfully completed a four year 25 residency to date in radiation oncology could comply

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

	46
1	with the requirements of the alternative pathway?
2	MEMBER DIAMOND: This is Dr. Diamond.
3	Once again, by the way I account for hours, the answer
4	would be yes.
5	MEMBER WILLIAMSON: The third question -
6	396.
7	MEMBER NAG: You haven't asked me.
8	MEMBER WILLIAMSON: Oh, I've asked both of
9	you.
10	MEMBER NAG: You haven't given me the
11	chance to answer.
12	MEMBER WILLIAMSON: I'm sorry. You're
13	right.
14	MEMBER NAG: It will depend on how the
15	hours are interpreted. That's what I'm trying to tell
16	you; that if you are saying that the 500 hours include
17	your experience in handling of radioisotope, that
18	includes the 600, but also includes the 400 - yes,
19	then you will meet it. But if someone says yes, you
20	have the experience in manual brachytherapy on the
21	400, that was the 500 hours. Now you have to show me
22	a separate 500 hours for the use in 600. That will be
23	very difficult in some of the training programs that
24	don't have their own HDR. But if it did comprise a
25	part of the overall training, yes, there is no problem

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

meeting it. So that was my reason for asking the NRC how are you affecting these hours.

MEMBER WILLIAMSON: And let me finish with 3 4 my third question, and then I'll shut up. The 300 now 5 requires 700 hours, and I think it is not -- in the alternate pathway it is distinguished between, of 6 7 course, classroom and laboratory, and supervised work experience. I think it is by NRC's own admission that 8 9 radiation oncologists today would not satisfy that, but the 396 pathway does seem to provide a solution 10 11 for practicing radiation oncologists that have either 12 in their residency or in subsequent practice acquired that experience to be able to easily comply and do 13 14 what they're doing, and someone who has never had that 15 - well, two weeks of training and three cases is some 16 barrier, but it doesn't seem to be a completely unreasonable one for someone who hasn't had that 17 So do you think that, does it matter 18 experience. 19 whether 300 requires 700 hours now? That's my 20 question.

21 MEMBER NAG: Yes. I think the -- I mean, 22 I did discuss this with the NRC officials because I am 23 going to be talking about this in a meeting, so I had 24 to clarify for my own understanding before I say it to 25 the general radiation oncology community. The general

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

(202) 234-4433

	48
1	radiation oncologists will not be able to meet the 300
2	requirement of 700 hours, but because they can qualify
3	under the 400 and the 600, then they can add the 396
4	and qualify by that log, so that is not a problem.
5	The one problem would be that until the board until
6	the American board of radiology requires an 80-hours
7	of unsealed sources built into that program, they will
8	have to somehow show that they have the 80-hours of
9	separate unsealed source somewhere, so that may be
10	slightly difficult, but not impossible.
11	MEMBER WILLIAMSON: So I guess the
12	question is, is whether the issue raised by Dr.
13	Diamond, which is certainly a frightening prospect, is
14	valid.
15	CHAIRMAN MALMUD: Thank you. Dr. Zelac,
16	I believe, had his hand next.
17	DR. ZELAC: Thank you, Dr. Malmud. I'd
18	like to point out several things that I think are
19	pertinent to the discussion. First, in terms of the
20	total number of hours required in the different
21	modalities there have been no adjustments from the
22	current rule. And there was clearly extensive
23	discussion involving the advisory committee, the
24	various boards, the public when the current rule was
25	adopted, so if we're talking about, for example, the

	49
1	700 hours, that has been on the books for two years
2	now, and apparently is not providing an impediment to
3	people achieving authorized user status.
4	Secondly, I'll wait until Dr. Diamond is
5	finished, because this I think is Dr. Diamond, I
6	wanted you to
7	MEMBER DIAMOND: I'm listening.
8	DR. ZELAC: Okay. Particularly hear this.
9	Since we are talking about now unchanged requirements
10	from the current rule, it's appropriate to take a look
11	at the statements of consideration that went along
12	with the publication of the current rule with regard
13	to things like the 700 hours, and where one acquires
14	it, and what qualifies for requiring it. And there
15	are two places in the statements of consideration for
16	the current rule that are applicable. One was to the
17	290 requirements, for which there are 700 hours, and
18	the second was for therapeutic utilization.
19	Quoting from the Federal Register, "We
20	recognize that physicians in training will not
21	dedicate all of their time specifically to the subject
22	areas in 35.290" - not talking about 700 hours there -
23	"and will be attending to other clinical matters
24	involving the diagnostic use of material under the
25	supervision of an authorized user; example, reviewing

(202) 234-4433

case histories or interpreting scans. Even though these clinical matters are not specifically required by the NRC, this type of supervised work experience may be counted toward the supervised work experience to obtain the required 700 hours." That's one area.

The second has to do with training and

experience requirements for sealed byproduct material, and the quote here from the Statements of Consideration, "The NRC agrees that concurrent training should be allowed for the clinical and work practical experience requirements in 35.490 and Therefore, we revise the regulatory text to 35.690. allow for concurrent work and clinical experience."

MEMBER DIAMOND: 14 This is very helpful 15 information, Ron, because listening to you, that Statement of Consideration is much closer to how in my 16 mind I enumerate for these hours, the same way I would 17 believe our Chairman does, and perhaps the entirety of 18 the committee. And also, sounds to me different than 19 20 what I heard yesterday. And I would go back to Jeff's 21 series of questions when he was asking do the training 22 programs satisfy these hours. And based upon those 23 Statement of Considerations with respect to 300 level 24 uses, I would say that many of the training programs 25 already do satisfy those hours, and the ones who do

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

9

10

11

12

13

not probably could meet them with very minor changes.

2 The other last point that I DR. ZELAC: 3 would make with respect to -- in response to what Dr. 4 Williamson had brought up is, if you look at what the 5 board requirements are versus the alternate pathway requirements for 190 and 290, it was built into the 6 7 board requirement meeting the requirement in the alternate pathway, except for again in terms of the 8 9 numbers of hours have to be met. We have been careful, however, in the rewrite in the working group 10 11 to try to not put additional requirements - and this 12 is the issue that's been raised by Dr. Malmud additional requirements that would apply specifically 13 14 to the board certification pathway. So the dilemma is 15 there, and I think it's perhaps somewhat unavoidable from the way we're approaching this if, in fact, we 16 17 are going to go down the pathway of specifying training -- excuse me, classroom and laboratory 18 19 subgroup of the total experience required.

20 DR. BROSEUS: Excuse me for interrupting, 21 but I want to supplement what Ron said by noting that 22 in the supplementary information for the draft final 23 rule, we have brought forward this discussion he just 24 quoted into the supplementary information, and added 25 a bit to it just to clarify that the NRC's intent is

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

(202) 234-4433

1to make sure that radiation safety training is2adequately addressed, because we're also dealing with3the didactic hours issue, and so that discussion is in4the supplementary information.5MEMBER WILLIAMSON: A point of6clarification. What is supplementary material?7DR. BROSEUS: Okay. I'm talking jargon -8excuse me. The Statements of Consideration - it's the9front part10MEMBER WILLIAMSON: Is this the thing that11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is25not up here. The only thing that we put in there is		52
3the didactic hours issue, and so that discussion is in the supplementary information.5MEMBER WILLIAMSON: A point of clarification. What is supplementary material?7DR. BROSEUS: Okay. I'm talking jargon - excuse me. The Statements of Consideration - it's the 99front part10MEMBER WILLIAMSON: Is this the thing that we heard12DR. BROSEUS: Yes. It's the first part of that. At the end of that is the rule text, but the supplementary information has a discussion for rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to the current Part 35 published in DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to the Federal Register version of the rule published April 24 <sup>th</sup> , 2002, or some other version of the rule? DR. BROSEUS: Let me give you a specific answer, a correct answer to that. Okay? The stars refer to text which is in the current rule which is	1	to make sure that radiation safety training is
4the supplementary information.5MEMBER WILLIAMSON: A point of6clarification. What is supplementary material?7DR. BROSEUS: Okay. I'm talking jargon -8excuse me. The Statements of Consideration - it's the9front part10MEMBER WILLIAMSON: Is this the thing that11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	2	adequately addressed, because we're also dealing with
5       MEMBER WILLIAMSON: A point of         6       clarification. What is supplementary material?         7       DR. BROSEUS: Okay. I'm talking jargon -         8       excuse me. The Statements of Consideration - it's the         9       front part         10       MEMBER WILLIAMSON: Is this the thing that         11       we heard         12       DR. BROSEUS: Yes. It's the first part of         13       that. At the end of that is the rule text, but the         14       supplementary information has a discussion for         15       rational rule change and comments and responses.         16       MEMBER WILLIAMSON: Do the stars refer to         17       the current Part 35 published in         18       DR. BROSEUS: Pardon me?         19       MEMBER WILLIAMSON: Do the stars refer to         20       the Federal Register version of the rule published         21       DR. BROSEUS: Let me give you a specific         22       DR. BROSEUS: Let me give you a specific         23       answer, a correct answer to that. Okay? The stars         24       refer to text which is in the current rule which is	3	the didactic hours issue, and so that discussion is in
6clarification. What is supplementary material?7DR. BROSEUS: Okay. I'm talking jargon -8excuse me. The Statements of Consideration - it's the9front part10MEMBER WILLIAMSON: Is this the thing that11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	4	the supplementary information.
7DR. BROSEUS: Okay. I'm talking jargon -8excuse me. The Statements of Consideration - it's the9front part10MEMBER WILLIAMSON: Is this the thing that11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	5	MEMBER WILLIAMSON: A point of
<ul> <li>8 excuse me. The Statements of Consideration - it's the</li> <li>9 front part</li> <li>10 MEMBER WILLIAMSON: Is this the thing that</li> <li>11 we heard</li> <li>12 DR. BROSEUS: Yes. It's the first part of</li> <li>13 that. At the end of that is the rule text, but the</li> <li>14 supplementary information has a discussion for</li> <li>15 rational rule change and comments and responses.</li> <li>16 MEMBER WILLIAMSON: Do the stars refer to</li> <li>17 the current Part 35 published in</li> <li>18 DR. BROSEUS: Pardon me?</li> <li>19 MEMBER WILLIAMSON: Do the stars refer to</li> <li>20 the Federal Register version of the rule published</li> <li>21 April 24<sup>th</sup>, 2002, or some other version of the rule?</li> <li>22 DR. BROSEUS: Let me give you a specific</li> <li>23 answer, a correct answer to that. Okay? The stars</li> <li>24 refer to text which is in the current rule which is</li> </ul>	6	clarification. What is supplementary material?
9 front part 10 MEMBER WILLIAMSON: Is this the thing that 11 we heard 12 DR. BROSEUS: Yes. It's the first part of 13 that. At the end of that is the rule text, but the 14 supplementary information has a discussion for 15 rational rule change and comments and responses. 16 MEMBER WILLIAMSON: Do the stars refer to 17 the current Part 35 published in 18 DR. BROSEUS: Pardon me? 19 MEMBER WILLIAMSON: Do the stars refer to 20 the Federal Register version of the rule published 21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	7	DR. BROSEUS: Okay. I'm talking jargon -
10MEMBER WILLIAMSON: Is this the thing that11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	8	excuse me. The Statements of Consideration - it's the
11we heard12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	9	front part
12DR. BROSEUS: Yes. It's the first part of13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	10	MEMBER WILLIAMSON: Is this the thing that
13that. At the end of that is the rule text, but the14supplementary information has a discussion for15rational rule change and comments and responses.16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24th, 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	11	we heard
14 supplementary information has a discussion for 15 rational rule change and comments and responses. 16 MEMBER WILLIAMSON: Do the stars refer to 17 the current Part 35 published in 18 DR. BROSEUS: Pardon me? 19 MEMBER WILLIAMSON: Do the stars refer to 20 the Federal Register version of the rule published 21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	12	DR. BROSEUS: Yes. It's the first part of
15 rational rule change and comments and responses. 16 MEMBER WILLIAMSON: Do the stars refer to 17 the current Part 35 published in 18 DR. BROSEUS: Pardon me? 19 MEMBER WILLIAMSON: Do the stars refer to 20 the Federal Register version of the rule published 21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	13	that. At the end of that is the rule text, but the
16MEMBER WILLIAMSON: Do the stars refer to17the current Part 35 published in18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24th, 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	14	supplementary information has a discussion for
17 the current Part 35 published in 18 DR. BROSEUS: Pardon me? 19 MEMBER WILLIAMSON: Do the stars refer to 20 the Federal Register version of the rule published 21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	15	rational rule change and comments and responses.
18DR. BROSEUS: Pardon me?19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	16	MEMBER WILLIAMSON: Do the stars refer to
19MEMBER WILLIAMSON: Do the stars refer to20the Federal Register version of the rule published21April 24 <sup>th</sup> , 2002, or some other version of the rule?22DR. BROSEUS: Let me give you a specific23answer, a correct answer to that. Okay? The stars24refer to text which is in the current rule which is	17	the current Part 35 published in
20 the Federal Register version of the rule published 21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	18	DR. BROSEUS: Pardon me?
21 April 24 <sup>th</sup> , 2002, or some other version of the rule? 22 DR. BROSEUS: Let me give you a specific 23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	19	MEMBER WILLIAMSON: Do the stars refer to
DR. BROSEUS: Let me give you a specific answer, a correct answer to that. Okay? The stars refer to text which is in the current rule which is	20	the Federal Register version of the rule published
23 answer, a correct answer to that. Okay? The stars 24 refer to text which is in the current rule which is	21	April $24^{th}$ , 2002, or some other version of the rule?
24 refer to text which is in the current rule which is	22	DR. BROSEUS: Let me give you a specific
	23	answer, a correct answer to that. Okay? The stars
25 not up here. The only thing that we put in there is	24	refer to text which is in the current rule which is
	25	not up here. The only thing that we put in there is

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	53
1	where rule text is changed. Current rule text
2	includes what was published in 2000, some minor
3	corrections put in to correct typographical errors in
4	the draft final rules published since then, and the
5	extension of Subpart J. That is current rule language
6	now, and so what you see here is changes from current
7	rule language. Current rule language on the books
8	legally.
9	MEMBER WILLIAMSON: My question is if I'm
10	looking at this Federal Register, April 24 <sup>th</sup> , 2002 -
11	am I accurately reading these stars.
12	DR. BROSEUS: No.
13	MEMBER WILLIAMSON: No.
14	DR. BROSEUS: No. What I just said -
15	April, 2002 does not take into account the most
16	current rules on the website here, and in January of
17	this year the Federal Register published Title 10,
18	which includes the typographical error updates and so
19	on.
20	DR. HOLAHAN: But those are minor changes,
21	so basically what you see in the rule text before you
22	is the current rule with some modifications, like
23	minor corrections.
24	MEMBER NAG: You very well clarified the
25	390, 490, 690. Could you do similarly for the 390,

(202) 234-4433

	54
1	that is, are you going to allow overlap in that 700
2	hours of training for the 390? The 390, 490 - you
3	were very clear. I thought I knew what 390 was, but
4	the 700 would be separate for unsealed source, but if
5	you're having if you're allowing overlapping 490
6	and 690, and ultimately 290, why are you not allowing
7	overlap in that 390?
8	DR. BROSEUS: I have a note for myself to
9	go back to the working group that says clarify in the
10	supplementary information the meaning of these hours
11	and look at this overlap, and we'll discuss that in
12	the working group, and make sure we have an
13	appropriate statement there.
14	CHAIRMAN MALMUD: Okay. So Dr. Nag will
15	get that information clarified by you, Dr. Broseus, or
16	Dr. Zelac?
17	DR. BROSEUS: We'll take it as a comment
18	on the draft final rule in our development of the
19	final supplementary information.
20	MEMBER NAG: If that 390 can be clarified
21	that there is overlap, then you don't even need 396
22	because the
23	CHAIRMAN MALMUD: Let see, I'm trying to
24	see who was next. Mr. Bailey.
25	MEMBER BAILEY: We have a real problem,

(202) 234-4433

1 and when I say "we", I think most of the states do. 2 When we go to adopt these NRC rules, we have to meet These regulations 3 standard of clarity. fail а 4 miserably on clarity, and I hope -- I mean, it's 5 obvious that if we're having this much trouble, it's going to be very difficult for lawyers in the Office 6 7 of Administrative Law in the 33 states to accept these 8 regulations as being clear. The second thing that we have to do is we 9 10 can't have interpretations in the regulations and 11 standards that you're going to apply an interpretation 12 of the regulations and Statements of Consideration. Those are called underground regulations in most 13 14 states. 15 Thirdly, when you add a provision such as you've done with 396, that is a - and I never can say 16 this word - substantive change in the regulations, and 17 we would have to go back out for public consideration 18 19 of those brand new requirements. So these regulations 20 as they're being proposed now will be extremely 21 difficult for many, many states to adopt. And because 22 they're not clear, we're just making a machine for misunderstanding of requirements from state to state. 23 24 CHAIRMAN MALMUD: Thank you, Mr. Bailey.

That was the concern that I was raising earlier. I

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

(202) 234-4433

1 think that from the Office of Counsel, Ms. Chidakel, 2 pointed out the process has been adhered to, and I 3 accept that personally. I can't speak for the whole 4 committee. However, clarity is not there. It is 5 simply not there. Here we are, months of discussion we don't understand it. How is someone in another 6 7 state going to understand it? How is anyone in a position of authority who doesn't deal with this 8 regularly going to understand it? There is no clear 9 quideline that is able to be looked at in one or two 10 11 pages and a conclusion drawn. That's my concern; that 12 we will bring embarrassment upon ourselves and the NRC in passing regulations that are so cloudy that no 13 14 intelligent educated Ph.D. who hasn't been involved -15 or M.D. - who hasn't been involved in these issues for months can understand them. That's my concern. 16 But 17 I'm speaking for myself here, and next, Dr. Diamond. 18 MEMBER DIAMOND: Let me give you an 19 example of that. I've just been reading the 396 20 language, if I could ask everyone here to take a look 21 at this, please. The construction - this is the 22 alternate pathway for the unsealed byproduct material

requiring a written directive. The construction, as
I'm reading it, is A, or B, plus C. Okay. A, or B,
plus C is the construction. A is essentially the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

Í	57
1	grandfather clause for A use, who became A use prior
2	to October, 2005. B is individuals who are certified
3	by the boards prior to October, 2005, and C.
4	As I understand this, for a resident, for
5	example, who finishes his or her radiation oncology
6	training in the spring of 2006 or 2007, 2008 it is not
7	humanly possible for that person to ever give
8	parenteral administration of unsealed byproduct
9	material unless there's a typographic error.
10	MEMBER WILLIAMSON: I think if I could
11	clarify, it's really A or A Prime, or B, or B Prime,
12	and C, so within the A clause and B clause it
13	distinguishes between satisfying Subpart J versus the
14	current regulation, so I think on a technical point,
15	I don't think the concern is warranted.
16	MR. MOORE: Dr. Malmud, Scott Moore. If
17	the advisory committee's comment is that the additions
18	with regard to didactic hours in 396 or any changes
19	since the proposed rule are not clear, those types of
20	comments would be helpful to us, because they give us
21	some direction as a group, as a writing group on what
22	we can do with respect to the draft final rule. And
23	if you can in particular point out the areas that
24	aren't clear or give us directions on how to clarify
25	them, those would be helpful.

(202) 234-4433

I would note that with regard to the public comments on the proposed rule, and also on the agreement state comments, Mr. Bailey, on the proposed rule, I don't recall that we got comments that the rule itself wasn't clear, so with regard to what went out and was commented on in the proposed rule stage, I don't recall that we got comments back saying it wasn't clear.

MEMBER DIAMOND: This is Dr. Diamond. But 9 10 again, getting back to my question which was premised 11 on clarity - let's take the hypothetical example of a 12 radiation oncology resident graduating from a program in 2006. That individual will not be able to sit for 13 14 his or her boards until 2007, so obviously not board 15 certified at that point. This individual will not satisfy Paragraph A, nor will they satisfy Paragraph 16 And because the construction -- Jeff, if I'm 17 Β. 18 wrong, please explain how I'm wrong.

MEMBER WILLIAMSON: Okay. A resident who graduates and is not board certified would be able to become an authorized user of 490 or 690 under the alternate pathway, and therefore, they would satisfy the first part of Clause A. It is an authorized user under 490 or 690, and then the "or before October 25<sup>th</sup>" this is for the previous people - but if they

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

	59
1	become by whatever pathway a 400 or 600 AU, they
2	satisfy A.
3	MEMBER DIAMOND: So you're saying that the
4	commas before and after "or", that that should be
5	October 24, 2005 - I see, that's how you're
6	interpreting the
7	MEMBER WILLIAMSON: Yes. That's
8	MEMBER NAG: For 940 and 960.
9	DR. BROSEUS: Let me expand. October,
10	2005 is capturing people. You can come in under
11	Subpart J. Subpart J disappears October, 2005, and so
12	everything that comes after the "or" disappears in
13	2005. But a person could use either pathway up to
14	that point.
15	MEMBER DIAMOND: So again - so, Jeff, that
16	hypothetical individual, the day he or she finishes
17	his training will already have AU status obviously
18	under 490 and 690.
19	MEMBER WILLIAMSON: Even before they
20	MEMBER DIAMOND: If they're in training,
21	right.
22	MEMBER WILLIAMSON: After three years if
23	they have the 700 hours mixture of didactic and
24	supervised training, just as fellows in current
25	training programs can become AUs through the action of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	60
1	the Radiation Safety Committee. I don't think that
2	it's not going to be a big problem.
3	CHAIRMAN MALMUD: Who is next? Mr. Lieto.
4	MEMBER LIETO: Yes. I have a point, just
5	to be sure I understand, a couple of questions for
б	clarification for Roger. The intent as to what is
7	going to be published would be the final rule. Is
8	that correct? There's not really going to be any more
9	public comment. Is that correct?
10	CHAIRMAN MALMUD: That's correct.
11	MEMBER LIETO: Okay. A specific question
12	related to 396. A physician, ABR certified under 290
13	wants to come in and be approved for parenteral
14	applications, therapy applications - he would not be
15	able to be qualified under the board certification
16	route. I mean, he would not be able to be qualified,
17	period. Right?
18	DR. BROSEUS: If I recall correctly from
19	previous discussions in this advisory committee, many
20	times the training that a person has under 290 is
21	going to get them close to or qualify them for 300
22	use, and so you don't have to worry about 396. Ron,
23	we talked about this before. Do you want to expand
24	upon that?
25	CHAIRMAN MALMUD: Dr. Zelac.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	61
1	DR. ZELAC: I think the point to be made
2	is that 396 was intended very specifically for
3	radiation oncologists to be able to use unsealed
4	material that required a written directive. For those
5	who have been trained specifically not for radiation
6	oncology, essentially for nuclear medicine, it would
7	be expected that those individuals would satisfy the
8	requirements for 390 if they intended to use materials
9	for which a written directive was required.
10	The last point to be made is that some of
11	the training that such individuals, and a large part
12	of it, actually, that individuals would receive under
13	the 290 would be applicable to the requirements under
14	390, a lot of the basic information would cross over.
15	Specific information relating to, if you will,
16	therapeutic use, use of unsealed materials in
17	therapeutic quantities would have to be added to the
18	training such individuals would receive before they
19	would qualify for 390 use.
20	MEMBER LIETO: Mr. Chair, a follow-up
21	point. I guess the reason I was asking is that there
22	may be a number of areas where nuclear medicine

23 physicians don't want to deal with Iodine, nor have 24 that authorization or those restrictions on their 25 license. Okay? I shouldn't say restrictions, but

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

	62
1	that latitude on their license, and want to only deal
2	with the non-Iodine therapy applications.
3	DR. BROSEUS: Well, they could apply for
4	just whatever they need. They don't have to apply for
5	
6	MEMBER LIETO: Well, that's kind of my
7	DR. BROSEUS: That's not an issue.
8	MEMBER LIETO: Well, that's my point, is
9	that if a physician comes in who's board certified and
10	is approved under 290, what you're saying is that he
11	has to come under 390 or that's it, because if you
12	look at A and B, it doesn't allow anybody who's board
13	certified and approved under 290 to come in and get
14	396.
15	MEMBER NAG: Well, I think the confusion
16	is 396 was meant only for people for radiation
17	oncologists, basically only for people who qualified
18	under 400 and 600 who solved the problem that the
19	radiation oncologists may not handle the unsealed
20	sources. The 396 has nothing to do with nuclear
21	medicine physician, so when you're talking about 396,
22	only refer to radiation oncology training.
23	CHAIRMAN MALMUD: That is my
24	understanding, as well, Dr. Nag.
25	DR. BROSEUS: That's it.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	63
1	CHAIRMAN MALMUD: And Dr. Broseus confirms
2	that. Does that answer your concern, Mr. Lieto?
3	MEMBER LIETO: Well, you answered my
4	question. Yes.
5	CHAIRMAN MALMUD: Thank you. I think that
6	Sally Schwarz, you were next.
7	MS. SCHWARZ: I just wanted to ask a
8	question.
9	CHAIRMAN MALMUD: I couldn't hear you.
10	I'm sorry.
11	MS. SCHWARZ: Sally Schwarz. I'm just
12	concerned about the authorization for nuclear medicine
13	physicians under 390. Actually, that's what I'm
14	concerned about, and I think that's what Dr. Eggli was
15	going to raise, as well.
16	CHAIRMAN MALMUD: All right. Then we'll
17	pass to Dr. Eggli.
18	MEMBER EGGLI: Okay. Actually, Jeff asked
19	his questions with respect to 400 and 600 users.
20	Nobody has so far asked the same questions for 100
21	series users, 200 series users, or 300 series users.
22	When I look at the there are a lot of
23	different boards who qualify people in these areas.
24	When I look at the American Board of Nuclear Medicine,
25	I have no problem assuming that the American Board of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 Nuclear Medicine will hit the training mark. My biq 2 problem is the vast 70 percent of all nuclear medicine 3 in this country is practiced by diplomats of the 4 American Board of Radiology, and the American Board of 5 Radiology trains people in a wide variety of imaging modalities, and the training allowed is governed 6 7 largely by the regulations. So as the American Board of Radiology looks at trimming its previously 1,000 8 hour training for a radiologist in nuclear medicine to 9 700 hours, it's hard to get everything in. 10 11 And the biggest problem that I'm seeing 12 here is the 200 hour requirement for 300 uses. First of all, I have a son who attends a well-known college 13 14 in the northeast. They spent three hours a week in 15 class, 15 weeks in a semester, so that about 45 hours Two hundred hours is 4-1/216 for a college course. 17 college courses devoted to issue of safe handling of radiopharmaceutical strikes me as a little on the high 18 19 side for safe handling. No, actually it strikes me as 20 wildly on the high side for safe handling. 21 The other issue is, now I only get these 22 people - first of all, I think I'm the only person 23 sitting at this table who trains people for 300 uses

If I now lose five weeks, which is 40 hours a week of

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

I only get these people for 700 hours.

(202) 234-4433

or 200 uses.

24

25

(202) 234-4433

	65
1	their time to didactic training and safe handling, I
2	now have less than three months to teach them clinical
3	nuclear medicine and make them competent.
4	I think this rule will have the unintended
5	effect of impairing the clinical experience of
6	diplomats of the American Board of Radiology in
7	clinical nuclear medicine, and that may have a
8	limiting effect on how they perform clinically, and
9	maybe a greater hazard to public safety than the hours
10	of training.
11	I sat down and designed a didactic
12	radiation safety program for my residents, including
13	every conceivable topic, plus supervised what I would
14	call laboratory experiments where we set up
15	experiments on the use of the equipment and safe
16	handling, and we monitor them in a laboratory
17	environment, much like you would have gone to a lab
18	section in a college course. I came up with 50 hours
19	of training, and I think 50 hours actually for Part
20	200 uses is very appropriate, and I think something
21	closer to 100 hours for Part 300 would be appropriate.
22	Because again, for 300 uses, we talk about the broad
23	uses of so many radiopharmaceuticals.
24	Now I've got two basically - I have orally
25	administered therapies, and I have parenterally

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

administered therapies. And for orally administered therapies, those we're only going to do radio Iodine, they have an 80-hour requirement of training right now on the alternate pathway. And again, the argument that I'm not going to have to train the alternate pathway is specious because I'm going to for the reasons that Dr. Diamond described, I'm going to have to train everybody to alternate pathway rules.

9 Now we're saying that we need another 120 hours of training, of didactic training to handle one 10 other category of administration, which is basically 11 12 beta emitters administered parenterally. And the safety issues don't change if I put it in a joint, if 13 14 I inject it into the peritoneal cavity, if I inject it 15 intravenously, whether it's really a coloital beta emitter or in solution - none of the safety issues 16 that I need to train for changed, so I've got two 17 categories of therapy that I need to train for under 18 19 300, oral administration and Part parenteral 20 administration.

I think NRC has recognized that there are two broad categories of therapeutics in the way they're now describing Part 396. So I think 200 hours is unnecessarily excessive, and will - since I'm only going to get them for 700 hours, is going to limit my

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

	67
1	ability to make them clinically competent. And I
2	think that is going to damage healthcare in the United
3	States.
4	DR. BROSEUS: Mr. Chairman.
5	CHAIRMAN MALMUD: Dr. Broseus.
6	DR. BROSEUS: We're moving into the other
7	topic, which I did want to address, and if I just
8	might present a couple of slides to talk about that,
9	and then we can come back to some of the other issues.
10	And that is, we did have a teleconference on October
11	$5^{th}$ to talk about the issue of - I'm going to put
12	quotes around - "didactic hours", and we presented
13	recommendations that came forward from our working
14	group, which are appearing on the slide behind me now,
15	which has the subdivision, including the 200 hours of
16	didactic training that Dr. Eggli just mentioned. And
17	one of the objectives of the working group today is to
18	get any recommendations that ACMUI may have about what
19	is the proper number of hours.
20	Additionally in that meeting, we heard
21	some discussion about definition of what the hours
22	are. And, for example, in those sections in Part 35
23	dealing with T&E, the term "didactic" isn't used.
24	What we have is classroom and laboratory training,
25	except for individuals to qualify as nuclear

(202) 234-4433

	68
1	pharmacists. And for that particular category in the
2	current rule, and in the proposed rule which we
3	published, there was a reference to didactic hours
4	requirement for nuclear pharmacists.
5	Now the working group has been thinking
6	about these issues, especially since the telecon, and
7	it would be also useful if you feel there's a need to
8	look at the definition more to get some feedback, and
9	a basis if you think there's a need to change the
10	definition.
11	Now the working group was considering
12	eliminating the term "didactic" from pharmacy for the
13	requirements for nuclear pharmacist, and substituting
14	the term classroom and laboratory hours to make it
15	clear. And so what I'm suggesting is that as we move
16	forward, and it's 9:32, that we also would benefit if
17	you have comments about what the proper balance of
18	hours is, a basis for a change, and Dr. Eggli
19	suggested some, as well as is there a need to look at
20	the definition of didactic hours, that is classroom
21	and laboratory hours, which is what most people I
22	think mean by that term, if there is a need to
23	elucidate that, should it be in definitions and rule
24	space, or in supplementary information. You, Dr.
25	Malmud, pointed out that one could get into a slippery

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	69
1	slope if you start defining things, and so on.
2	I'd also like to - since I got the chair
3	back - just mention, we've already talked about our
4	closing period for comment being October $18^{th}$ . We
5	plan right now to hopefully have this rule go to the
6	Commission by mid-November, and would anticipate
7	publication in 2005. Thank you for letting move on a
8	little.
9	CHAIRMAN MALMUD: Certainly. Dr.
10	Williamson is chomping at the bit.
11	DR. BROSEUS: I'm at your disposal.
12	MEMBER WILLIAMSON: I wanted to ask a
13	question to Mr. Bailey, who has gone away, so perhaps
14	I should I'll just ask. I'll ask, I think, a
15	follow-up question to what Dr. Eggli has presented.
16	In radiation oncology, which is a 4-year
17	program, I think the 200 hours, while not absolutely
18	required by the ABR, I think is met by virtually most
19	of the diplomats. And this is met not just by courses
20	that deal with sealed sources and brachytherapy. They
21	have a long radiation physics sequence. They have
22	radiation biology. They also have probably formal
23	instruction in statistics and design of clinical
24	trials and interpretation of clinical studies, et
25	cetera; as well as numerous sessions on radiation

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

safety dealing with more specific devices and programs that they have.

3 For the 700 hour training program you 4 administer, I assume these are diagnostic radiology 5 residents who also get a similar broad didactic training experience in radiation physics, radiation 6 7 biology, and what happens if you get inadvertent exposures to fetuses and so forth, teratology which is 8 equally applicable to external sources of radiation 9 and internal in terms of the basic principles. So you 10 11 really have to give 200 hours of your 700 hour 12 segment.

MEMBER EGGLI: If I look at the diagnostic 13 14 radiology physics curriculum, I come up with another 15 50 hours of didactic training in the rest of physics for radiology, so for our radiology residents now have 16 17 actually planned a roughly 100 hour course; 50 of those hours, which as we look at it, we felt were 18 relevant to the nuclear medicine requirements, and 50 19 20 hours that we thought were probably not relevant to 21 nuclear medicine requirements because they deal with 22 devices and don't fall under what we thought was the 23 spirit of the regulation.

24 CHAIRMAN MALMUD: Dr. Nag.

MEMBER NAG: Dr. Broseus, you had in your

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

1

2

(202) 234-4433

1 previous slide, you had the requirement for 35 up to 35 390, could you enumerate now for 490 and 690 in one 2 3 slide. That way we can show the whole thing. I mean, 4 that again - 700 and 200, but my question is that 5 someone who has this 200 has -- included in that body of knowledge is the requirement partly of the 390, so 6 7 in the 396 you are asking for additional 80-hours 8 specifically for unsealed sources. And that is the 9 specific requirement. It's not part of your 10 overlapping requirement.

11 For someone who has spent 200 hours in 12 didactic to then have another 80-hours that is separately for unsealed which is partly covered in the 13 14 radiation oncology training, but hard to dissect out 15 that there was 80-hours built within that 200 hours is going to be an excessive requirement for a board 16 certified radiation oncologist, because when you are 17 trying -- I give my course in brachytherapy, and my 18 19 course is probably one of the more extensive in 20 brachytherapy in the country. And I can accomplish 21 that within a period of two to three years in about 80 22 hours that is all about the specific brachytherapy 23 things. So that includes some of the requirements in 24 handling liquid or unsealed source also. So if you 25 ask me how many hours did I give last year on

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	72
1	specifically unsealed source out of my 200 hours,
2	that's very difficult to dissect out, so I think that
3	80 hours additional for 396 is very, very it's
4	probably an over-burden.
5	DR. BROSEUS: Would you like me to address
6	the first question, which is how many hours for 490
7	and 690 it's 200 hours.
8	MEMBER NAG: I know, 200 and 700.
9	DR. BROSEUS: Okay.
10	MEMBER NAG: What I meant was having it on
11	that so someone can look at it and automatically see
12	it. I mean, I know how many hours it takes.
13	CHAIRMAN MALMUD: Excuse me. May I
14	interrupt. I just want to clarify Dr. Broseus'
15	answer; that the total hours for 490 and 690 is 700,
16	of which 200 would be didactic in each case. Is that
17	what you said?
18	DR. BROSEUS: Classroom and laboratory
19	training.
20	CHAIRMAN MALMUD: Thank you. Now the
21	second question - Dr. Nag's question. Well, actually
22	it's a point. You're making a point that you believe
23	the 80 hours of additional training for the handling
24	of unsealed sources for radiation oncologists who are
25	otherwise fully trained and will have had already

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

73
completed physics training, which includes some hours
that overlap into unsealed sources, that the 80-hour
requirement may be excessive.
MEMBER NAG: Yes. I mean, basically at
that point the only extra thing you need to know is
what do you do in terms of a liquid spill that we
generally do not handle in a sealed source, although
we partially do, so there is really very little extra
knowledge required to then be able to handle unsealed
source.
CHAIRMAN MALMUD: Dr. Diamond.
MEMBER DIAMOND: Just to clarify
something; so you're asking about grandfathering of
board certified radiation oncologists who are not
licensed for 300 level uses.
MEMBER NAG: Right.
MEMBER DIAMOND: And you feel that a
radiation oncologist who's been in practice 10 or 20
years, who has never been licensed to give Strontium
or Iodine, or P-32, that that individual can start
giving these agents, or Zevelin, or whatever - going
from zero to that level in less than 80 hours.
MEMBER NAG: In less than 80 hours,
because you have already the body of knowledge on what
to do for therapy. Now you have to get the additional

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

requirement on what to do if you have a spill. In 80 hours, what are you going to teach someone, a curriculum that will cover 80 hours.

4 MEMBER DIAMOND: If I may respond to focus 5 this discussion just towards the radiation oncology community for a minute. My feeling is, is that I 6 7 would be satisfied if the following exists. I'll be satisfied if it is either in the Statements of 8 9 Consideration or in other manners that the spirit that Ron Zelac mentioned for 490 and 690, and which was 10 11 mentioned elsewhere today regarding the enumeration of 12 hours, if that is in that same spirit, I would be happy, because what that means is that an individual 13 14 going through the board pathway, which we intended all 15 along to be the AU pathway, if that individual, once he or she becomes board certified, can satisfy all the 16 300 level uses. So if that spirit is interpreted in 17 that manner, I'm very happy in that regard, number 18 19 one.

20 Number two, recognizing that every single 21 radiation oncology resident coming out will have to 22 fall under 396 until he or she becomes board certified at a minimum, I think that that is okay, as well, 23 24 because during the course of his or her training, he 25 she will easily have satisfied the 80-hour or

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

(202) 234-4433

1 requirement, and you need to, of course, have the 2 three cases which is not a big deal. And they've 3 already satisfied Paragraph A by virtue of their other 4 training, so that's good.

5 The third scenario is what Dr. Nag is mentioning - what about those radiation oncologists 6 7 who are Aus, have been in practice for many years, but are not licensed for 300 level uses. 8 In that 9 particular case, I do think that individual needs additional training. Is the number 80 hours? I don't 10 11 know. Is the number 5 hours? No.

12 Quite honestly, my opinion, for that physician who has not been doing any of these uses and 13 14 may have been out of practice for 10 or 20 years, I 15 really don't have a big problem with the 80 hours, I really don't. So anyway, to bring this to 16 Subir. 17 focus, I think if we can come to consensus on the spirit of enumeration, that will satisfy a major 18 We now have clarification for the 19 396 issue. 20 alternate pathway use that these residents coming out 21 of training or folks who have not yet passed their 22 boards because they failed the first time or two, will 23 be taken care of.

And as far as the grandfathering issue for folks that have never been licensed for 300 level

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	76
1	uses, I personally believe they do need additional
2	training. And I think we can discuss what the number
3	is - is it 80, is it maybe a little less than 80, but
4	certainly not, in my opinion, going to be 5 or 10.
5	MEMBER NAG: No, I think, David, you are
6	somewhat mistaken. A person who had finished their
7	residency, just finished their residency and became an
8	authorized user in 490 and 690, will still require 80
9	hours to be able to do the 390. And that will require
10	that you have to demonstrate an additional 80 hours,
11	and that is excessive because that person has recently
12	finished training, and many of those 80 hours were
13	already included in that 490 training.
14	MEMBER DIAMOND: By my understanding,
15	Subir, and please, staff, correct me if I'm wrong - by
16	my understanding, those 80 hours should easily have
17	been satisfied during the residency program. In other
18	words, that person, the day he finishes training, does
19	not need to then go and take an additional 80-hour
20	course. All you need to do is have attestation that
21	those 80 hours were satisfied during your 4-year
22	residency. Am I correct on that?
23	MS. SCHWARZ: That's correct.
24	MEMBER DIAMOND: Okay.
25	CHAIRMAN MALMUD: Thank you. Sally.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	77
1	MS. SCHWARZ: I still have concerns about
2	the 200 hours for the nuclear medicine physicians.
3	That's a concern of mine that I believe that that 200
4	hours is too high in terms of nuclear medicine
5	physicians in additional training.
6	MEMBER EGGLI: I would like to speak to
7	the logic of that. This is Dr. Eggli. My
8	understanding of the way the regulation is written, as
9	the subparts get higher numbers, those are both
10	greater complexity and higher risk for the patient.
11	But yet, as we look at Part 300 T&E requirements, Part
12	400 T&E requirements, and Part 600 T&E requirements,
13	they are identical.
14	If, in fact, there is an escalation in
15	risk and complexity of therapy as we go from Part 300
16	therapies to Part 400 therapies, to Part 600
17	therapies, then again it seems that the requirement
18	for 200 didactic hours in Part 300 is excessive
19	because it, in fact, matches the didactic requirement
20	for what are acknowledged to be higher risk and more
21	complex therapies that a Part 300 user could not do.
22	DR. BROSEUS: I'd like to just interject,
23	that when you get to the 300 level, the split starts
24	to become the form. The 300 is unsealed, 400 and 600
25	is sealed. And so you may have equal level of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	78
1	complexity doing Zevelin, and dealing with some of the
2	things that Dr. Nag was talking about
3	MEMBER EGGLI: I would, in fact, argue
4	that there is a different level of complexity. And,
5	in fact, you argue that - "you" being NRC staff -
6	argued that when you put the spheres into
7	brachytherapy, because you considered them more
8	complex than could be covered. And again, it looks to
9	me for all practical purpose, like a 300 material, so
10	that again, I think your own logic system says that
11	there is greater complexity and higher risk in manual
12	brachytherapy.
13	CHAIRMAN MALMUD: Excuse me. Did you want
14	to respond to that, Dr. Broseus?
15	DR. BROSEUS: One thing I want to say is
16	that the major split at that level is the physical
17	form.
18	CHAIRMAN MALMUD: Dr. Zelac, did you want
19	to respond to that?
20	DR. ZELAC: Yes, I'd like to make a point.
21	For 490 use and for 690 use, in addition to the
22	classroom and laboratory, plus work experience which
23	are common among 390, 490, and 690, the additional
24	risk levels that you speak of are dealt with by the
25	additional requirements for 490 and 390 in the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	79
1	alternate pathways to have three years of supervised
2	clinical experience. That doesn't appear for the 390,
3	so the higher risk levels that are associated with 490
4	and 690 are covered in the requirements by the
5	additional clinical experience of three years.
6	CHAIRMAN MALMUD: Thank you. Does that
7	clarify it? Does that satisfy your concern?
8	MEMBER EGGLI: No. My concern that 200
9	hours in Part 300 uses is excessive is not satisfied.
10	CHAIRMAN MALMUD: So your point is that
11	the 200 hours for 490 and 690 may be valid, but if
12	that's the case, your argument is that the 200 hours
13	for the 390 is excessive by comparison.
14	MEMBER EGGLI: Yes.
15	CHAIRMAN MALMUD: All right. Your
16	argument has been heard. Yes. Is it Mr. Moore or Dr.
17	Moore? I'm sorry.
18	MR. MOORE: Mr. Moore.
19	CHAIRMAN MALMUD: Mr. Moore.
20	MR. MOORE: I guess an other thing to
21	consider is that there is a very large group of
22	stakeholders that recommended something in the range
23	of 200, and that's the agreement states for the 300
24	series. And that's something we have to consider.
25	The working group certainly looked at that, and they

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

24

25

5 I do want to let the ACMUI know that there It has been docketed. 6 is a petition. It's from the 7 Organization of Agreement States, many, many agreement 8 states signed onto it. It has been accepted by the 9 agency as a petition. I think it's premature to say 10 that it will result in a separate rulemaking. There 11 are a number of options that the agency has in how to 12 deal with petitions. They range from addressing it as a comment, to handling it as an absolute separate 13 14 formal rulemaking in parallel to this rulemaking. It 15 certainly deals directly with these issues of didactic hours, both for the alternate pathway and for boards, 16 so it overlaps entirely with the issues that are here. 17 But it's a very formal mechanism in the rulemaking 18 19 process, and we will treat is very formally as an 20 agency, so the committee needs to know about that. 21 I guess I'd like to also go into something 22 will maybe take this above the technical that 23 discussion that we're having. The rule is due to the

date is non-violable unless the Commission gives us

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

Commission by the staff in mid-November.

(202) 234-4433

(202) 234-4433

That due

	81
1	relaxation in the date. We would need a strong basis
2	for an extension to that date, and so we're looking at
3	a due date to the Commission about a month from now.
4	If the ACMUI believes that additional time
5	is needed for the ACMUI to review and comment back to
6	us, or for the public to look at again for that
7	matter, then we would need you to provide us a comment
8	to that effect. One option you have is to make that
9	comment to us as a body, but beyond just telling us
10	that you need additional time to do that, I think you
11	would be well served in telling us the basis for
12	needing that additional time, because we would
13	certainly need to tell the Commission why we would
14	need the additional time. And then it's up to the
15	Commission to decide whether they're going to give the
16	staff additional time before we present the rule to
17	the Commission.
18	In addition, we've certainly heard you,
19	the body, saying today that public comment -
20	certainly, Dr. Diamond raised this - is needed on some
21	of the more significant areas, like 396. We checked
22	with our Office of General Counsel. The comments that

2 came in during the public comment period and the 23 changes that were made by the staff subsequent to the 24 public comment period, namely, the addition of 396 and 25

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

1this addition of didactic hours, don't pass the2threshold for going out for public comment again in3terms of significance, so we're not legally required4to go out for public comment again.5That said, if the ACMUI believes that we6should go out for public comment again, that's7certainly a comment that you can give us, and you can8make a recommendation that we should do so. Again, I9would recomment that you give us a reason for going10out for public comment again, and the staff would11certainly take that into consideration, and inform the12Commission that you recommended that, and the13Commission would take that under advisement.14CHAIRMAN MALMUD: Thank you, Mr. Moore.15Perhaps I16MR. MOORE: Charlie may have additional17comments about that.18MR. MILLER: I want to make some comments,19but Ralph has had his hand up, and if he has a point20he wants to make21CHAIRMAN MALMUD: Well, rather than doing22that at the moment, may we get back to Mr. Moore's23observation, because there are two issues that have24arisen, Mr. Moore - one came from Mr. Bailey, and that25is his view, meaning the view of the states that Part		82
3       terms of significance, so we're not legally required         4       to go out for public comment again.         5       That said, if the ACMUI believes that we         6       should go out for public comment again, that's         7       certainly a comment that you can give us, and you can         8       make a recommendation that we should do so. Again, I         9       would recomment that you give us a reason for going         10       out for public comment again, and the staff would         11       certainly take that into consideration, and inform the         12       Commission that you recommended that, and the         13       Commission would take that under advisement.         14       CHAIRMAN MALMUD: Thank you, Mr. Moore.         15       Perhaps I         16       MR. MOORE: Charlie may have additional         17       comments about that.         18       MR. MILLER: I want to make some comments,         19       but Ralph has had his hand up, and if he has a point         10       he wants to make         21       CHAIRMAN MALMUD: Well, rather than doing         22       that at the moment, may we get back to Mr. Moore's         23       observation, because there are two issues that have         24       arisen,	1	this addition of didactic hours, don't pass the
4to go out for public comment again.5That said, if the ACMUI believes that we6should go out for public comment again, that's7certainly a comment that you can give us, and you can8make a recommendation that we should do so. Again, I9would recommend that you give us a reason for going10out for public comment again, and the staff would11certainly take that into consideration, and inform the12Commission that you recommended that, and the13Commission would take that under advisement.14CHAIRMAN MALMUD: Thank you, Mr. Moore.15Perhaps I16MR. MOORE: Charlie may have additional17comments about that.18MR. MILLER: I want to make some comments,19but Ralph has had his hand up, and if he has a point10he wants to make21CHAIRMAN MALMUD: Well, rather than doing22that at the moment, may we get back to Mr. Moore's23observation, because there are two issues that have24arisen, Mr. Moore - one came from Mr. Bailey, and that	2	threshold for going out for public comment again in
5       That said, if the ACMUI believes that we         6       should go out for public comment again, that's         7       certainly a comment that you can give us, and you can         8       make a recommendation that we should do so. Again, I         9       would recommend that you give us a reason for going         10       out for public comment again, and the staff would         11       certainly take that into consideration, and inform the         12       Commission that you recommended that, and the         13       Commission would take that under advisement.         14       CHAIRMAN MALMUD: Thank you, Mr. Moore.         15       Perhaps I         16       MR. MOORE: Charlie may have additional         17       comments about that.         18       MR. MILLER: I want to make some comments,         19       but Ralph has had his hand up, and if he has a point         10       he wants to make         21       CHAIRMAN MALMUD: Well, rather than doing         22       that at the moment, may we get back to Mr. Moore's         23       observation, because there are two issues that have         24       arisen, Mr. Moore - one came from Mr. Bailey, and that	3	terms of significance, so we're not legally required
6 should go out for public comment again, that's 7 certainly a comment that you can give us, and you can 8 make a recommendation that we should do so. Again, I 9 would recommend that you give us a reason for going 10 out for public comment again, and the staff would 11 certainly take that into consideration, and inform the 12 Commission that you recommended that, and the 13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 16 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	4	to go out for public comment again.
<pre>7 certainly a comment that you can give us, and you can 8 make a recommendation that we should do so. Again, I 9 would recommend that you give us a reason for going 10 out for public comment again, and the staff would 11 certainly take that into consideration, and inform the 12 Commission that you recommended that, and the 13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 16 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that</pre>	5	That said, if the ACMUI believes that we
8 make a recommendation that we should do so. Again, I 9 would recommend that you give us a reason for going 10 out for public comment again, and the staff would 11 certainly take that into consideration, and inform the 12 Commission that you recommended that, and the 13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 10 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	6	should go out for public comment again, that's
9 would recommend that you give us a reason for going out for public comment again, and the staff would certainly take that into consideration, and inform the Commission that you recommended that, and the Commission would take that under advisement. CHAIRMAN MALMUD: Thank you, Mr. Moore. Perhaps I MR. MOORE: Charlie may have additional comments about that. MR. MILLER: I want to make some comments, but Ralph has had his hand up, and if he has a point he wants to make CHAIRMAN MALMUD: Well, rather than doing that at the moment, may we get back to Mr. Moore's observation, because there are two issues that have arisen, Mr. Moore - one came from Mr. Bailey, and that	7	certainly a comment that you can give us, and you can
10out for public comment again, and the staff would11certainly take that into consideration, and inform the12Commission that you recommended that, and the13Commission would take that under advisement.14CHAIRMAN MALMUD: Thank you, Mr. Moore.15Perhaps I16MR. MOORE: Charlie may have additional17comments about that.18MR. MILLER: I want to make some comments,19but Ralph has had his hand up, and if he has a point20he wants to make21CHAIRMAN MALMUD: Well, rather than doing22that at the moment, may we get back to Mr. Moore's23observation, because there are two issues that have24arisen, Mr. Moore - one came from Mr. Bailey, and that	8	make a recommendation that we should do so. Again, I
<pre>11 certainly take that into consideration, and inform the 12 Commission that you recommended that, and the 13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that</pre>	9	would recommend that you give us a reason for going
12 Commission that you recommended that, and the 13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 10 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	10	out for public comment again, and the staff would
13 Commission would take that under advisement. 14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 10 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	11	certainly take that into consideration, and inform the
14 CHAIRMAN MALMUD: Thank you, Mr. Moore. 15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	12	Commission that you recommended that, and the
15 Perhaps I 16 MR. MOORE: Charlie may have additional 17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	13	Commission would take that under advisement.
MR. MOORE: Charlie may have additional Comments about that. MR. MILLER: I want to make some comments, but Ralph has had his hand up, and if he has a point he wants to make CHAIRMAN MALMUD: Well, rather than doing that at the moment, may we get back to Mr. Moore's observation, because there are two issues that have arisen, Mr. Moore - one came from Mr. Bailey, and that	14	CHAIRMAN MALMUD: Thank you, Mr. Moore.
<pre>17 comments about that. 18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that</pre>	15	Perhaps I
18 MR. MILLER: I want to make some comments, 19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	16	MR. MOORE: Charlie may have additional
19 but Ralph has had his hand up, and if he has a point 20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	17	comments about that.
20 he wants to make 21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	18	MR. MILLER: I want to make some comments,
21 CHAIRMAN MALMUD: Well, rather than doing 22 that at the moment, may we get back to Mr. Moore's 23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	19	but Ralph has had his hand up, and if he has a point
that at the moment, may we get back to Mr. Moore's observation, because there are two issues that have arisen, Mr. Moore - one came from Mr. Bailey, and that	20	he wants to make
23 observation, because there are two issues that have 24 arisen, Mr. Moore - one came from Mr. Bailey, and that	21	CHAIRMAN MALMUD: Well, rather than doing
24 arisen, Mr. Moore - one came from Mr. Bailey, and that	22	that at the moment, may we get back to Mr. Moore's
	23	observation, because there are two issues that have
25 is his view, meaning the view of the states that Part	24	arisen, Mr. Moore - one came from Mr. Bailey, and that
11	25	is his view, meaning the view of the states that Part

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

396 is, in fact, from their view a substantive change. That's the term that he used.

3 Counsel for the NRC, you tell us, feels that it's not a substantive change, so there seems to 4 5 be a disagreement between the states and Counsel for the NRC as to what constitutes a substantive change. 6 7 But NRC has the final say, and I will defer to you in a moment, then there is no substantive change because 8 9 NRC has the final say. But Mr. Bailey did say, and I 10 was taking down notes as he was talking, that the states regard 396 as a substantive change and want it 11 12 to go public. That comment will come forward from the ACMUI, namely, a protest that the states regard 396 as 13 14 a substantive change which has not had adequate 15 opportunity for public comment. That's one point.

16 The second point is that Dr. Zelac agrees 17 with us, though it was not his presentation, that there is a dilemma in the board versus alternate 18 19 pathway in the fact that the alternate pathway does 20 dictate to the boards that which they should teach in 21 order for a graduate of the boards to qualify for 22 practicing, even though that individual may not have had the opportunity to, or may have failed taking the 23 24 board certification exam the first time. And I would 25 point out to you, which is a matter of concern to me,

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 that if we graduate a number of physicians after four 2 years of college, four years of medical school, four 3 years of residency training in radiation oncology to 4 enter a field that is nationally under-supplied and 5 create a roadblock to that individual practicing in a small town in a rural state, as represented by the 6 7 states, we will have created a great embarrassment for 8 us, the NRC, and I am sure it will reverberate in 9 Congress, because this is a field which is terribly short of individuals. The number of training programs 10 11 in radiation oncology is not enormous to begin with, 12 the number of graduates is not enormous, the shortage These individuals are not incompetent 13 is great. 14 because they didn't pass the boards. They simply 15 haven't passed the boards. There's a cut-off point, 16 so I believe that we have to look at this very carefully, both for the public good - mainly the 17 patients, as well as for those individuals who have 18 19 spent so many years in training. And with all due 20 respect, it's not quite analogous to passing the bar 21 There are differences, though there are exam. 22 Now I defer to distinguished Counsel. similarities. MS. CHIDAKEL: Thank you. I just want to 23 24 clarify a couple of things. First of all, please note 25 I did not say that 396 was not a substantive change.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

Actually, I specifically mentioned that 396 was one of the only changes, the only real changes that I saw to 2 the rule from the time that the rule was proposed. 3 Ι 4 specifically said that.

5 I didn't pass on the issue of whether it was a substantive change. In that connection, let me 6 7 raise - since we were talking about the Office of General Counsel's view on republication in the Federal 8 Register. The test is whether the change is such that 9 10 it is so far from what was proposed that the person 11 who read the rule would not have been given proper 12 notice that they could comment on that issue. I know that's kind of complicated, but what I'm trying to say 13 14 is the decision was made that this was not outside the 15 whole area of T&E, of training and experience, which was the focus of the rulemaking, so that is why I'm 16 talking about the hours now - the hours issue now, 17 396. That is why the decision was made by OGC 18 19 management that this was not necessary, legally 20 necessary to be republished. As I believe Scott 21 pointed out, certainly that doesn't mean we can't 22 republish it if there are policy issues, if the ACMUI wants to come out and make that argument and have a 23 24 basis, and give us reasons why they feel that this is 25 not -- while it isn't legally necessary, you know,

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

	86
1	certainly you can make an argument as to why you think
2	it's a good idea. But that is the issue. And the
3	issue is that we didn't see anything in the changing
4	in the hours issue that was totally, completely
5	outside of the scope of the proposed rule. Does your
б	answer your question?
7	You made another point. I'm sorry that it
8	has escaped me now.
9	CHAIRMAN MALMUD: There were two issues.
10	One was with respect to 396, and the other was with
11	respect to the dilemma created by establishing
12	criteria for the alternate pathway which would be
13	applicable to all residency training programs because
14	a certain number of people who complete their
15	residency successfully do not pass their board
16	certification within a year. By the time they've
17	graduated from the residency, completed the residency,
18	if you will; and, therefore, they would be limited in
19	their employment opportunities to very large
20	institutions where they'd be under the umbrella of
21	someone else, leaving the smaller facilities,
22	particularly those represented by the states which are
23	very often in smaller cities, uncovered by graduating
24	fellows.
25	DR. BROSEUS: I put on my health physicist

**NEAL R. GROSS** 

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

nat :
-------

1

2

17

## at for a minute.

## CHAIRMAN MALMUD: Please do.

3 DR. BROSEUS: And those are exactly the 4 people that sometimes the health physicist is 5 concerned about. Many serve as their own RSO, and that's in the rule. So the concern is to make sure 6 7 they have sufficient training. Now if they could get it with less hours and it applies to unsealed sources, 8 9 I'm assuming that these individuals, even though they're not board certified, can go out and practice 10 11 medicine, and that's not our concern. Okay. They're 12 a licensed physician. That's all it takes in the So the real question then is what is a 13 rules. 14 sufficient number of hours - and if we can focus on 15 that today and by the 18<sup>th</sup>, and satisfy both needs, we've gotten home. 16

## CHAIRMAN MALMUD: Dr. Diamond.

MEMBER DIAMOND: To answer Dr. Malmud's 18 19 question regarding do we think this needs to be 20 published for comment - based upon the discussions we 21 had earlier, my personal feeling, and this is not 22 represented by necessarily the radiation oncology 23 community. This is my personal feeling. My personal 24 feeling is that if the Statements of Consideration do reflect what I believe is a logical enumeration of 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

5 CHAIRMAN MALMUD: Thank you. Dr. Miller. MR. MILLER: If you will indulge me - as 6 7 a layman, I've listened to this discussion for about an hour and a half now, and I think it's been a lot of 8 9 discussion, debate, whatever you might want to call At the risk of sounding obnoxious, I hope I 10 it. 11 don't, but what we have to understand is the 12 Commission has given the staff a challenge of stabilizing the medical regulations. I think we all 13 14 agree - Dr. Diamond made a statement early, bad 15 regulation - if I remember the quote - with good 16 guidance is not the way to go. So no one wants to put 17 out - the staff certainly does not want to put out bad regulations. 18

That said, Dr. Broseus and the working group and members of my staff have been working extremely hard over the last couple of years to try to come up with regulations that will meet what NRC feels needs to be done with regard to regulating the community. However, taking in all stakeholder's comments, I'm drawn to the conclusion that there is no

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	89
1	regulation that we can promulgate in this area that is
2	going to satisfy everyone.
3	The agreement states have expressed some
4	serious concerns with regard to the regulations. Part
5	of what the agreement states dilemma is, they are co-
6	regulators with us, and in talking to many members of
7	the agreement states, I think their preference would
8	be to have something that's more prescriptive, that
9	would allow them to regulate.
10	In talking to members of the medical
11	community, I think people want flexibility so that
12	it's not so prescriptive, that people are limited in
13	what they can do, so that creates somewhat of a
14	dilemma to satisfy our stakeholders.
15	With regard to the dates, the schedules
16	for the promulgation of the rule, I don't want the
17	staff to come across as being bureaucratic, and we
18	have to meet this date come hell or high water. We're
19	going to meet it regardless of what people's views
20	are. However, my concern is for those of us in the
21	room who are old enough to have taken FORTRAN in
22	college and used it as a computer language, I don't
23	want to get stuck in an infinite do-loop in trying to
24	get this rule out, and that's what I feel that we're
25	getting to. We can't continue to have bring me a

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

90

rock, comment on it. Bring me a rock, comment on it. We have to be able to reach a point that we can get a rule that's meaningful, that puts people in place that we are satisfied are qualified to do this job, but not put such a burden on the industry, if I may call it that for this aspect of it, that they can't practice.

7 So if we were to go to the Commission, and I don't know the Commission's view of that, because 8 9 the Commission gets very anxious to not to want to 10 delay rulemakings. If I were to go to the Commission and ask them for more time, I'd have to be able to 11 articulate why that time is needed, what's going to 12 come out of it for the general good, and give them 13 14 some rigid answers as to why at the end of that time 15 we're going to come up with a product that's better.

16 The product that's better in my view would 17 need to have a consensus, at least by the staff, the committee - I don't know if we can get a consensus 18 19 with the agreement states - that what we've come up 20 with is workable. And if we were to go out and ask 21 for more time, make further changes to the language as 22 Roger and the working group have crafted it, I would ask the committee to have the involvement to the 23 24 extent that whatever is recrafted is liveable with the 25 committee, so that we don't have to come back here in

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

1six more months and continue to debate the issue as we2have for the last couple of years.3That said, as time marches on, part of the4reason we had to extend Subpart J was we were unable5to draw a conclusion over the past year, and6promulgate a rule that would give boards enough time7to do what they need to do with regard to8certification. My fear is we're going to end up in9that same dilemma again this year. That's a dilemma,10and what do we do about it? So that's the world that11I see that we, the regulator, live in. How can we get12through it?13CHAIRMAN MALMUD: Thank you. Are you14going to address the comments that Dr. Miller made,15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major25areas of what looks to me as changes in this piece		91
3That said, as time marches on, part of the4reason we had to extend Subpart J was we were unable5to draw a conclusion over the past year, and6promulgate a rule that would give boards enough time7to do what they need to do with regard to8certification. My fear is we're going to end up in9that same dilemma again this year. That's a dilemma,10and what do we do about it? So that's the world that11I see that we, the regulator, live in. How can we get12through it?13CHAIRMAN MALMUD: Thank you. Are you14going to address the comments that Dr. Miller made,15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	1	six more months and continue to debate the issue as we
reason we had to extend Subpart J was we were unable to draw a conclusion over the past year, and promulgate a rule that would give boards enough time to do what they need to do with regard to certification. My fear is we're going to end up in that same dilemma again this year. That's a dilemma, and what do we do about it? So that's the world that I see that we, the regulator, live in. How can we get through it? CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. All right. And we don't have an alternative. I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	2	have for the last couple of years.
5to draw a conclusion over the past year, and6promulgate a rule that would give boards enough time7to do what they need to do with regard to8certification. My fear is we're going to end up in9that same dilemma again this year. That's a dilemma,10and what do we do about it? So that's the world that11I see that we, the regulator, live in. How can we get12through it?13CHAIRMAN MALMUD: Thank you. Are you14going to address the comments that Dr. Miller made,15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	3	That said, as time marches on, part of the
6 promulgate a rule that would give boards enough time 7 to do what they need to do with regard to 8 certification. My fear is we're going to end up in 9 that same dilemma again this year. That's a dilemma, and what do we do about it? So that's the world that 11 I see that we, the regulator, live in. How can we get 12 through it? 13 CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? 16 MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where 19 we are with what Mr. Moore said, we're kind of 20 really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more 23 weeks to address these changes, because I'd like - 24 again, this is my opinion - what I see are three major	4	reason we had to extend Subpart J was we were unable
<ul> <li>to do what they need to do with regard to</li> <li>certification. My fear is we're going to end up in</li> <li>that same dilemma again this year. That's a dilemma,</li> <li>and what do we do about it? So that's the world that</li> <li>I see that we, the regulator, live in. How can we get</li> <li>through it?</li> <li>CHAIRMAN MALMUD: Thank you. Are you</li> <li>going to address the comments that Dr. Miller made,</li> <li>Dr. Lieto?</li> <li>MEMBER LIETO: Yes, and then some. I</li> <li>guess what I see as a problem is the sort of like</li> <li>almost less than a week deadline that we have, where</li> <li>we are with what Mr. Moore said, we're kind of</li> <li>really, from my perspective, being put into a corner.</li> <li>All right. And we don't have an alternative.</li> <li>I think if we could maybe have a few more</li> <li>weeks to address these changes, because I'd like -</li> <li>again, this is my opinion - what I see are three major</li> </ul>	5	to draw a conclusion over the past year, and
8 certification. My fear is we're going to end up in 9 that same dilemma again this year. That's a dilemma, and what do we do about it? So that's the world that 11 I see that we, the regulator, live in. How can we get 12 through it? 13 CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? 16 MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. All right. And we don't have an alternative. 21 I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	6	promulgate a rule that would give boards enough time
9 that same dilemma again this year. That's a dilemma, and what do we do about it? So that's the world that I see that we, the regulator, live in. How can we get through it? 13 CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? 16 MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more 23 weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	7	to do what they need to do with regard to
10and what do we do about it? So that's the world that11I see that we, the regulator, live in. How can we get12through it?13CHAIRMAN MALMUD: Thank you. Are you14going to address the comments that Dr. Miller made,15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	8	certification. My fear is we're going to end up in
I see that we, the regulator, live in. How can we get through it? CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. All right. And we don't have an alternative. I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	9	that same dilemma again this year. That's a dilemma,
12 through it? 13 CHAIRMAN MALMUD: Thank you. Are you going to address the comments that Dr. Miller made, Dr. Lieto? 16 MEMBER LIETO: Yes, and then some. I guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	10	and what do we do about it? So that's the world that
13 CHAIRMAN MALMUD: Thank you. Are you 14 going to address the comments that Dr. Miller made, 15 Dr. Lieto? 16 MEMBER LIETO: Yes, and then some. I 17 guess what I see as a problem is the sort of like 18 almost less than a week deadline that we have, where 19 we are with what Mr. Moore said, we're kind of 20 really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more 23 weeks to address these changes, because I'd like - 24 again, this is my opinion - what I see are three major	11	I see that we, the regulator, live in. How can we get
14going to address the comments that Dr. Miller made,15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	12	through it?
15Dr. Lieto?16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	13	CHAIRMAN MALMUD: Thank you. Are you
16MEMBER LIETO: Yes, and then some. I17guess what I see as a problem is the sort of like18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	14	going to address the comments that Dr. Miller made,
17 guess what I see as a problem is the sort of like almost less than a week deadline that we have, where we are with what Mr. Moore said, we're kind of really, from my perspective, being put into a corner. All right. And we don't have an alternative. I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	15	Dr. Lieto?
18almost less than a week deadline that we have, where19we are with what Mr. Moore said, we're kind of20really, from my perspective, being put into a corner.21All right. And we don't have an alternative.22I think if we could maybe have a few more23weeks to address these changes, because I'd like -24again, this is my opinion - what I see are three major	16	MEMBER LIETO: Yes, and then some. I
19 we are with what Mr. Moore said, we're kind of 20 really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more 23 weeks to address these changes, because I'd like - 24 again, this is my opinion - what I see are three major	17	guess what I see as a problem is the sort of like
20 really, from my perspective, being put into a corner. 21 All right. And we don't have an alternative. 22 I think if we could maybe have a few more 23 weeks to address these changes, because I'd like - 24 again, this is my opinion - what I see are three major	18	almost less than a week deadline that we have, where
All right. And we don't have an alternative. I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	19	we are with what Mr. Moore said, we're kind of
I think if we could maybe have a few more weeks to address these changes, because I'd like - again, this is my opinion - what I see are three major	20	really, from my perspective, being put into a corner.
23 weeks to address these changes, because I'd like - 24 again, this is my opinion - what I see are three major	21	All right. And we don't have an alternative.
24 again, this is my opinion - what I see are three major	22	I think if we could maybe have a few more
	23	weeks to address these changes, because I'd like -
25 areas of what looks to me as changes in this piece	24	again, this is my opinion - what I see are three major
	25	areas of what looks to me as changes in this piece

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 One has to do with the radiation safety here. 2 officer, which appears to have met the intent of the 3 ACMUI, but again I'm going to come back to this - I 4 want to see this in the context of the whole Part 35. 5 The training and experience, which probably is the number one issue that is before this group, and the 6 7 grandfathering aspect, especially with respect to 8 authorized medical physicists.

I think if we - again my opinion is that 9 10 if we could have all these changes, including the 11 proposed by the working group, before us and maybe in 12 a teleconference in the next week or so with the committee, or maybe even a subcommittee if the Chair 13 14 deems appropriate, to look at all these changes, and 15 then get back to the committee as a whole, we might be able to address these within a matter of two, three, 16 17 four weeks at most.

Now I don't know if that's unreasonable. 18 19 I mean, if that's too long, then I guess we're painted 20 into a corner, and I don't have a suggestion. So 21 that's a suggestion. I do still have some points to 22 make on the hours, and Dr. Eqgli's issue about 390 23 So I don't know if we want to address that hours. 24 comment that I --

CHAIRMAN MALMUD: Well, why don't you

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

(202) 234-4433

finish your comments, and then we'll move on to the next one.

1

2

3 MEMBER LIETO: I tried to -- I think 4 there's some -- trying to understand where the working 5 group came from in terms of the number of hours that are proposed in here. I think what have been also --6 7 the 392s, and 94, and 96 in here also, but if you look at Subpart J, which is the current where we're at 8 9 right now, if I am interpreting 930 right now correctly, it requires 80 hours of training 10 and 11 experience, plus 13 thyroid cases, is the way 12 currently is the 390 requirement. And that the 80 hours would be the didactic portion of training and 13 14 experience.

15 If we look at the proposed 390, we've now gone up from 80 hours to 700 hours, and 200 of those 16 17 700 hours, which were 80 before; in other words, we've gone from 80 to 200 hours of didactic training, 18 19 laboratory and classroom experience. If we look at 20 the 392 and 4, which are the thyroid in the parenteral 21 requirements requiring 80 hours for thyroid, 80 hours 22 for the other - which comes out to 160 hours if you 23 wanted to sort of go back the route of I want to get 24 parenteral, and then I want to get thyroid without 25 going the 390 route. Basically, I'm trying to get to

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	94
1	some type of an equivalency.
2	The 200 hours still is almost a factor of
3	one-third higher, just even using that relationship.
4	So it gets, I think if we're even trying to keep
5	things at even scale, the 200 hours is probably a
6	factor of maybe two or close to that high. In other
7	words, maybe something like 100 to 120 or 30 hours
8	might be more appropriate for the 390 aspects, and
9	bring it more into line what we're requiring for the
10	other uses. But not having sort of a sense of where
11	these numbers came from originally, other than they
12	were just proposed by, I'm assuming the OAS. Is that
13	correct? Is that where the numbers are - okay. So
14	that might be maybe a starting point to suggest in
15	adjusting the 200 hours, if that's one of the things
16	we wanted to achieve right now.
17	CHAIRMAN MALMUD: Does that complete your
18	comment?
19	MEMBER LIETO: Yes, thank you.
20	CHAIRMAN MALMUD: May I oh, Dr.
21	Williamson.
22	MEMBER WILLIAMSON: I have a comment, too,
23	which I think is relevant. I think I agree with Dr.
24	Diamond that from radiation oncology and medical
25	physics point of view, this seems to me to be a great

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

improvement, and within the limits of my sort of ability to digest the details of legalistic language, I think it's resolved many of the major concerns that our community has had.

5 Having said that, I'm a strong believer in the dictum that the devil is in the details, and there 6 7 are changes of commas and ands, and ors that are very difficult to follow. And I have not been able to 8 descend to that sort of level of detail, and indeed 9 working with others outside of this group is the best 10 I think to shake down this regulation and 11 way 12 determine whether there are small bits.

The second point is, it does seem like a 13 14 substantive issue of the 200 hours in 390 is a 15 significant concern, and could cause harm to our colleagues' practice in therapeutic nuclear medicine. 16 And I would defer to Dr. Eggli's recommendation that 17 the definition of the additional hours or whatever be 18 19 better calibrated to the actual teaching practices 20 that are now used in the program, that exist -21 assuming that we accept the premise that what is being 22 done now is an adequate standard of educational rigor. 23 And I guess the third point I wanted to 24 make is that I would like to follow-up on a question 25 Mr. Bailey has -- a challenge Mr. Bailey has put

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

before us. He's made, in addition to the -- he's indicated the agreement states are dissatisfied with the current final regulation on three grounds. I think the issue of substantiveness is clear. Then there's the issue of vagueness, and I guess the charge that the regulation is not clear.

7 Now I spent three hours reviewing this on my way here, and within my limitations I thought it 8 9 reasonably clear. Of course, I have some was 10 questions - I am not a lawyer, and I'm not an expert 11 in regulatory affairs. I'm an amateur, but it does 12 seem like the nature of this regulation has a certain level of complexity that is essentially the bottom 13 14 line. You have to distinguish between Subpart J, 15 which was a temporary regulation, and what happens in That's a sort of a required element of 16 the future. 17 complexity, when you have a two-track system where the boards are not hard-wired into 18 the regulatory 19 language, they need to have complying regulations to 20 define what are appropriate boards that is going to 21 introduce an element of complexity that you simply 22 cannot dispense with, if that's the approach that is going to be taken. You have a set of criteria for the 23 24 boards, and you have a set of criteria for the 25 alternate pathway. I think that there's a consensus,

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

(202) 234-4433

1 maybe the agreement states don't share it, but that 2 nature of the boards is such that their the requirements are not written in the language of the 3 4 alternate pathway, and that public health, which is an 5 important goal - not just public safety, but public health requires that the system of health care 6 7 education not be disrupted, unless there's really and 8 overriding concern. So grant that. 9 So having been through this, I mean I guess I would ask Mr. Bailey to expand on this, and 10 11 tell us what is wrong with this regulation. And 12 secondly, since the 700 and 200 hours has been put into the alternative pathway, what is the concern of 13 14 the agreement states? 15 DR. BROSEUS: Mr. Chairman, I must beg for a short break. 16 17 CHAIRMAN MALMUD: Dr. Broseus asked for a short break, and I think that's a reasonable thing 18 19 to ask for at 10:15. Does Mr. Essig agree? 20 MR. ESSIG: I want to give Dr. Broseus the 21 relief that he's seeking. However, I have one point 22 with regard to the agenda. We had allocated time for 23 the committee to write a memo, and I realize we 24 obviously aren't at that point. But what I wanted to 25 raise is there are four items remaining on the agenda

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

5 Another agenda item is on the National Source Tracking System, which was an information brief 6 7 for the committee. We could do that at another time. 8 We are prepared to do it, we can do it another time, 9 so that would save us some time there. We have two hours allocated for Dr. Vetter to present the ICRP-10 11 2005 recommendations. That is something that perhaps 12 we could do in abbreviated form. The purpose of it was for Dr. Vetter to seek the committee's views, 13 14 because he is representing the committee next week at 15 an ACNW working group which is convening for a day, and he wants to make sure that he carries any concerns 16 that the committee had. Now I realize that some of 17 you maybe have little or no interest in the ICRP-2005 18 19 recommendations, and others do have some, and so I 20 just raise that as maybe an item that we could either 21 -- we could shorten or handle it in some other way. 22 CHAIRMAN MALMUD: Dr. Vetter indicates that he may not require the two hours, and it could be 23 24 handled in a lesser period of time.

MR. ESSIG: Okay.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

25

1

2

3

4

(202) 234-4433

ĺ	99
1	CHAIRMAN MALMUD: I just asked him that
2	question while you were speaking.
3	MR. ESSIG: Okay. Fine. And then the
4	fourth item is the tail-end, sort of the wrap-up to
5	make sure we have agreement on the action items, and
6	that kind of thing. I guess a break is in order, but
7	after we come back then I would like to still keep on
8	the table, if we could, the notion of whether or not
9	some thoughts can come forth in a collective manner
10	from the committee for the rule that we've been
11	talking about.
12	CHAIRMAN MALMUD: Well, having listened to
13	all of the opinions, I think that we probably can.
14	We'll do that after the break.
15	(Whereupon, the proceedings in the above-
16	entitled matter went off the record at 10:17 a.m. and
17	went back on the record at 10:35 a.m.)
18	CHAIRMAN MALMUD: You're all invited to
19	come back to the table for reconvening. Dr. Broseus
20	is ready.
21	DR. BROSEUS: Thank you for the break.
22	CHAIRMAN MALMUD: I enjoyed sharing it
23	with you.
24	(Laughter.)
25	CHAIRMAN MALMUD: It was not joint. It

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	100
1	was sequential.
2	May I do a little introduction to the
3	reconvening of the last session?
4	MR. ESSIG: You may, but I just want to
5	make one point first, which is the adjustment in the
6	agenda.
7	CHAIRMAN MALMUD: Yes.
8	MR. ESSIG: The abnormal occurrence,
9	criteria discussion which we want to see the views of
10	the committee, I had talked with Ms. Jones, and she's
11	agreeable to come back at one o'clock.
12	CHAIRMAN MALMUD: Thank you.
13	In the latter part of the last session and
14	during the break, I had the opportunity to speak to
15	some of the members of the committee, and if I may, I
16	would like to summarize what might be an appropriate
17	action at this point.
18	Let's just review for a moment the
19	material on Dr. Broseus' slide. Nuclear pharmacy,
20	35.55, total hours 700, didactic 200, <u>in vitro</u> 35.190,
21	total hours 60, didactic eight, diagnostic only
22	35.290, 700 hours including 80 didactic, and then
23	therapeutic and diagnostic 35.390, 700 total hours,
24	200. That's unsealed.
25	Then if we had extended, if Dr. Broseus
I	·

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	101
1	would give us editorial permission to extend his
2	table, the next line would be 35.396, 80 hours
3	specifically for unsealed sources applying only to
4	Board certified radiation oncologists. Is it Board
5	certified or Board eligible?
6	DR. BROSEUS: Board certified.
7	CHAIRMAN MALMUD: Board certified
8	radiation oncologists.
9	DR. BROSEUS: Or authorized users.
10	CHAIRMAN MALMUD: Or AUs, plus three
11	cases.
12	Then we have 35.490 and 25.690, each of
13	which would have 700 hours in the first column, 200
14	hours in the second column, and that's sealed, more
15	complex, to include classroom laboratory work and
16	three years of clinical experience.
17	Does that summarize factually what would
18	appear in that table or what does appear in that
19	table?
20	DR. BROSEUS: Sounds right to me.
21	CHAIRMAN MALMUD: Thank you.
22	Now, the real issue that seems to be
23	percolating around the table is the issue of didactic
24	hours, not the issue of total hours, and here we come
25	back to the definition of didactic, which we raised in

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	102
1	an earlier session.
2	Didactic includes a classroom and
3	laboratory experience. No one has an argument with
4	that as long as laboratory experience includes
5	clinical laboratory experience. When I'm in a
6	clinical laboratory with a resident, I'm instructing
7	the resident. The resident is essentially functioning
8	in a training role.
9	The proof of that is that I could probably
10	do three to five times as much work without the
11	resident present as I am with the resident
12	(Laughter.)
13	CHAIRMAN MALMUD: because I am
14	instructing the resident.
15	DR. BROSEUS: I thought it was a patient.
16	CHAIRMAN MALMUD: And Dr. Eggli and Dr.
17	Diamond and Dr. Nag all have the same experience. So
18	that is didactic time. It's a one-to-one didactic
19	time, much better than sitting in the classroom with
20	600 students in a 101 course in college, which is
21	certainly didactic by anyone's definition.
22	So I think that the issue arises for the
23	definition of didactic, and the concern, quite
24	frankly, that's coming from various members of the
25	committee is that no one in this room but a lower

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

level employee of minimal experience becomes overly enthusiastic and decides that the training program at Harvard or at Yale or at Washington University or at Hopkins does not have 200 hours of classroom time. Hence it does not meet the requirements of the NRC, and that that employee's citing of that program can escalate into something which would be embarrassing to everyone involved.

So the question really is not any of the 9 issues that we've reviewed, but the issue, again, of 10 11 what is didactic. If didactic includes instruction in laboratory, and clinical 12 the classroom, in the laboratory, everything on the table is acceptable, I 13 14 believe, to everyone who has raised a concern about 15 this, including the states who wanted to have these 16 numbers of hours as they are.

Now, is that acceptable to the staff hereof NRC? What do you consider to be didactic?

19 DR. BROSEUS: Let me discuss some of the 20 issues that have come up. One of them is expressed in 21 a concern from the states that the 700 hours includes 22 the classroom laboratory training in safety related items that are enumerated, for example, 390, under 23 24 little Roman i. Little Roman ii is supervised 25 clinical experience loosely termed. Okay?

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

8

The concern of some states is that that 2 time over there would be used to count when they're 3 not really learning safety. That's the idea, and so 4 if there is a definition or re-definition, they have to be careful about that.

You know, I personally believe from my 6 7 experience as a health physicist -- and is there something we can do with the ringing on the speaker, 8 9 please? It's driving me nuts -- that a physician, for example, or a pharmacist working with a physician or 10 11 a supervisory nuclear pharmacist is learning safety in 12 the clinic lab, you know, but some of the arguments are, well, the use in time reading scans and call that 13 14 classroom and laboratory training, and so that's the 15 concern, I believe, that people have.

16 Also, you know -- I'm sorry. That's all. Well, then you and I 17 CHAIRMAN MALMUD: agree, if I interpreted what you say correctly, that 18 19 when a physician and/or physicist and/or radiochemist 20 or pharmacist is working with the resident in 21 providing care to a patient while being instructed in 22 safe handling of radioisotopes in, for example, doing 23 lymphocytography in the separating of the dose into 24 its various syringes in gloving, in indicating what 25 the radiation exposure might be to both the worker and

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

	105
1	to the patient from this, that that is didactic
2	training on a one-to-one basis, much more valuable
3	than sitting in a classroom with 400 students in a
4	Physics 101 course. This is one-to-one didactic
5	training by a fully qualified professional.
6	If we accept that as didactic, then a
7	portion of the time that we are spending with the
8	residents is, in fact, didactic. I can't imagine any
9	better training.
10	MR. MOORE: Dr. Malmud, this is Scott
11	Moore.
12	I think the intent of the staff is that
13	with regard to classroom and lab, a portion of the
14	time that's spent on rad protection instrumentation,
15	rad physics, chemistry, and rad bio, if it's performed
16	in, say, a nuclear medicine hot lab, if it's performed
17	in a scan room, if it's performed in an I-191
18	administration room, if it's focused on those issues,
19	radiation protection instrumentation, rad physics,
20	chemistry, or rad bio would count as didactic
21	training.
22	CHAIRMAN MALMUD: Now, having said that,
23	Mr. Moore, is there any indication to the training
24	program directors that this, in fact, NRC policy that
25	would be accepted so that when perhaps a lower level

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 employee of a region comes into a department and challenges whether or not this is didactic, there is 2 3 an NRC statement that what you just said is true? 4 MR. MOORE: I think it's up to us to make 5 that clear in the final rule. The staff's preference in the 6 would be to make that statements of 7 consideration, which Roger refers to as the supplementary information. The reason the staff would 8 9 prefer to put that in the statements of consideration 10 is because we're concerned about unintended consequences by putting it into the rule itself. 11 12 CHAIRMAN MALMUD: Amen. So am I. MR. MOORE: The terminology that is used 13 14 in the current rule is classroom and laboratory. We 15 have taken a broad interpretation of classroom and 16 laboratory, and I think we can put text in the statements of consideration that reiterate what I just 17 said, that we've taken a broad interpretation of 18 19 classroom and laboratory, and we consider classroom 20 and laboratory to include, you know, the nuclear 21 medicine hot lab, the scanning room, patient rooms, as 22 long they cover the required topics in rad safety and protection, instrumentation, rad physics, chemistry, 23 radiation biology in those locations. 24 25 CHAIRMAN MALMUD: Having said that, may I

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	107
1	ask the members of the committee if they are,
2	therefore, with that definition, willing to move
3	forward with approval of the current recommendations?
4	Would someone wish to make a motion?
5	MEMBER DIAMOND: I believe there's a
6	question.
7	MEMBER SULEIMAN: Sorry. I want
8	clarification.
9	CHAIRMAN MALMUD: Okay.
10	MEMBER SULEIMAN: You know, the sign is
11	changing where you're doing computer training, remote
12	site training.
13	DR. HOLAHAN: On-line training.
14	MEMBER SULEIMAN: That's right. On-line
15	training. Would that be considered part of the
16	didactic classroom?
17	CHAIRMAN MALMUD: If it's related to
18	radiation safety training, if it is radiation safety
19	training. If it's simply transmitting images which
20	has nothing whatsoever to do with radiation protection
21	and radiation safety, in my mind and I speak for
22	myself, not for the group. I haven't polled them on
23	this I wouldn't consider that radiation safety
24	training.
25	On the other hand, if it relates to the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	108
1	calculation of doses, if it relates to the correct
2	to the standardization of instrumentation, if it
3	relates to the correct checking of a dose in a well
4	counter, to the calibration of a well counter, the
5	answer is absolutely.
6	PARTICIPANT: We would agree with Dr.
7	Malmud's response.
8	CHAIRMAN MALMUD: Dr. Vetter.
9	MEMBER VETTER: In the spirit of moving
10	forward, I am inclined to agree with these, but I must
11	say and from personal experience in being involved in
12	the training of residents that on the whole they are
13	very, very smart people, and it simply does not take
14	200 hours to give them the training in the area of 300
15	uses. That's simply a lot of time.
16	What do we do? We give them reading
17	assignments. We'll give them NCRP 116 and some other
18	things and then they come back and we'll discuss that
19	together, but I just want to say they're very smart
20	people, and you can give them this information in much
21	less than 200 hours.
22	DR. BROSEUS: Does your training program
23	include laboratory time exercises with the geiger
24	counter?
25	MEMBER VETTER: All of these things, oh,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	109
1	yes, all of these things.
2	CHAIRMAN MALMUD: I think that Dr. Eggli
3	was next.
4	Dr. Eggli.
5	MEMBER EGGLI: Yeah, and again, I need to
6	stay say that I think 200 is way too long and we need
7	to look at a proportion of time. I had these
8	residents for 1,000 hours. Then 200 hours represented
9	a portion of that total 1,000 hours. It represented
10	20 percent.
11	Now that I have these residents for 700
12	hours, 200 hours on safety represents a significantly
13	larger portion of their time and, again, compromises
14	my ability to make them clinically competent as well
15	as safe.
16	And I think we need to try to maintain
17	some sort of balance here. I think 200 hours is
18	really way more than it takes to train them in safety,
19	and I need to train a well rounded, clinically
20	competent, safe nuclear medicine physician, and this
21	new regulation and, again, I realize this is
22	alternate pathway, but I have to train to alternate
23	pathway this new regulation will hamper my ability
24	to make them clinically competent.
25	DR. BROSEUS: This is draft right now.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	110
1	Let me emphasize that. So what is your the
2	irreducible minimum?
3	MEMBER EGGLI: Truthfully, I think for 200
4	uses 50 hours is adequate, and for 300 uses 100 hours
5	is adequate.
6	CHAIRMAN MALMUD: Thank you, Dr. Eggli.
7	MEMBER LIETO: I was just going to make a
8	motion to the committee. It seems like the whole
9	stumbling block here is this number of hours for 390.
10	I think we're all in agreement pretty much with
11	everything else. So I'd like to make a motion that
12	the committee propose 80 hours of didactic training
13	and experience for 35.390 authorized uses, plus the
14	already stated 12 varied therapy cases.
15	CHAIRMAN MALMUD: Is there a second to
16	that motion?
17	MS. SCHWARZ: I second the motion.
18	CHAIRMAN MALMUD: Dr. Schwarz seconds the
19	motion.
20	Is there discussion of that motion? I'm
21	sorry. Sally.
22	MS. SCHWARZ: From my perspective
23	certainly what we're trying to teach is safe handling
24	of isotopes. With 290, nuclear medicine physicians
25	receive a significant amount of training to handle

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	111
1	unsealed sources.
2	To move from the unsealed sources in
3	nuclear medicine to the therapeutic
4	radiopharmaceuticals that are also trained in nuclear
5	medicine, I believe that they certainly have within
6	that 80 hours a significant amount of time in terms of
7	the safe handling of unsealed radioactive sources.
8	They are different types, and there are
9	different considerations, but I think that the total
10	80 hours is a sufficient amount of time to cover what
11	is required.
12	CHAIRMAN MALMUD: Dr. Nag.
13	MEMBER NAG: Yes. Well, one possible good
14	thing you could do is then you could eliminate now the
15	396 because 396 requires a no, requires a Board
16	certified radiation oncologist to have 80 hours.
17	MEMBER EGGLI: Specifically for unsealed
18	sources.
19	MEMBER NAG: Right, and then if they can
20	qualify under 396, they will also now be able to
21	qualify under 35.390 or 35.390 will have
22	MEMBER EGGLI: No, No.
23	MEMBER NAG: Why not?
24	MEMBER EGGLI: Because the 700 hours.
25	MEMBER NAG: but the 700 is I agree

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	112
1	with what you said before. The 700 can overlap
2	between the different training modalities.
3	MEMBER WILLIAMSON: The 700 for unsealed
4	radioactive sources. I think you would be making a
5	big mistake to oppose these.
6	CHAIRMAN MALMUD: Mr. Lieto.
7	MEMBER LIETO: I would disagree with Dr.
8	Nag because 396 only addresses parenteral
9	applications. Three, ninety includes both that plus
10	the oral. So 390 would be a much larger application
11	of unsealed radiopharmaceuticals.
12	CHAIRMAN MALMUD: There's a motion on the
13	table.
14	I beg your pardon?
15	DR. BROSEUS: You're shooting yourself in
16	the foot if you put 396 up.
17	CHAIRMAN MALMUD: There is a motion on the
18	table for approval and discussion.
19	Mr. Moore?
20	MR. MOORE: With respect to the
21	discussion, I guess an important factor that everybody
22	needs to be aware is that the agreement states in the
23	proposed rule, I believe it was Alabama and Iowa did
24	recommend a specific number, 200 of didactic hours in
25	comments on the proposed rule, and they may have

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	113
1	recommended in the petition itself 200 hours also.
2	And so if the ACMUI does pass such a
3	motion, then the staff will have to consider the
4	motion relative to the comments on the proposed rule
5	and also the petition itself. So Mr. Bailey may have
6	some comments relative to that.
7	CHAIRMAN MALMUD: Dr. Diamond.
8	MEMBER DIAMOND: I would defer to Mr.
9	Bailey.
10	CHAIRMAN MALMUD: Mr. Bailey is looking
11	for something.
12	MEMBER BAILEY: Go ahead. Let me find the
13	paper.
14	MEMBER DIAMOND: Because there's a motion
15	on the table, I'd like to discuss it further.
16	Ralph, if I may be clear, in your motion
17	it would be 80 hours specifically of didactic for 390
18	in the context of a total of 700 hours; is that
19	correct?
20	MEMBER LIETO: That's correct.
21	MEMBER DIAMOND: Thank you.
22	MEMBER NAG: Again, on that same thing,
23	now you are having a 390 for 80 hours, 390. This
24	includes both the parenteral and the oral
25	administration for unsealed sources.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	114
1	MEMBER DIAMOND: That's correct.
2	MEMBER NAG: In the 396 pathway, you are
3	now having a radiation oncologist who has done oral
4	therapy to now require also the same number of 80
5	hours only for the parenteral portions. So that does
6	not really match. I mean, I would say in that case
7	that for the 396 you would probably require a letter
8	number than the 80.
9	CHAIRMAN MALMUD: That doesn't address the
10	motion on the table, which we'd like to move forward
11	first. Are you addressing the motion on the table,
12	Ralph?
13	MEMBER LIETO: Yes. I would like to also
14	point out that 390 requires 12 cases total. In other
15	words, three cases of each of the four different
16	classes of radiopharmaceutical therapies, whereas in
17	396 it only addresses three cases of any one form of
18	the parenteral.
19	So from the standpoint of the clinical
20	case documentation, 390 is, again, more varied and has
21	a wider range of requirements than the 396.
22	CHAIRMAN MALMUD: Thank you.
23	The motion on the table is to reduce the
24	200 didactic under 35.390 to 80. Is everyone happy
25	and the the number of an above of a second sec

with the number 80 or -- oh, more discussion. Mr.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

1

2

3

4

5

6

MEMBER BAILEY: I was just going to respond. I quickly looked through the petition and whereas 200 is referenced, I only see it specifically in reference to the pharmacist, and that the petition really asks for simply some numbers to be put in.

7 And I know these numbers have been tossed around, but as late as October 5th, there was no -- it 8 9 was the first time there was really a poll on whether or not the agreement states agreed with these numbers. 10 11 So I don't know that the agreement states have agreed 12 on these numbers because the poll has not been tabulated to my knowledge, and I know at least one 13 14 state, since it was me, did not agree with the numbers 15 and, in fact, suggested that basically the equivalent of what I considered one graduate health physics 16 course, three lecture hours and four hours of lab for 17 120 hours 18 one semester about would be or an 19 appropriate amount of training in the health physics 20 radiation protection.

Now, people have come back and made arguments for 200, but those arguments are a little, to my way of thinking, a little weird in that they are comparing what an agreement state person who goes to the Oak Ridge five-week course gets.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

115

	116
1	So I don't think we're talking about an
2	equivalent situation.
3	I also want to take this opportunity.
4	When I spoke before about clarity and all, I was
5	speaking not for the agreement statements in a poll
6	that had been taken, but as a personal opinion having
7	worked for two agreement states and how we adopted
8	regulations. I wanted the record to be clear.
9	CHAIRMAN MALMUD: Thank you for clarifying
10	that.
11	Dr. Diamond, did you have a comment?
12	MEMBER DIAMOND: Yes. I would just
13	comment that given that 390 does require 700 total
14	hours, given the requirements for three cases for each
15	of the four classes, I think it would be reasonable to
16	keep the 700 total hours and proceed in a favorable
17	fashion with the reduction of 200 hours didactic to 80
18	hours of didactic, given that I do not believe this
19	would have any negative impact on public safety.
20	CHAIRMAN MALMUD: Any further discussion
21	of this item on the table?
22	If not, may we vote? All in favor of
23	this?
24	(Show of hands.)
25	CHAIRMAN MALMUD: Any opposed?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	117
1	(No response.)
2	CHAIRMAN MALMUD: Any abstentions?
3	(Show of hands.)
4	CHAIRMAN MALMUD: It carries with
5	unanimity except for one abstention. So the
6	recommendation is that the table presented by Dr.
7	Broseus be amended for 35.390 to show 700 hours in
8	Column 1 and 80 hours in Column 2, recognizing that
9	that's plus 12 cases, three of each type of the four,
10	and this is for unsealed sources.
11	DR. BROSEUS: I might make a small
12	correction. Twelve cases are not required in all
13	situations. It was a footnote which grants us at
14	least three cases in Category G2, also satisfies
15	Category G1. So one can get away with nine cases.
16	CHAIRMAN MALMUD: I stand corrected
17	because your table didn't specify that. You are
18	correct.
19	DR. BROSEUS: Yeah. Secondly, we had a
20	motion. I've recorded that to go back to the staff
21	with. It's useful also though to have a strong basis
22	for this. What is the committee saying in terms of a
23	basis of sufficiency of 80 hours?
24	CHAIRMAN MALMUD: That which I have heard,
25	and please, anyone augment or change my comments if

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

you wish, is that Category 35.290, which is diagnostic 1 2 only, includes 700 plus 80 of didactic, and the 3 therapeutic application on top of the diagnostic is 4 generally covered in the 80 hours that are presented 5 in the diagnostic. Since the therapeutic relates primarily to the use of beta emitters, the same 6 7 radiation safety practices apply, as do for the gamma emitters, though there's recognition that beta and 8 gamma emitters are different and that the radiation 9 burdens from them are different, and that 10 the 11 shielding for them is somewhat different. 12 And, therefore, 80 hours would represent

an adequate number of hours. It is also the number of 13 14 hours which is used in nuclear radiology training 15 programs currently, as documented by Dr. Eggli, who nuclear radiology training program 16 has а and represents 80 hours of training, which is the rough 17 equivalent of three courses of three hours a week in 18 19 any college program.

Tricia.

21 DR. HOLAHAN: Could I ask a question? 22 Two-ninety (35.290) training is 80 hours as well. So 23 would you envision any differences in the 290 training 24 versus the 390 training, Dr. Eggli?

MEMBER EGGLI: I can speak to that

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

20

25

1question only in that I think, again, the group we're2talking about are diplomats of the American Board of3Radiology because the other training programs would4probably for 390 encompass easily the 200 hours.5But diagnostic radiologists train in 126different modalities, and therefore, their time is a7little bit more limited.8It is my understanding that it is the9intention of the American Board of Radiology to have10their training programs train residents in diagnostic11radiology for certification or licensure for uses12under Subpart 300, and therefore, it may be moot13whether the requirements for 200 or 300 are different,14given that the Board intends that all of the residents15should be trained to the level of Part 300 uses.16CHAIRMAN MALMUD: Thank you, Dr. Eggli.17The other comment is, I believe, that 390	)
<ul> <li>Radiology because the other training programs would</li> <li>probably for 390 encompass easily the 200 hours.</li> <li>But diagnostic radiologists train in 12</li> <li>different modalities, and therefore, their time is a</li> <li>little bit more limited.</li> <li>It is my understanding that it is the</li> <li>intention of the American Board of Radiology to have</li> <li>their training programs train residents in diagnostic</li> <li>radiology for certification or licensure for uses</li> <li>under Subpart 300, and therefore, it may be moot</li> <li>whether the requirements for 200 or 300 are different,</li> <li>given that the Board intends that all of the residents</li> <li>should be trained to the level of Part 300 uses.</li> <li>CHAIRMAN MALMUD: Thank you, Dr. Eggli.</li> </ul>	ž
4 probably for 390 encompass easily the 200 hours. 5 But diagnostic radiologists train in 12 6 different modalities, and therefore, their time is a 7 little bit more limited. 8 It is my understanding that it is the 9 intention of the American Board of Radiology to have 10 their training programs train residents in diagnostic 11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	-
5 But diagnostic radiologists train in 12 6 different modalities, and therefore, their time is a 7 little bit more limited. 8 It is my understanding that it is the 9 intention of the American Board of Radiology to have 10 their training programs train residents in diagnostic 11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	1
<ul> <li>different modalities, and therefore, their time is a</li> <li>little bit more limited.</li> <li>It is my understanding that it is the</li> <li>intention of the American Board of Radiology to have</li> <li>their training programs train residents in diagnostic</li> <li>radiology for certification or licensure for uses</li> <li>under Subpart 300, and therefore, it may be moot</li> <li>whether the requirements for 200 or 300 are different,</li> <li>given that the Board intends that all of the residents</li> <li>should be trained to the level of Part 300 uses.</li> <li>CHAIRMAN MALMUD: Thank you, Dr. Eggli.</li> </ul>	
7 little bit more limited. 8 It is my understanding that it is the 9 intention of the American Board of Radiology to have 10 their training programs train residents in diagnostic 11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	2
8 It is my understanding that it is the 9 intention of the American Board of Radiology to have 10 their training programs train residents in diagnostic 11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	ì
<ul> <li>9 intention of the American Board of Radiology to have</li> <li>10 their training programs train residents in diagnostic</li> <li>11 radiology for certification or licensure for uses</li> <li>12 under Subpart 300, and therefore, it may be moot</li> <li>13 whether the requirements for 200 or 300 are different,</li> <li>14 given that the Board intends that all of the residents</li> <li>15 should be trained to the level of Part 300 uses.</li> <li>16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.</li> </ul>	
10 their training programs train residents in diagnostic 11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	ž
11 radiology for certification or licensure for uses 12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	ž
12 under Subpart 300, and therefore, it may be moot 13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	2
13 whether the requirements for 200 or 300 are different, 14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	3
14 given that the Board intends that all of the residents 15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	-
15 should be trained to the level of Part 300 uses. 16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	,
16 CHAIRMAN MALMUD: Thank you, Dr. Eggli.	3
17 The other comment is, I believe, that 390	
	)
18 does not require the 12 cases of varying types, that	-
19 290 doesn't require them and 390 does.	
20 MEMBER EGGLI: Yes, that's correct.	
21 CHAIRMAN MALMUD: So that's a difference.	,
22 DR. HOLAHAN: Yes, but the argument that	-
23 the agreement states made, and correct me if I'm	n
24 wrong, but they felt that there was a risk with 390	)
25 uses that there wasn't associated with the 290 uses.	•

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

MEMBER EGGLI: And the only thing I would say is that 80 hours for uses under Subpart 200 is probably excessive, but again, since it's the intent to train everybody to at least the 300 level, it's unimportant.

But if you feel it's important to make the 6 7 distinction, then I have no problem with reducing the number of hours under Part 290 T&E requirements, which 8 9 I actually did suggest a few minutes ago, that I 10 thought 50 hours would be more than appropriate at 11 Part 290 T&E, but again, I believe that the American 12 Board of Radiology intends to train all of its under the rules of Subpart 13 diplomats 390, and 14 therefore, the distinction may be more theoretical 15 than real.

16 CHAIRMAN MALMUD: But there is a 17 distinction in the requirement for the cases between 18 290 and 390.

MEMBER EGGLI: Yes.

20 CHAIRMAN MALMUD: Does that answer your
21 question, Dr. Holahan?
22 DR. HOLAHAN: Yes.
23 CHAIRMAN MALMUD: Dr. Broseus?
24 DR. BROSEUS: I missed something. You
25 attributed to Dr. Eggli a comment about 80 hours is

attributed to Dr. Eggli a comment about 80 hours is

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

19

	121
1	required by ABR, but I didn't really hear a number.
2	MEMBER EGGLI: No, I don't believe I said
3	a number.
4	DR. BROSEUS: What is the requirement? Do
5	you know?
6	MEMBER EGGLI: For ABR?
7	DR. BROSEUS: Yeah.
8	MEMBER EGGLI: Right now ABR is waiting
9	for NRC to say something. As a matter of fact,
10	there's a lot of uncertainty in ABR training programs
11	right now waiting for this final regulation. I can
12	tell you that because there are 12 modalities out
13	there that diagnostic radiologists have to train for,
14	that wherever NRC sets the threshold, that will be
15	what the training programs require.
16	It used to be that we trained our
17	residents to \$1,000 because that's what was required
18	for NRC authorized user status under Parts 290 and 390
19	previously. Now if it's going to be 700 hours, then
20	the ABR requirement will be 700 hours, and it's just
21	a necessity because there are 12 modalities.
22	And if the training requirement becomes 80
23	hours for subpart 390 T&E requirements, then that is
24	what the American Board of Radiology will suggest to
25	its training programs that they ought to offer.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 DR. BROSEUS: Let me ask one more devil's 2 advocate question, and that is where you're describing 3 a scenario in which medicine becomes more complex and 4 there are more applications and more and more and 5 more, and therefore, being the devil's advocate. This tells me that the physician who's doing that needs 6 7 more radiation safety, not less, and so maybe somebody should add hours to the total training program to make 8 sure there's enough radiation safety rather than 9 10 trimming the safety part to make sure there's enough 11 time for clinic. 12 I emphasize devil's advocate. MEMBER EGGLI: Keep in mind that we are 13 14 providing almost as many hours again in physics 15 training that is pertinent to the other modalities in radiology, such as CT, plain film, and all of the 16 17 other areas where ionizing radiation issues, and again, that is, we have designed our program. 18 We 19 designed 100 hours of classroom lecture. Half of those would fit the description in the regulation for 20 21 nuclear medicine. The other half we considered to be 22 more limited to other forms of diagnostic radiology 23 and not directly applicable to the handling of 24 unsealed sources.

There was some crossover, but at least 40

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

(202) 234-4433

122

percent did not readily cross over. So we're providing far more physics training, health physics training to our resident than will satisfy NRC because we have other modalities where we're training these kinds of issues where we didn't see a direct crossover.

Now, maybe we should have been more generous in our own internal definition and said it all crosses over, but we didn't do that. We separated diagnostic radiology physics from nuclear medicine physics.

12 CHAIRMAN MALMUD: Dr. Broseus, does that 13 satisfy your devil's advocacy question?

PARTICIPANT: Well, I think what I'm hearing is that you're using the term "physics," which some people may interpret as principles of physics more broadly to include health physics, radiation safety related topics; is that correct?

DR. BROSEUS: Yes.

20 CHAIRMAN MALMUD: Dr. Williamson?

21 MEMBER WILLIAMSON: Yeah, I'm worried now 22 that this motion for 80 hours is based on a 23 misunderstanding of what the 200 hours are allowed to 24 be. Okay. The 200 hours, it doesn't say they have to 25 be on radiation safety and only the physics, narrow

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

19

	124
1	physics that's relevant to radiation safety.
2	If I read what it says, it says radiation
3	physics and instrumentation. It doesn't say that
4	learning to use instrumentation to determine a dose
5	for X-ray computed tomography can't be counted. You
6	know, it says radiation physics. It says radiation
7	biology. This could be any kind of radiation. It
8	doesn't even specify that it has to be ionizing
9	radiation biology. It could be, for example,
10	ultraviolet light biology.
11	PARTICIPANT: And we do count the
12	radiation biology in the
13	MEMBER WILLIAMSON: Now, mathematics
14	pertaining to the use of measurement of radioactivity
15	and then, you know, chemistry of byproduct material
16	for medical use is more specific, but I'm asking, I
17	guess, if in this calculation of hours the sort of
18	broadness of what is allowed to be counted has been
19	considered.
20	CHAIRMAN MALMUD: I imagine that question
21	is directed to Dr. Eggli.
22	MEMBER WILLIAMSON: It is.
23	MEMBER EGGLI: And we tried to consider
24	that, and we did consider that there was an area of
25	overlap. Probably about 30 percent of our lectures

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	125
1	overlapped the two areas where we have obligation to
2	train, and then we had an area where we thought there
3	was clearly not an overlap, and as we are looking at
4	coming up with total hours, that's where we were
5	running into trouble, is coming up with total hours.
6	And, again, I think we have a fairly
7	comprehensive program, and if you look at the total
8	amount of time we have, it's certainly equivalent to
9	a semester long college course.
10	CHAIRMAN MALMUD: Thank you, Dr. Eggli.
11	Mr. Lieto has a question.
12	MEMBER LIETO: I wanted to clarify just a
13	question or point. The wording in the original
14	proposal says "has completed 700 hours of training and
15	experience including a minimum of 200 hours of
16	classroom and laboratory training in basic
17	radionuclide handling techniques applicable to the
18	medical use of unsealed byproduct material."
19	So the 80 hours that we're referring to or
20	that the motion, the approved motion took place is in
21	that definition. So the more general definition of
22	physics and safety in X-ray and CT would not have been
23	applicable the way that the definition is for that
24	section.
25	So I would say that we're fine in what we

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	126
1	proposed.
2	CHAIRMAN MALMUD: Thank you.
3	Now, the motion was passed with unanimity,
4	one abstention. May we move on to the next item? And
5	does this satisfy the NRC's need to bring this forward
6	to the next step?
7	DR. BROSEUS: I'd just like to make one
8	clarifying comment. I'm not sure that Dr. Williamson
9	was serious about including ultraviolet, but we're
10	talking about ionizing radiation here. While it's not
11	defined in Part 35, it is defined in Part 20.
12	Radiation means ionizing radiation.
13	CHAIRMAN MALMUD: Thank you for clarifying
14	that for the record, Dr. Broseus.
15	May we move on?
16	Thank you. It has been a most stimulating
17	session, which has come to a resolution.
18	MR. MILLER: I think we can all agree on
19	that.
20	MEMBER NAG: Now that we have had no 390,
21	what I'd like to bring up for a brief discussion here
22	is 396. Eighty hours is a submission for unsealed
23	sources (phonetic) both for parenteral and for oral
24	administration. Am I right? Yes, no?
25	MEMBER EGGLI: Three, ninety or 396?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	127
1	MEMBER NAG: Three, ninety.
2	MEMBER EGGLI: Three, ninety.
3	MEMBER NAG: So 80 hours submission for
4	both the oral and for the parenteral. With 396 we are
5	only going to do parenteral because the 396 under the
б	parenteral for those who are Board certified in
7	radiation oncology who have now already spent quite a
8	lot of time in therapy and now need to know about
9	unsealed sources for the parenteral administration
10	only.
11	For that group of people, are you going to
12	need the same eight hours that you require for
13	somebody who is learning both about thyroids and about
14	parenteral administration, yttrium (phonetic), and so
15	on, or my proposal is that for somebody who already is
16	an expert on handling radioactive material in the
17	source, but the parenteral only 80 hours is excessive.
18	If you want me to put a number, I would say it has to
19	be less than 80. Whether 60 or 40, I think we can
20	deliberate, but if the APR rate is going to be
21	sufficient for only a limited component of that, by
22	definition it should be somewhat less.
23	CHAIRMAN MALMUD: Does anyone else wish to
24	address that or do you want to make that as a motion
25	and see what the response is?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	128
1	MEMBER NAG: If you want me to make a
2	motion, I would make a motion that for 396, the
3	didactic component of that be 60 hours.
4	CHAIRMAN MALMUD: Is there a second to
5	that motion?
6	Not hearing a second, we will
7	MEMBER EGGLI: I'll give him a second.
8	CHAIRMAN MALMUD: You're going to give him
9	a second?
10	MEMBER EGGLI: Sure.
11	CHAIRMAN MALMUD: Dr. Eggli gives you a
12	second, which now opens it up to discussion. Dr.
13	Broseus.
14	DR. BROSEUS: It would be helpful to
15	include in the motion if possible, not to make it too
16	complex, a basis for this of sufficiency.
17	MEMBER NAG: The basis is that for the
18	entire scope of unsealed sources, including the
19	parenteral and the oral administration, we are
20	requiring 80 hours. What percentage of that is oral
21	and what percentage of that is for parenteral is hard
22	to say, but allowing for overlap and so forth, I would
23	say, you know, that is why we bring it down. Instead
24	of half-half, I'm looking at 760 rather than, you
25	know, 40 and 40.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

129 1 CHAIRMAN MALMUD: The point might be made 2 that in providing the therapeutic application of radionuclides, one often does a diagnostic test first 3 4 with another isotope or a lesser amount of the same 5 isotope. In addition, it may come to pass that the 6 7 oral administration of a therapeutic or diagnostic isotope would be associated with the use of 8 a 9 therapeutic isotope in the future, and for that reason it would be safer to leave a number at 80. 10 11 And we recall that under Part 35.396, it 12 specifically says 80 plus three cases. Under 35.390, it's 80 plus 12 cases. So there is a difference, and 13 14 in the sense that we don't know what will evolve in the future, it might be best to leave it as it is. 15 However, that is open for discussion. 16 17 Dr. Williamson. Well, I think in 18 MEMBER WILLIAMSON: 19 practice, complying with the 80 hours, you know, given

21 oncologists get, you know, much of the physics and 22 instrumentation would be applicable.

the extensive base of didactic training that radiation

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

I think that in practice the incremental burden would be very small. I think the only case that I can think the 80 hours would affect, you know,

(202) 234-4433

20

	130
1	a very direct way in the way you're thinking would be
2	those that fail the recency of training test. I've
3	forgotten which paragraph. It is in Part 35, but it
4	seems to me that someone who is seven years beyond
5	their residency training and has not had experience
6	with radionuclide therapy probably would, in fact,
7	have to have 80 hours' worth of training in order to
8	add this new credential.
9	MEMBER NAG: Basically that is what I was
10	thinking of.
11	MEMBER WILLIAMSON: And, you know, I'm not
12	sure that someone who is out away from this for ten
13	years, speaking as a physicist, whether it would be
14	such a bad thing that they repeat, you know, this much
15	training.
16	CHAIRMAN MALMUD: Mr. Lieto, you had a
17	comment?
18	MEMBER LIETO: Well, I was going to state
19	that I would oppose reducing the 80 hours because I
20	think there are more radiation safety considerations
21	associated with the administration of parenteral
22	radiopharmaceuticals than oral, and also it would
23	remain consistent with what we have in 392 and 394 as
24	requirements for all administrations. So I would like
25	to just keep it as is.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1CHAIRMAN MALMUD: Thank you.2Any other comments?3(No response.)4CHAIRMAN MALMUD: If not, should we call5the vote on it?6MEMBER NAG: I withdraw my motion.7CHAIRMAN MALMUD: The motion is withdrawn.8Thank you, Dr. Nag.9MR. MOORE: Dr. Malmud, point of10clarification. This is Scott Moore.11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23to make a comment on Part 35.24DR. WHITE: Thanks.25Jerry White, American Association of		131
3       (No response.)         4       CHAIRMAN MALMUD: If not, should we call         5       the vote on it?         6       MEMBER NAG: I withdraw my motion.         7       CHAIRMAN MALMUD: The motion is withdrawn.         8       Thank you, Dr. Nag.         9       MR. MOORE: Dr. Malmud, point of         10       clarification. This is Scott Moore.         11       When you're talking about moving on to the         12       next subject, are you talking about moving on to the         13       National Source Tracking System or are you talking         14       about moving on to the next subject within Part 35         15       T&E?         16       CHAIRMAN MALMUD: Is there another subject         17       under 35?         18       PARTICIPANTS: Yes.         19       CHAIRMAN MALMUD: Then we'll move on to         20       the next part of 35 T&E. Is that what you wanted to         21       do?         22       We have a member of the public who wishes         23       to make a comment on Part 35.         24       DR. WHITE: Thanks.	1	CHAIRMAN MALMUD: Thank you.
4       CHAIRMAN MALMUD: If not, should we call         5       the vote on it?         6       MEMBER NAG: I withdraw my motion.         7       CHAIRMAN MALMUD: The motion is withdrawn.         8       Thank you, Dr. Nag.         9       MR. MOORE: Dr. Malmud, point of         10       clarification. This is Scott Moore.         11       When you're talking about moving on to the         12       next subject, are you talking about moving on to the         13       National Source Tracking System or are you talking         14       about moving on to the next subject within Part 35         15       T&E?         16       CHAIRMAN MALMUD: Is there another subject         17       under 35?         18       PARTICIPANTS: Yes.         19       CHAIRMAN MALMUD: Then we'll move on to         20       the next of 35 T&E. Is that what you wanted to         21       do?         22       We have a member of the public who wishes         23       to make a comment on Part 35.         24       DR. WHITE: Thanks.	2	Any other comments?
5the vote on it?6MEMBER NAG: I withdraw my motion.7CHAIRMAN MALMUD: The motion is withdrawn.8Thank you, Dr. Nag.9MR. MOORE: Dr. Malmud, point of10clarification. This is Scott Moore.11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23to make a comment on Part 35.24DR. WHITE: Thanks.	3	(No response.)
6MEMBER NAG: I withdraw my motion.7CHAIRMAN MALMUD: The motion is withdrawn.8Thank you, Dr. Nag.9MR. MOORE: Dr. Malmud, point of10clarification. This is Scott Moore.11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23to make a comment on Part 35.24DR. WHITE: Thanks.	4	CHAIRMAN MALMUD: If not, should we call
<ul> <li>CHAIRMAN MALMUD: The motion is withdrawn.</li> <li>Thank you, Dr. Nag.</li> <li>MR. MOORE: Dr. Malmud, point of</li> <li>clarification. This is Scott Moore.</li> <li>When you're talking about moving on to the</li> <li>next subject, are you talking about moving on to the</li> <li>next subject, are you talking about moving on to the</li> <li>national Source Tracking System or are you talking</li> <li>about moving on to the next subject within Part 35</li> <li>T&amp;E?</li> <li>CHAIRMAN MALMUD: Is there another subject</li> <li>under 35?</li> <li>PARTICIPANTS: Yes.</li> <li>CHAIRMAN MALMUD: Then we'll move on to</li> <li>the next part of 35 T&amp;E. Is that what you wanted to</li> <li>do?</li> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	5	the vote on it?
8Thank you, Dr. Nag.9MR. MOORE: Dr. Malmud, point of10clarification. This is Scott Moore.11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23to make a comment on Part 35.24DR. WHITE: Thanks.	6	MEMBER NAG: I withdraw my motion.
9MR. MOORE:Dr. Malmud, point of10clarification. This is Scott Moore.11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23to make a comment on Part 35.24DR. WHITE: Thanks.	7	CHAIRMAN MALMUD: The motion is withdrawn.
<ul> <li>clarification. This is Scott Moore.</li> <li>When you're talking about moving on to the</li> <li>next subject, are you talking about moving on to the</li> <li>National Source Tracking System or are you talking</li> <li>about moving on to the next subject within Part 35</li> <li>T&amp;E?</li> <li>CHAIRMAN MALMUD: Is there another subject</li> <li>under 35?</li> <li>PARTICIPANTS: Yes.</li> <li>CHAIRMAN MALMUD: Then we'll move on to</li> <li>the next part of 35 T&amp;E. Is that what you wanted to</li> <li>do?</li> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	8	Thank you, Dr. Nag.
11When you're talking about moving on to the12next subject, are you talking about moving on to the13National Source Tracking System or are you talking14about moving on to the next subject within Part 3515T&E?16CHAIRMAN MALMUD: Is there another subject17under 35?18PARTICIPANTS: Yes.19CHAIRMAN MALMUD: Then we'll move on to20the next part of 35 T&E. Is that what you wanted to21do?22We have a member of the public who wishes23DR. WHITE: Thanks.	9	MR. MOORE: Dr. Malmud, point of
<ul> <li>next subject, are you talking about moving on to the</li> <li>National Source Tracking System or are you talking</li> <li>about moving on to the next subject within Part 35</li> <li>T&amp;E?</li> <li>CHAIRMAN MALMUD: Is there another subject</li> <li>under 35?</li> <li>PARTICIPANTS: Yes.</li> <li>CHAIRMAN MALMUD: Then we'll move on to</li> <li>the next part of 35 T&amp;E. Is that what you wanted to</li> <li>do?</li> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	10	clarification. This is Scott Moore.
<ul> <li>National Source Tracking System or are you talking</li> <li>about moving on to the next subject within Part 35</li> <li>T&amp;E?</li> <li>CHAIRMAN MALMUD: Is there another subject</li> <li>under 35?</li> <li>PARTICIPANTS: Yes.</li> <li>CHAIRMAN MALMUD: Then we'll move on to</li> <li>the next part of 35 T&amp;E. Is that what you wanted to</li> <li>do?</li> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	11	When you're talking about moving on to the
<ul> <li>14 about moving on to the next subject within Part 35</li> <li>15 T&amp;E?</li> <li>16 CHAIRMAN MALMUD: Is there another subject</li> <li>17 under 35?</li> <li>18 PARTICIPANTS: Yes.</li> <li>19 CHAIRMAN MALMUD: Then we'll move on to</li> <li>20 the next part of 35 T&amp;E. Is that what you wanted to</li> <li>21 do?</li> <li>22 We have a member of the public who wishes</li> <li>23 to make a comment on Part 35.</li> <li>24 DR. WHITE: Thanks.</li> </ul>	12	next subject, are you talking about moving on to the
15 T&E? 16 CHAIRMAN MALMUD: Is there another subject 17 under 35? 18 PARTICIPANTS: Yes. 19 CHAIRMAN MALMUD: Then we'll move on to 20 the next part of 35 T&E. Is that what you wanted to 21 do? 22 We have a member of the public who wishes 23 to make a comment on Part 35. 24 DR. WHITE: Thanks.	13	National Source Tracking System or are you talking
16 CHAIRMAN MALMUD: Is there another subject 17 under 35? 18 PARTICIPANTS: Yes. 19 CHAIRMAN MALMUD: Then we'll move on to 20 the next part of 35 T&E. Is that what you wanted to 21 do? 22 We have a member of the public who wishes 23 to make a comment on Part 35. 24 DR. WHITE: Thanks.	14	about moving on to the next subject within Part 35
<ul> <li>17 under 35?</li> <li>18 PARTICIPANTS: Yes.</li> <li>19 CHAIRMAN MALMUD: Then we'll move on to</li> <li>20 the next part of 35 T&amp;E. Is that what you wanted to</li> <li>21 do?</li> <li>22 We have a member of the public who wishes</li> <li>23 to make a comment on Part 35.</li> <li>24 DR. WHITE: Thanks.</li> </ul>	15	T&E?
<ul> <li>PARTICIPANTS: Yes.</li> <li>CHAIRMAN MALMUD: Then we'll move on to</li> <li>the next part of 35 T&amp;E. Is that what you wanted to</li> <li>do?</li> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	16	CHAIRMAN MALMUD: Is there another subject
<ul> <li>19 CHAIRMAN MALMUD: Then we'll move on to</li> <li>20 the next part of 35 T&amp;E. Is that what you wanted to</li> <li>21 do?</li> <li>22 We have a member of the public who wishes</li> <li>23 to make a comment on Part 35.</li> <li>24 DR. WHITE: Thanks.</li> </ul>	17	under 35?
20 the next part of 35 T&E. Is that what you wanted to 21 do? 22 We have a member of the public who wishes 23 to make a comment on Part 35. 24 DR. WHITE: Thanks.	18	PARTICIPANTS: Yes.
21 do? 22 We have a member of the public who wishes 23 to make a comment on Part 35. 24 DR. WHITE: Thanks.	19	CHAIRMAN MALMUD: Then we'll move on to
<ul> <li>We have a member of the public who wishes</li> <li>to make a comment on Part 35.</li> <li>DR. WHITE: Thanks.</li> </ul>	20	the next part of 35 T&E. Is that what you wanted to
<ul> <li>23 to make a comment on Part 35.</li> <li>24 DR. WHITE: Thanks.</li> </ul>	21	do?
DR. WHITE: Thanks.	22	We have a member of the public who wishes
	23	to make a comment on Part 35.
25 Jerry White, American Association of	24	DR. WHITE: Thanks.
	25	Jerry White, American Association of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	132
1	Physicists in Medicine.
2	I'm impressed with the great attention to
3	detail that you've given to the training requirements
4	for various physicians, but there are some T&E issues,
5	I think, that we made comments on regarding authorized
6	medical physicists, grandfathering of authorized
7	medical physicists, and RSOs for medical physicists,
8	and I'd just like to ask the ACMUI if they have had
9	the opportunity to consider those, and if the changes
10	might be substantive, if there could be some way that
11	I know the paper copy of these changes is not
12	available, but if there were some oral discussion that
13	you might want to have or have some way to have other
14	eyeballs look or know about these changes.
15	CHAIRMAN MALMUD: We have several
16	physicists here who have not commented yet. Dr.
17	Williamson, we haven't heard from you for a while.
18	(Laughter.)
19	MEMBER WILLIAMSON: Well, I think that,
20	you know, I have reviewed this, and I think for RSO
21	I think. I say this very tentatively because it is a
22	complex regulation. I don't think it is unclearly
23	written, but I know how disastrous the misplacement of
24	a comma and the transposition of an "and" or "or" can
25	be, and I would think that it would serve the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	133
1	regulated community and the NRC to have a few more
2	eyes look closely and analytically at these various
3	revisions because while they may not be substantive
4	according to the letter of the Administrative
5	Procedures Act, nonetheless, we have had mistakes in
6	the past that have been very embarrassing, and I would
7	think that we should find some way to on a short-term
8	basis make these pre-decisional document public or
9	available to people who wish to look at it.
10	I think this would help the ACMUI in
11	crafting its final memo to have some additional input
12	from expert reviewers. So I would ask that we figure
13	out some way, if necessary, reading this into the
14	public record or making a motion to append it to the
15	meeting summary which must be posted in ten days or
16	simply taking the common sense step of putting it on
17	the Web so that those people who wish to see it can
18	see it.
19	CHAIRMAN MALMUD: Thank you.
20	MEMBER WILLIAMSON: I think it can only
21	help improve the final product to have some unforeseen
22	or unanticipated consequence or, you know, mistake
23	revealed.
24	CHAIRMAN MALMUD: Thank you.
25	Dr. Vetter, do you have a comment?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

134 1 MEMBER VETTER: Yes. I don't have the test in front of me, but when we reviewed this prior 2 3 to our conference call, it appeared to me that the 4 question that Jerry raised about RSOs has been 5 adequately answered. That is, there was a gap for those physicists who qualified under ABR, and now 6 7 there is one of the "ors" that says if you have a 8 Master's degree in physics and two years of 9 experience, you will qualify as the RSO, and I think 10 that takes care of ABR's concerns, doesn't it, 11 relative to RSO? 12 CHAIRMAN MALMUD: Dr. White, you raised the question. 13 DR. WHITE: Dr. Vetter, I just have to say 14 15 I don't know because without seeing the actual text, 16 it's just so hard to respond. Sorry. 17 MEMBER VETTER: Okay. Point well taken, but in my opinion it does take care of it. 18 19 CHAIRMAN MALMUD: So Dr. Vetter reassures 20 you, Dr. White, that in his opinion it is taken care 21 of, though you haven't seen the text, Dr. White. 22 Mr. Lieto. 23 MEMBER LIETO: I would like to also 24 support Jeff's recommendation that we release this 25 predecisional document for people to look at. Ι

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	135
1	think, you know, Jerry White's, you know, comment
2	being a point that the medical physics community would
3	like to see that this is addressed.
4	I do agree with Dick though that I think
5	it does answer the concern. I have an additional
6	question regarding the RSO preceptor issue.
7	CHAIRMAN MALMUD: Before we go on to your
8	additional question, is there any objection to
9	distributing this document?
10	Dr. Miller.
11	MR. MILLER: The committee is certainly
12	within its rights to make such a recommendation if you
13	so choose. We recognize that will be a recommendation
14	if you choose to make it that the staff will have to
15	take to the Commission itself for approval, and if the
16	Commission were to approve it, and I think what I'm
17	hearing is a recommendation.
18	To put it out for public comment again, to
19	put it out just for the public to look at and as a set
20	of eyes serves no purpose in my view with regard to
21	trying to reach a final product unless there's a view
22	that you would want to seek as a committee the
23	public's views on this before we go forward.
24	And I go back to my comments this morning
25	of we've got to get to a point where we're not stuck

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	136
1	in an iterative process that we can't get out of. At
2	what point in time do we move forward?
3	So you know, with that, the question
4	becomes does the committee think at least from the
5	staff's perspective that the rule should be put out
б	for public comment and, if so and I need General
7	Counsel's help on this, Susan, if you can listen
8	I'm going to ask a question if you'll indulge me of
9	our representative from the Office of General Counsel.
10	If we were to consider putting the rule
11	out for public comment, could you limit it to some
12	portion of the rule or do you have to put the whole
13	thing out again for public comment?
14	MS. CHIDAKEL: The reason I was just
15	talking to Sandy when you called my attention to your
16	questions is that I need to take these issues back to
17	the Office of General Counsel. I'm not really
18	prepared at this point to answer those questions, and
19	I raised the issue of Sandy.
20	I think, you know, these are
21	recommendations you can make, but I think I need to go
22	back to my management and have these issues resolved.
23	MR. MILLER: Exactly. I mean, before we
24	could act on the recommendation, we would have to get
25	approval.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	137
1	MS. CHIDAKEL: You would have to get an
2	official opinion from the agency.
3	MR. MILLER: Scott is trying to get a
4	point in here, I think.
5	MR. MOORE: Yes. If I may, there are
6	rulemaking mechanisms whereby we can make
7	predecisional rulemaking maybe I should call it
8	draft rulemaking available for the public to see.
9	The Office of Nuclear Reactor Regulation is using that
10	mechanism, namely, posting it on the Web, for the
11	public to see.
12	If the ACMUI believes that we should do
13	so, you know, it's certainly within your prerogative
14	to make such a motion and pass it. This has certainly
15	been such a controversial rule and that mechanism has
16	not been used within NMSS very frequently. You know,
17	we would certainly consider it, and may consult with
18	the Commission before we would do so.
19	MR. MILLER: Well, we would consult with
20	the Commission, yes.
21	MR. MOORE: Okay. Please recognize that
22	the Commission itself has not seen this language
23	that's before you. So you're seeing a draft final
24	rule that the Commission itself has not seen.
25	So you know, if you want to pass a motion

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	138
1	that either it be made public so that you can share it
2	and talk to your counterparts and colleagues or that
3	it be made public and it be commented on again, that's
4	certainly all within
5	MR. MILLER: Scott, so that they're clear
6	on the motion that they need to make
7	MR. MOORE: I think Dr. Suleiman had a
8	comment.
9	MEMBER SULEIMAN: I have. I need some
10	clarification. What we're talking about that the
11	public hasn't seen that's pre-decisional, will that be
12	published as the final rule to take effect after a
13	certain amount of days or is that going to be
14	published as proposed rulemaking?
15	MR. MOORE: I can answer that. If it goes
16	out now without any change in process, after we would
17	get your comments, we would and the agreement
18	states' comments, we would send it up to the
19	Commission in mid-November. The Commission would
20	eventually vote on it as Roger's last slide showed,
21	and it would go out as a final rule. It would not go
22	out again for public comment.
23	MEMBER SULEIMAN: Okay, all right.
24	Interesting.
25	CHAIRMAN MALMUD: Does that answer your

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	139
1	question, Dr. Suleiman?
2	MEMBER SULEIMAN: At some point NRC will
3	determine whether there have been substantive changes
4	to the document, whether, in fact, you'll reconsider
5	and go back and propose it as a new rule because it's
6	up to your
7	MR. MOORE: No, no. I can answer that.
8	I checked with the General Counsel yesterday, and the
9	General Counsel's office yesterday actually, Stu
10	Treby, was of the opinion that it did not need to go
11	out for public comment. I don't think "substantive
12	comments" is the actual phrase. I think Susan gave
13	the correct legal threshold.
14	MS. CHIDAKEL: And please let me clarify.
15	He's not the General Counsel.
16	MR. MOORE: Okay. The General Counsel's
17	Office.
18	MS. CHIDAKEL: For the record, his
19	position is the Assistant General Counsel for
20	Rulemaking and Fuel Cycle. So to make clear that, you
21	know, he's not the General Counsel.
22	But in any event, Scott Moore is certainly
23	right. That is still our position.
24	MR. MOORE: It did not pass the legal
25	threshold that it needed to go out for public comment,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

<pre>1 again, but that doesn't mean that it can't go out f 2 public comment again. 3 Now, in response to Charlie's point 4 clarify, there are a couple of options. One is the following of the second second</pre>	to he go
3 Now, in response to Charlie's point	he go
	he go
4 clarify, there are a couple of options. One is t	go
5 ACMUI could recommend to the staff that it should	зu
6 out for public comment again, and we'd ask that y	
7 give us a basis for that if you pass a motion to	do
8 so.	
9 Another comment that the ACMUI could gi	ve
10 us, you could pass a motion that it be made availab	le
11 to the public not necessarily for comment, but ju	st
12 made available publicly, and there are mechanisms th	at
13 the staff could do that.	
14 CHAIRMAN MALMUD: Excuse me. By the te	rm
15 "made available," that means it will be made availab	le
16 to the public to see prior to anyone in the NRC seei	ng
17 it? I mean, does that create an embarrassment f	or
18 anyone?	
19 MR. MOORE: No, no. It won't be	an
20 embarrassment.	
21 CHAIRMAN MALMUD: I just want to ma	ke
22 sure.	
23 Dr. Williamson.	
24 MEMBER WILLIAMSON: Well, then, you know	w,
25 let me state my intention was not to materially try	to

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	141
1	delay the process of ultimate approval, but only to
2	aid this committee by sharing this with colleagues or
3	being able to share this, to be able to solicit
4	additional input on the details.
5	So given that, I would make the motion
6	that we make it available to the public and not
7	request a separate cycle of public commentary.
8	CHAIRMAN MALMUD: Mr. Lieto?
9	MEMBER LIETO: I was going to second that
10	until he said not make it available and not allow
11	public commentary. I think that's the reason you want
12	to do this, is so that they can get some input from
13	the other parties.
14	I mean, I don't disagree with that we
15	don't want another around of rulemaking and that whole
16	business, but you know, I think you need to see
17	this
18	MEMBER WILLIAMSON: Well, sending it for
19	public commentary is a formal mechanism. It has to be
20	published in the <u>Federal Register</u> again. It would be
21	a substantial delay in their process of several
22	months. I am simply proposing to make it available to
23	the public immediately.
24	MEMBER LIETO: What's the value of making
25	it available if no one is going to have the ability to

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

Í	142
1	provide input to the staff to see if there are issues
2	that we may have not recognized that create
3	difficulties?
4	CHAIRMAN MALMUD: I understand your
5	question.
6	Dr. Suleiman.
7	MEMBER SULEIMAN: Right. We need to
8	follow some discipline in the process. If we want
9	this to be published and not get any comments, I agree
10	with Charlie Miller. There's no point in it. The
11	decision is made. We've been given the opportunity to
12	see it, but it's the NRC's decision.
13	That's why I was asking earlier for
14	clarification. If there was, for lack of a better
15	word, significant, substantive, whatever changes where
16	it has changed enough and that's the NRC's call, then
17	they would say, you know, "We have to go back and go
18	through the whole public comment period."
19	But it sounds like to me that we're beyond
20	that, and this was just a courtesy. Here's what the
21	final rule is going to be.
22	CHAIRMAN MALMUD: You've raised the
23	question which I was going to ask in a different
24	manner, and that is that we have physicists on our
25	committee. Dr. Vetter has seen it and has no

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1objection to it. Dr. Williamson has no substantive2objection to it. It. Wough he says he has not reviewed3every last detail of it to his satisfaction, but he4has no objection to it. I don't see why the usual5process has to be invaded.6MEMBER WILLIAMSON: Can I state my7rationale, please?8CHAIRMAN MALMUD: Yes, you may.9MEMBER WILLIAMSON: My rationale would be10that there would be individuals I could personally11solicit feedback from on the details and be able to12give a more informed evaluation of this regulation as13a member of the ACMUI. That's maybe a weak rationale,14but that's, in fact, what I would do if it were made15available16CHAIRMAN MALMUD: Thank you.17MEMBER WILLIAMSON: to those who are18interested in reading it.19At least I personally would solicit some20additional input from members.21MEMBER LIETO: But then you'd be providing22input into the working group.23MEMBER WILLIAMSON: That's correct. I24would, you know, attempt to do this. I think the time25frame of three, four days from now is very tight to do		143
<pre>every last detail of it to his satisfaction, but he has no objection to it. I don't see why the usual process has to be invaded. MEMBER WILLIAMSON: Can I state my rationale, please? CHAIRMAN MALMUD: Yes, you may. MEMBER WILLIAMSON: My rationale would be that there would be individuals I could personally solicit feedback from on the details and be able to give a more informed evaluation of this regulation as a member of the ACMUI. That's maybe a weak rationale, but that's, in fact, what I would do if it were made available CHAIRMAN MALMUD: Thank you. MEMBER WILLIAMSON: to those who are interested in reading it. At least I personally would solicit some additional input from members. MEMBER LIETO: But then you'd be providing input into the working group. MEMBER WILLIAMSON: That's correct. I would, you know, attempt to do this. I think the time</pre>	1	objection to it. Dr. Williamson has no substantive
<ul> <li>has no objection to it. I don't see why the usual process has to be invaded.</li> <li>MEMBER WILLIAMSON: Can I state my rationale, please?</li> <li>CHAIRMAN MALMUD: Yes, you may.</li> <li>MEMBER WILLIAMSON: My rationale would be that there would be individuals I could personally solicit feedback from on the details and be able to give a more informed evaluation of this regulation as a member of the ACMUI. That's maybe a weak rationale, but that's, in fact, what I would do if it were made available</li> <li>CHAIRMAN MALMUD: Thank you.</li> <li>MEMBER WILLIAMSON: to those who are interested in reading it.</li> <li>At least I personally would solicit some additional input from members.</li> <li>MEMBER LIETO: But then you'd be providing input into the working group.</li> <li>MEMBER WILLIAMSON: That's correct. I would, you know, attempt to do this. I think the time</li> </ul>	2	objection to it, though he says he has not reviewed
5       process has to be invaded.         6       MEMBER WILLIAMSON: Can I state my         7       rationale, please?         8       CHAIRMAN MALMUD: Yes, you may.         9       MEMBER WILLIAMSON: My rationale would be         10       that there would be individuals I could personally         11       solicit feedback from on the details and be able to         12       give a more informed evaluation of this regulation as         13       a member of the ACMUI. That's maybe a weak rationale,         14       but that's, in fact, what I would do if it were made         15       available         16       CHAIRMAN MALMUD: Thank you.         17       MEMBER WILLIAMSON: to those who are         18       interested in reading it.         19       At least I personally would solicit some         20       additional input from members.         21       MEMBER LIETO: But then you'd be providing         22       input into the working group.         23       MEMBER WILLIAMSON: That's correct. I         24       would, you know, attempt to do this. I think the time	3	every last detail of it to his satisfaction, but he
6       MEMBER WILLIAMSON: Can I state my         7       rationale, please?         8       CHAIRMAN MALMUD: Yes, you may.         9       MEMBER WILLIAMSON: My rationale would be         10       that there would be individuals I could personally         11       solicit feedback from on the details and be able to         12       give a more informed evaluation of this regulation as         13       a member of the ACMUI. That's maybe a weak rationale,         14       but that's, in fact, what I would do if it were made         15       available         16       CHAIRMAN MALMUD: Thank you.         17       MEMBER WILLIAMSON: to those who are         18       interested in reading it.         19       At least I personally would solicit some         20       additional input from members.         21       MEMBER LIETO: But then you'd be providing         22       input into the working group.         23       MEMBER WILLIAMSON: That's correct. I         24       would, you know, attempt to do this. I think the time	4	has no objection to it. I don't see why the usual
7rationale, please?8CHAIRMAN MALMUD: Yes, you may.9MEMBER WILLIAMSON: My rationale would be10that there would be individuals I could personally11solicit feedback from on the details and be able to12give a more informed evaluation of this regulation as13a member of the ACMUI. That's maybe a weak rationale,14but that's, in fact, what I would do if it were made15available16CHAIRMAN MALMUD: Thank you.17MEMBER WILLIAMSON: to those who are18interested in reading it.19At least I personally would solicit some20additional input from members.21MEMBER UILLIAMSON: That's correct. I22MEMBER WILLIAMSON: That's correct. I23MEMBER WILLIAMSON: That's correct. I24would, you know, attempt to do this. I think the time	5	process has to be invaded.
8       CHAIRMAN MALMUD: Yes, you may.         9       MEMBER WILLIAMSON: My rationale would be         10       that there would be individuals I could personally         11       solicit feedback from on the details and be able to         12       give a more informed evaluation of this regulation as         13       a member of the ACMUI. That's maybe a weak rationale,         14       but that's, in fact, what I would do if it were made         15       available         16       CHAIRMAN MALMUD: Thank you.         17       MEMBER WILLIAMSON: to those who are         18       interested in reading it.         19       At least I personally would solicit some         20       additional input from members.         21       MEMBER LIETO: But then you'd be providing         22       input into the working group.         23       MEMBER WILLIAMSON: That's correct. I         24       would, you know, attempt to do this. I think the time	6	MEMBER WILLIAMSON: Can I state my
9       MEMBER WILLIAMSON: My rationale would be         10       that there would be individuals I could personally         11       solicit feedback from on the details and be able to         12       give a more informed evaluation of this regulation as         13       a member of the ACMUI. That's maybe a weak rationale,         14       but that's, in fact, what I would do if it were made         15       available         16       CHAIRMAN MALMUD: Thank you.         17       MEMBER WILLIAMSON: to those who are         18       interested in reading it.         19       At least I personally would solicit some         20       additional input from members.         21       MEMBER LIETO: But then you'd be providing         22       input into the working group.         23       MEMBER WILLIAMSON: That's correct. I         24       would, you know, attempt to do this. I think the time	7	rationale, please?
10that there would be individuals I could personally11solicit feedback from on the details and be able to12give a more informed evaluation of this regulation as13a member of the ACMUI. That's maybe a weak rationale,14but that's, in fact, what I would do if it were made15available16CHAIRMAN MALMUD: Thank you.17MEMBER WILLIAMSON: to those who are18interested in reading it.19At least I personally would solicit some20additional input from members.21MEMBER LIETO: But then you'd be providing22input into the working group.23MEMBER WILLIAMSON: That's correct. I24would, you know, attempt to do this. I think the time	8	CHAIRMAN MALMUD: Yes, you may.
11solicit feedback from on the details and be able to12give a more informed evaluation of this regulation as13a member of the ACMUI. That's maybe a weak rationale,14but that's, in fact, what I would do if it were made15available16CHAIRMAN MALMUD: Thank you.17MEMBER WILLIAMSON: to those who are18interested in reading it.19At least I personally would solicit some20additional input from members.21MEMBER LIETO: But then you'd be providing22input into the working group.23MEMBER WILLIAMSON: That's correct. I24would, you know, attempt to do this. I think the time	9	MEMBER WILLIAMSON: My rationale would be
<pre>12 give a more informed evaluation of this regulation as 13 a member of the ACMUI. That's maybe a weak rationale, 14 but that's, in fact, what I would do if it were made 15 available 16 CHAIRMAN MALMUD: Thank you. 17 MEMBER WILLIAMSON: to those who are 18 interested in reading it. 19 At least I personally would solicit some 20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time</pre>	10	that there would be individuals I could personally
13       a member of the ACMUI. That's maybe a weak rationale,         14       but that's, in fact, what I would do if it were made         15       available         16       CHAIRMAN MALMUD: Thank you.         17       MEMBER WILLIAMSON: to those who are         18       interested in reading it.         19       At least I personally would solicit some         20       additional input from members.         21       MEMBER LIETO: But then you'd be providing         22       input into the working group.         23       MEMBER WILLIAMSON: That's correct. I         24       would, you know, attempt to do this. I think the time	11	solicit feedback from on the details and be able to
14 but that's, in fact, what I would do if it were made available 16 CHAIRMAN MALMUD: Thank you. 17 MEMBER WILLIAMSON: to those who are 18 interested in reading it. 19 At least I personally would solicit some 20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	12	give a more informed evaluation of this regulation as
<pre>15 available 16 CHAIRMAN MALMUD: Thank you. 17 MEMBER WILLIAMSON: to those who are 18 interested in reading it. 19 At least I personally would solicit some 20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time</pre>	13	a member of the ACMUI. That's maybe a weak rationale,
16 CHAIRMAN MALMUD: Thank you. 17 MEMBER WILLIAMSON: to those who are 18 interested in reading it. 19 At least I personally would solicit some 20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	14	but that's, in fact, what I would do if it were made
MEMBER WILLIAMSON: to those who are interested in reading it. At least I personally would solicit some additional input from members. MEMBER LIETO: But then you'd be providing input into the working group. MEMBER WILLIAMSON: That's correct. I would, you know, attempt to do this. I think the time	15	available
18 interested in reading it. 19 At least I personally would solicit some 20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	16	CHAIRMAN MALMUD: Thank you.
19At least I personally would solicit some20additional input from members.21MEMBER LIETO: But then you'd be providing22input into the working group.23MEMBER WILLIAMSON: That's correct. I24would, you know, attempt to do this. I think the time	17	MEMBER WILLIAMSON: to those who are
20 additional input from members. 21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	18	interested in reading it.
21 MEMBER LIETO: But then you'd be providing 22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	19	At least I personally would solicit some
22 input into the working group. 23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	20	additional input from members.
23 MEMBER WILLIAMSON: That's correct. I 24 would, you know, attempt to do this. I think the time	21	MEMBER LIETO: But then you'd be providing
24 would, you know, attempt to do this. I think the time	22	input into the working group.
	23	MEMBER WILLIAMSON: That's correct. I
25 frame of three, four days from now is very tight to do	24	would, you know, attempt to do this. I think the time
	25	frame of three, four days from now is very tight to do

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	144
1	this, you know. To try to get a few more days would
2	be helpful.
3	CHAIRMAN MALMUD: Does anyone wish to make
4	a motion to that effect or shall we just
5	MEMBER WILLIAMSON: I have made the
6	motion.
7	CHAIRMAN MALMUD: Trish?
8	DR. HOLAHAN: Yes, excuse me I'd like
9	to emphasize what Dr. Miller said. First of all, we'd
10	have to go to the Commission and ask if we'd have to
11	put out the draft rule language on the Web, but what
12	I understand is what you're saying is if we put it up
13	on the Web and you would solicit comments from
14	specific stakeholders and get back to us, and so you'd
15	need more time.
16	MEMBER LIETO: This is Ralph Lieto.
17	I would agree with what you just said,
18	Trish.
19	DR. HOLAHAN: Okay.
20	MEMBER LIETO: Now, how much time? Is two
21	weeks unreasonable or ten days or something like that?
22	I mean, I know we want to try to keep it short, but I
23	think what you're talking about in terms of basically
24	two business days is not really practical.
25	MEMBER WILLIAMSON: Yeah. So I think my

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 motion would have to be amended to include enough time 2 accommodate your process for querying to the 3 Commission and then give people a few days to the 4 selected few people that perhaps I and other members 5 of the ACMUI would solicit to get input; we would need a few days to --6

7 DR. HOLAHAN: We would have to make it 8 available to all the public. You can't just go out to 9 a few.

MEMBER WILLIAMSON: Well, it would be available to all the public, but you know, I am not going to personally contact each member of the public who reads this. I would contact a, you know, few knowledgeable people, you know, and Dr. Vetter, could detect errors in this.

Т think 16 MEMBER VETTER: what. Dr. 17 Williamson has suggested does have value, but I also think there's a huge risk there in going out and 18 19 soliciting input from a few selected individuals. Someone out there will not be contacted and will be 20 21 very unhappy with the process.

22 CHAIRMAN MALMUD: Thank you, and there's 23 a member of the public that wishes to make a 24 statement.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

DR. WHITE: Yes, I would just like to, in

(202) 234-4433

25

146 1 answer to Dr. Hiller's (phonetic) question, I think 2 the value is clearly the staff has taken guidance from 3 the ACMUI in this regard, and that if there's some way 4 for the regulated community to have consultation with 5 or voice an opinion to the ACMUI, I think that's an appropriate method for perhaps effecting change in 6 7 I think it's not really a "do" loop issue. this. Ι 8 think it's more a limits issue. You know, the epsilon 9 and sigma issue. 10 We're getting very close to the final 11 product after many years of effort, and these last few 12 details would benefit from just one more look, and it doesn't need to take more than a week or so. I mean, 13 14 I don't know exactly how much time, but we're really 15 not talking about extending another request for public comments, but just rather one more set of eyeballs for 16 these final things which for physicists are very 17 18 important. The grandfathering of AMPs is a vital

 19
 The grandfathering of AMPs is a vital

 20
 issue for us, and we don't know what the language

 21
 looks like.

 22
 CHAIRMAN MALMUD: Thank you. We've heard

 23
 your concern.

24There is a motion on the floor. Has it25been seconded?

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	147
1	MEMBER LIETO: I will second.
2	CHAIRMAN MALMUD: Mr. Lieto seconded it.
3	Any further discussion of the motion?
4	MEMBER SULEIMAN: What is the motion?
5	CHAIRMAN MALMUD: Would you repeat your
6	motion, Dr. Williamson?
7	MEMBER WILLIAMSON: The motion is to make
8	the predecisional rule publicly available so that
9	ACMUI members may be able to solicit additional input
10	in formulating written opinions for the staff.
11	MEMBER NAG: I would suggest that same
12	motion just leave out the last part of the
13	sentence. You don't need to hear why it has to be
14	made public.
15	MEMBER WILLIAMSON: All right. So I'll
16	rephrase. The motion is to make the predecisional
17	material publicly available and extend the deadline
18	for ACMUI input to give us five working days from the
19	date it is made publicly available to finalize
20	individual comments to the staff.
21	CHAIRMAN MALMUD: Dr. Suleiman.
22	MEMBER SULEIMAN: I think this modifies
23	the whole process. I think we should just go I
24	would not support.
25	CHAIRMAN MALMUD: You're not supportive of

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

148
it.
MEMBER SULEIMAN: No.
CHAIRMAN MALMUD: Any other comments?
Call the question. All in favor.
(Show of hands.)
CHAIRMAN MALMUD: All opposed?
(Show of hands.)
CHAIRMAN MALMUD: The motion does not
pass.
May we move on to the next item if there
is another one under Part 35?
DR. BROSEUS: I've completed my
presentation.
CHAIRMAN MALMUD: You've completed your
presentation, Dr. Broseus?
DR. BROSEUS: Save one item, and that is
to thank you all for the extraordinary effort put into
this because everybody has put a lot of labor into
having the rule that comes out. Yes, pat yourselves
on the back. We are, too. This is a difficult rule,
and we're doing our best to make it good, and you guys
have done a lot in that direction. I really
appreciate this.
CHAIRMAN MALMUD: And the committee

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	149
1	we've had from you and your staff.
2	DR. BROSEUS: Well, I am at your disposal
3	if there are anymore questions.
4	CHAIRMAN MALMUD: We do have a full
5	agenda. Is it something that's urgent, Ralph?
6	MEMBER LIETO: Well, if we're not going to
7	be putting this out for a predecisional, then I think
8	we need to address these specific points then, and if
9	it takes a while, then I guess that's going to be the
10	case.
11	MEMBER WILLIAMSON: This is the last
12	moment. We need to take the time.
13	CHAIRMAN MALMUD: What would you like to
14	take a little time on?
15	MEMBER LIETO: Well, my next point that I
16	would like to address, I've got actually two. It
17	appears that in this predecisional documentation it
18	states that a person who was an RSO and then is no
19	longer an active listed RSO cannot be a preceptor. So
20	if our esteemed colleague, Dr. Vetter, leaves his
21	institution as an RSO and is no longer the listed RSO
22	on the license, he cannot be the preceptor for anybody
23	else's training and experience.
24	And so I would like you to address that
25	point first.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	150
1	DR. BROSEUS: Is that a question?
2	CHAIRMAN MALMUD: Is that a question to
3	Dr. Vetter?
4	MEMBER LIETO: No, it's a question to the
5	NRC staff.
б	DR. BROSEUS: We haven't changed the
7	definition of a preceptor except to add to it as
8	recommended by the ACMUI to say it could be a person
9	who is familiar with the training. In other words,
10	they don't have to direct the training. Okay? That's
11	in 35.2, is the definition.
12	So we haven't changed the definition
13	except to add to, as per your recommendation. Okay?
14	And the other areas where we talk about
15	the preceptor rule itself are basically unchanged. So
16	I'm not quite sure what the basis for the question
17	really is.
18	MEMBER LIETO: Well, it's on actually page
19	33. It says if an individual status as an RSO, ANP,
20	ANP or AU is dropped, revoked or removed from the
21	license or because of poor compliance with the NRC's
22	regulation, that person can no longer serve as a
23	preceptor. I mean that's what it states.
24	Now, I don't know if that was the intent,
25	but what it states is that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	151
1	DR. BROSEUS: I'm not sure that we have
2	the same page number. Is this is there an issue
3	number associated with this? Because the
4	MEMBER LIETO: Actually it's issue number
5	two on page 33 on what I have. It's your pagination.
6	So even an authorized user who may have been on a
7	license and maybe the Director of Training; so I think
8	there needs to be a clarification.
9	And I think this also gets to the issue of
10	authorized medical physicists and who can be a
11	preceptor for an authorized medical physicist. We've
12	got to, you know that would basically almost
13	eliminate a first pool of authorized medical
14	physicists.
15	DR. BROSEUS: I think as I read this, this
16	is in response to a comment from an agreement state
17	about who can and can't serve, and at the end we're
18	talking about if somebody is removed for cause that
19	that would be
20	MEMBER LIETO: Well, it says "or" and it
21	doesn't
22	DR. BROSEUS: Right, but we would have to
23	go back and, again, look at your comment and insure
24	that we haven't put something into the response that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	152
1	conflict with the definition intended for
2	MEMBER WILLIAMSON: Well, I guess this is
3	a good question. If the director of one's training
4	program retires and ceases to be an authorized user at
5	some future point in time, can that person serve as
6	the preceptor for a graduate of the program, presuming
7	they were under the assumption that they were an
8	authorized user, you know, at the time, in the time
9	frame that's relevant for documenting the applicant's
10	credentials.
11	That's the question.
12	DR. BROSEUS: My first stop is to read the
13	rule. Ron, do you want to add anything?
14	My first stop would be to read the rule
15	and see what it says.
16	MEMBER WILLIAMSON: Well, tell us. We are
17	asking you.
18	DR. BROSEUS: Yes.
19	MEMBER WILLIAMSON: I mean, that's
20	evading.
21	MEMBER LIETO: I think, you know, and I
22	know I'm sounding repetitive, it gets back to being
23	able to look at the rules that we're going to be, you
24	know, recommending and submitting changes for. You
25	know, if we're not going to I don't know if we need

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	153
1	to go to a formal motion or not, but I think if we've
2	only got a few days to provide comments to the NRC
3	staff, you know, I think we need to be given the tools
4	to make, you know, valid comments and knowledgeable
5	comments to you and to see it in the whole context of
6	the preceptor definition, especially with the RSO and
7	especially with the authorized medical physicist
8	aspects because there has been a number of changes,
9	that I would like to see that, you know, within the
10	next day or so.
11	I mean, if I've only got basically to the
12	18th, then I'd like to see that, you know, by the end
13	of the day tomorrow.
14	MEMBER WILLIAMSON: I just would like to
15	have the answer to my question.
16	DR. BROSEUS: If I understood the question
17	correctly, could a person who was an authorized user
18	continue to serve as a preceptor.
19	MEMBER LIETO: Correct.
20	DR. BROSEUS: And I would have to look and
21	see what the rule says, but on the face of it, I would
22	say, no, they're not an authorized user. If a person
23	isn't named in the rule as a person who can serve as
24	a preceptor, then the answer to the question would be
25	no, but I also have to look at the definition, and if

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	154
1	that person, for example, was in a training program,
2	during that training program, I'm not sure about this.
3	Ron?
4	DR. ZELAC: This is Dr. Zelac.
5	If one looks specifically, Ralph, at the
6	question of the radiation safety officer, the best
7	thing to do is to look back at the definition that
8	appears now in the rule for radiation safety officer,
9	and it reads that an individual who meets the
10	requirements in 3550(a), meaning Board certified, and
11	3559, recentness of training and experience, or is
12	identified as a radiation safety officer on a license.
13	So in Dr. Vetter's case, for example, if
14	he were to cease being the radiation safety officer at
15	Mayo Clinic, he would still qualify as radiation
16	safety officer on a quick read under the first
17	provision that I read, that he meets the requirements
18	in 3550(a) and 3559. At least for the next seven
19	years he would.
20	DR. BROSEUS: This is really not a new
21	question. This is an interpretation of the current
22	rule. So I think that answers the question.
23	Thank you.
24	MR. MOORE: And if I may address Dr.
25	Lieto's comment on the timing question, first of all,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	155
1	with regard to getting, you know, full information by
2	tomorrow, with regard to the red line strikeout
3	version, the staff is preparing a red line strikeout
4	version. One has been developed, but it's not QAed.
5	Going back to the comments from the
6	telecon, I think we said in response to Lynn's
7	recommendation that we thought it was a good idea and
8	we would certainly consider it.
9	The staff plans to do so for issuance of
10	the final rule. With regard to getting it out, we
11	want to make sure that we get the right thing out and
12	there are not errors in it before we issue it.
13	With regard to getting out a full rule, we
14	agree that that would be helpful. If the committee
15	needs additional time, that would be certainly
16	something we could consider, but as I had mentioned,
17	we would need to ask the Commission for that, and to
18	do that, you know, we would need you all to tell us
19	that you need additional time for that and give us a
20	basis for that, and you know, we would tell the
21	Commission that.
22	But absent that, we would have to work
23	under the schedule that we have now.
24	CHAIRMAN MALMUD: Dr. Williamson.
25	MEMBER WILLIAMSON: I think the other

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 issue that was raised on the teleconference is the 2 issue of grandfathering for the authorized medical physicist. Why that is of special concern is that the 3 4 authorized medical physicist as an entity within the 5 regulations hasn't existed until recently, and so there is a concern about how the details of the 6 7 grandfathering would work in order to assure that there are enough individuals who are grandfathered 8 9 into that status that there would be an appropriate supply, an adequate supply of preceptors. 10 This is a confusing issue to me. 11 As I 12 understand the concern, it's that in many agreement licenses there is no counterpart to 13 state the 14 authorized medical physicist or HDR physicist that's named in the license, and so that there is a pool of

15 potential individuals fully competent HDR, gamma 16 stereotactic and Cobalt 60 teletherapy physicists who 17 are carrying out all of the duties named in the 600, 18 19 but simply because of the peculiarities, the 20 semantical differences effectively in the way licenses 21 are written in some agreement states versus in NRC 22 directly regulated states, there will be a group of 23 individuals who won't be grandfathered, and so there 24 is some concern, you know, how large this pool of individuals will be, whether this was going to cause 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

156

157 1 difficulties in the early implementation of the rule 2 to be able to get the individuals named on the 3 licenses, et cetera. 4 And so I think as I recall from the 5 teleconference this was sort of answered in the negative as being, well, just tough luck. 6 These 7 people won't count as AMPs and can't be preceptors. And I was wondering if you had put some further 8 9 thought and have any idea on how this might be 10 resolved either in rule language or in the 11 implementation of the rule. 12 DR. BROSEUS: We in the working group gave considerable attention to this issue, but I'm going to 13 14 defer to Ron and MSIB to see if he can address this a 15 little later. I might be able to. Dr. Zelac? 16 CHAIRMAN MALMUD: 17 DR. ZELAC: What the working group had recognized was exactly the same issue that you've just 18 19 raised, and what the working group had hoped could 20 take place was a suggestion to be made available to 21 the general medical physics community as well as their 22 regulators, many of whom are in the agreement states, 23 to move ahead forthright before Subpart J is gone, to 24 in some way become named on a license, to become 25 listed on a license and thereby be eligible to serve

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

158 1 preceptor for others seeking similar as а 2 authorization. 3 I know that there was reluctance on the 4 part of our Office of State and Tribal Programs to 5 convey this in that fashion, to make such a suggestion through an all agreement states letter or some other 6 7 mechanism to the agreement states, but I think that issue was probably at least one that I would have 8 expected would have been discussed at the recent OAS 9 meeting in some fashion so that there wouldn't be 10 11 people in such a gap in the future. 12 DR. BROSEUS: The reluctance, Ron, was in putting a requirement in here that would be laid on 13 14 agreement states because we have to be very careful 15 about that. 16 DR. ZELAC: I wasn't speaking of а 17 requirement. I was speaking specifically of а suggestion to be made, and I think there was --18 -- SPB and others and the 19 DR. BROSEUS: 20 state members of the working group are aware of this. 21 CHAIRMAN MALMUD: Thank you. 22 Mr. Bailey. MEMBER BAILEY: 23 I have to address that. 24 I mean, only one-fifth of the medical licensees are in 25 NRC territory. So you're going to have four-fifths of

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	159
1	the facilities not having named medical physicists.
2	Quite frankly, this is the first time I've heard of
3	this potential problem, but I think we've probably got
4	wrapped around the axle on 10(e) for doctors, quite,
5	frankly.
6	I can tell you right off we in California
7	would object to it because it's an increase in work
8	load to go just to meet a new whim, to go through and
9	evaluate the medical physicists that are presently
10	operating on our licenses.
11	We do have a list of people that we
12	consider to be qualified as medical physicists, but to
13	go through and name them on a license would be a
14	tremendous work load, I think, on the states to do.
15	So I'm sure we would object to doing it.
16	DR. BROSEUS: But what I'm hearing though
17	is that the state recognizes that these people are
18	qualified and almost by implication that your state,
19	persons who are well qualified will likely be
20	authorized.
21	MEMBER BAILEY: I have to respond to that
22	that in most cases I would say we do not know who the
23	medical physicist is at a hospital. We know how the
24	RSO is. We know in most cases who the authorized
25	users are, but in many, many cases, we don't know who

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	160
1	the medical physicist is or whether there is even a
2	resident medical physicist on the staff of that
3	hospital or whether or not they're contracting with
4	someone outside the hospital itself.
5	CHAIRMAN MALMUD: Dr. Williamson.
6	MEMBER WILLIAMSON: So what will your
7	state do then in this situation? Because a new
8	regulation will come around which says that you have
9	to have authorized medical physicists. One of the
10	criteria for being an authorized medical physicist is
11	that another authorized medical physicist attests to
12	the competence of the individual.
13	So what would be a solution to this in
14	your state? I'm curious to know.
15	CHAIRMAN MALMUD: The question is directed
16	to you, Mr. Bailey.
17	MEMBER BAILEY: Basically, what we are
18	doing right now is if this question comes up, and it
19	came up in the mammography field, is that we look for
20	Board certified people. Absent someone being Board
21	certified, then we have basically an underground
22	regulation that says, hey, you're going to get on the
23	list, and to do that, you have to have your training
24	and experience, your equipment, and your protocols
25	you're going to use.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	161
1	Now, I will go back and see what, if any,
2	plans we have made to add medical physicists to the
3	license, and I think we need to query all of the
4	agreement states. I'm not sure that all of the
5	agreement states in fact, I'm sure not all of the
6	agreement states are really aware of this provision.
7	MEMBER WILLIAMSON: I guess the other
8	question I would ask to the staff along the same lines
9	is, you know, my understanding of how we function as
10	a broad scope licensee, even as an NRC regulated state
11	is specific physicists and authorized users are not
12	actually mentioned on the license, but the license
13	gives the radiation safety committee the authority to
14	review the training credentials of candidates for
15	authorized user and authorized medical physicist.
16	And as an act of the radiation safety
17	committee, basically designate these individuals in
18	these roles. So would you consider individuals that
19	have been designated by the radiation safety committee
20	of a broad scope licensee in either an agreement
21	statement or in an NRC state to acceptable preceptors?
22	CHAIRMAN MALMUD: To whom is that question
23	addressed, Dr. Williamson?
24	MEMBER WILLIAMSON: This is addressed to,
25	I think, Dr. Broseus and Dr. Zelac, who seem to be

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

fielding these questions.

1

5

2 DR. BROSEUS: Let me tell you what I'm 3 hearing, and we need to go back with. First, you have 4 identified the potential problem that a person cannot serve as a preceptor who is not an authorized medical physicist, but has never been authorized, and it's a 6 7 chicken and egg syndrome.

we have to look at have we 8 And SO adequately provided for an avenue for people to serve 9 as preceptors to be precepting for an authorized --10 11 attesting for a medical physicist. That's number one. 12 Number two is an issue that is already there and dealt with routinely on broad licensees, and 13 14 that is basically the broad licensees have the same 15 responsibilities that license reviewers do. Ι shouldn't say it that way, but they're bound by the 16 same rules. Okay? 17

Now, generally speaking, and I'd have to 18 look at this in detail, if an individual is named by 19 a broad licensee or a permittee, like in the VA, they 20 21 can serve in the same role as an authorized user, 22 authorized medical physicist or whatever. Please 23 correct me if I'm wrong, but I think that that's a 24 non-problem.

The problem we need to go back with to the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

	163
1	working group is to make sure we have provided an
2	avenue appropriate for a person to attest for medical
3	physics.
4	MR. MOORE: Roger, if I may, in answer to
5	Dr. Williamson's question, I guess first I'd like to
6	say that the question that you raise, it's a problem
7	under the current rule as much as it's a problem under
8	the draft final rule, and so it's not a new problem
9	that you're raising. It's a problem with the rule
10	that's out there right now. The wording itself
11	doesn't change.
12	That said, you know, it's a valid
13	question. I can't speak for the legal interpretation,
14	but I think we would take a common sense approach, and
15	if a person is identified as a user under a broad
16	scope license or under a master material license and
17	that identification is made in writing somewhere, I
18	would think that we as a regulatory agency would
19	recognize that the same as if somebody was identified
20	on a license itself and accept that as a preceptor
21	identification.
22	And what you're really getting to is how
23	often do we challenge the credentials of a preceptor
24	and that's fairly rare.
25	MEMBER WILLIAMSON: Well, it's only rare

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1because, in fact, the country is being governed by2Subpart J where this is a non-issue, and so, you know,3you say that, yes, it's in the current regulation, but4the reason we're all here discussing this today is5because we all know that the current regulation is6broken. That's why we're trying to fix it.7And so I think this is a I'm sorry if8I don't find your answer satisfying.9DR. BROSEUS: But let me repeat. I10understand that your issue is a person may never have11been named as an authorized medical physicist, and so12there's a potential problem. The definition requires13that a person be an authorized medical physicist to14serve as a preceptor, but no such party exists.15Bottom line.16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMOD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.25MEMBER WILLIAMSON: So the fact that there		164
you say that, yes, it's in the current regulation, but the reason we're all here discussing this today is because we all know that the current regulation is broken. That's why we're trying to fix it. And so I think this is a I'm sorry if I don't find your answer satisfying. DR. BROSEUS: But let me repeat. I understand that your issue is a person may never have been named as an authorized medical physicist, and so there's a potential problem. The definition requires that a person be an authorized medical physicist to serve as a preceptor, but no such party exists. Bottom line. MEMBER WILLIAMSON: That's my concern, is how you're going to convert the existing user base. For authorized users, I presume this is much less significant a difficulty because that's a well established entity within both state and federal regulations. So it's sort of transparent to match. CHAIRMAN MALMUD: We have presented you, Dr. Broseus with that dilemma, which we hop you will report back to us about at our next meeting.	1	because, in fact, the country is being governed by
the reason we're all here discussing this today is because we all know that the current regulation is broken. That's why we're trying to fix it. And so I think this is a I'm sorry if I don't find your answer satisfying. DR. BROSEUS: But let me repeat. I understand that your issue is a person may never have been named as an authorized medical physicist, and so there's a potential problem. The definition requires that a person be an authorized medical physicist to serve as a preceptor, but no such party exists. Bottom line. MEMBER WILLIAMSON: That's my concern, is how you're going to convert the existing user base. For authorized users, I presume this is much less significant a difficulty because that's a well established entity within both state and federal regulations. So it's sort of transparent to match. CHAIRMAN MALMUD: We have presented you, Dr. Broseus with that dilemma, which we hop you will report back to us about at our next meeting.	2	Subpart J where this is a non-issue, and so, you know,
<ul> <li>because we all know that the current regulation is</li> <li>broken. That's why we're trying to fix it.</li> <li>And so I think this is a I'm sorry if</li> <li>I don't find your answer satisfying.</li> <li>DR. BROSEUS: But let me repeat. I</li> <li>understand that your issue is a person may never have</li> <li>been named as an authorized medical physicist, and so</li> <li>there's a potential problem. The definition requires</li> <li>that a person be an authorized medical physicist to</li> <li>serve as a preceptor, but no such party exists.</li> <li>Bottom line.</li> <li>MEMBER WILLIAMSON: That's my concern, is</li> <li>how you're going to convert the existing user base.</li> <li>For authorized users, I presume this is much less</li> <li>significant a difficulty because that's a well</li> <li>established entity within both state and federal</li> <li>regulations. So it's sort of transparent to match.</li> <li>CHAIRMAN MALMUD: We have presented you,</li> <li>Dr. Broseus with that dilemma, which we hop you will</li> </ul>	3	you say that, yes, it's in the current regulation, but
<ul> <li>broken. That's why we're trying to fix it.</li> <li>And so I think this is a I'm sorry if</li> <li>I don't find your answer satisfying.</li> <li>DR. BROSEUS: But let me repeat. I</li> <li>understand that your issue is a person may never have</li> <li>been named as an authorized medical physicist, and so</li> <li>there's a potential problem. The definition requires</li> <li>that a person be an authorized medical physicist to</li> <li>serve as a preceptor, but no such party exists.</li> <li>Bottom line.</li> <li>MEMBER WILLIAMSON: That's my concern, is</li> <li>how you're going to convert the existing user base.</li> <li>For authorized users, I presume this is much less</li> <li>significant a difficulty because that's a well</li> <li>established entity within both state and federal</li> <li>regulations. So it's sort of transparent to match.</li> <li>CHAIRMAN MALMUD: We have presented you,</li> <li>Dr. Broseus with that dilemma, which we hop you will</li> <li>report back to us about at our next meeting.</li> </ul>	4	the reason we're all here discussing this today is
7       And so I think this is a I'm sorry if         8       I don't find your answer satisfying.         9       DR. BROSEUS: But let me repeat. I         10       understand that your issue is a person may never have         11       been named as an authorized medical physicist, and so         12       there's a potential problem. The definition requires         13       that a person be an authorized medical physicist to         14       serve as a preceptor, but no such party exists.         15       Bottom line.         16       MEMBER WILLIAMSON: That's my concern, is         17       how you're going to convert the existing user base.         18       For authorized users, I presume this is much less         19       significant a difficulty because that's a well         20       established entity within both state and federal         21       regulations. So it's sort of transparent to match.         22       CHAIRMAN MALMUD: We have presented you,         23       Dr. Broseus with that dilemma, which we hop you will         24       report back to us about at our next meeting.	5	because we all know that the current regulation is
8       I don't find your answer satisfying.         9       DR. BROSEUS: But let me repeat. I         10       understand that your issue is a person may never have         11       been named as an authorized medical physicist, and so         12       there's a potential problem. The definition requires         13       that a person be an authorized medical physicist to         14       serve as a preceptor, but no such party exists.         15       Bottom line.         16       MEMBER WILLIAMSON: That's my concern, is         17       how you're going to convert the existing user base.         18       For authorized users, I presume this is much less         19       significant a difficulty because that's a well         20       established entity within both state and federal         21       regulations. So it's sort of transparent to match.         22       CHAIRMAN MALMUD: We have presented you,         23       Dr. Broseus with that dilemma, which we hop you will         24       report back to us about at our next meeting.	6	broken. That's why we're trying to fix it.
9DR. BROSEUS: But let me repeat. I10understand that your issue is a person may never have11been named as an authorized medical physicist, and so12there's a potential problem. The definition requires13that a person be an authorized medical physicist to14serve as a preceptor, but no such party exists.15Bottom line.16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMUD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.	7	And so I think this is a I'm sorry if
10 understand that your issue is a person may never have 11 been named as an authorized medical physicist, and so 12 there's a potential problem. The definition requires 13 that a person be an authorized medical physicist to 14 serve as a preceptor, but no such party exists. 15 Bottom line. 16 MEMBER WILLIAMSON: That's my concern, is 17 how you're going to convert the existing user base. 18 For authorized users, I presume this is much less 19 significant a difficulty because that's a well 20 established entity within both state and federal 21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	8	I don't find your answer satisfying.
11been named as an authorized medical physicist, and so12there's a potential problem. The definition requires13that a person be an authorized medical physicist to14serve as a preceptor, but no such party exists.15Bottom line.16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMUD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.	9	DR. BROSEUS: But let me repeat. I
12there's a potential problem. The definition requires13that a person be an authorized medical physicist to14serve as a preceptor, but no such party exists.15Bottom line.16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMUD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.	10	understand that your issue is a person may never have
13that a person be an authorized medical physicist to14serve as a preceptor, but no such party exists.15Bottom line.16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMUD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.	11	been named as an authorized medical physicist, and so
14 serve as a preceptor, but no such party exists. 15 Bottom line. 16 MEMBER WILLIAMSON: That's my concern, is 17 how you're going to convert the existing user base. 18 For authorized users, I presume this is much less 19 significant a difficulty because that's a well 20 established entity within both state and federal 21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	12	there's a potential problem. The definition requires
Bottom line. MEMBER WILLIAMSON: That's my concern, is how you're going to convert the existing user base. For authorized users, I presume this is much less significant a difficulty because that's a well established entity within both state and federal regulations. So it's sort of transparent to match. CHAIRMAN MALMUD: We have presented you, Dr. Broseus with that dilemma, which we hop you will report back to us about at our next meeting.	13	that a person be an authorized medical physicist to
16MEMBER WILLIAMSON: That's my concern, is17how you're going to convert the existing user base.18For authorized users, I presume this is much less19significant a difficulty because that's a well20established entity within both state and federal21regulations. So it's sort of transparent to match.22CHAIRMAN MALMUD: We have presented you,23Dr. Broseus with that dilemma, which we hop you will24report back to us about at our next meeting.	14	serve as a preceptor, but no such party exists.
17 how you're going to convert the existing user base. 18 For authorized users, I presume this is much less 19 significant a difficulty because that's a well 20 established entity within both state and federal 21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	15	Bottom line.
For authorized users, I presume this is much less significant a difficulty because that's a well established entity within both state and federal regulations. So it's sort of transparent to match. CHAIRMAN MALMUD: We have presented you, Dr. Broseus with that dilemma, which we hop you will report back to us about at our next meeting.	16	MEMBER WILLIAMSON: That's my concern, is
19 significant a difficulty because that's a well 20 established entity within both state and federal 21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	17	how you're going to convert the existing user base.
20 established entity within both state and federal 21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	18	For authorized users, I presume this is much less
21 regulations. So it's sort of transparent to match. 22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	19	significant a difficulty because that's a well
22 CHAIRMAN MALMUD: We have presented you, 23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	20	established entity within both state and federal
23 Dr. Broseus with that dilemma, which we hop you will 24 report back to us about at our next meeting.	21	regulations. So it's sort of transparent to match.
24 report back to us about at our next meeting.	22	CHAIRMAN MALMUD: We have presented you,
	23	Dr. Broseus with that dilemma, which we hop you will
25 MEMBER WILLIAMSON: So the fact that there	24	report back to us about at our next meeting.
	25	MEMBER WILLIAMSON: So the fact that there

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	165
1	aren't ready answers to his, you know, shakes my
2	confidence somewhat in, you know, giving an
3	unqualified endorsement to this rule
4	CHAIRMAN MALMUD: Dr. Miller.
5	MR. MILLER: Something you just said was
6	troubling to me concerning reporting back at the next
7	meeting. I think Ralph and Jeff have offered a
8	concern in this area, and it sounds to me, if I
9	understand the concern that you raise, if we go
10	forward and promulgate the regulation as it's written,
11	it's going to be problematic.
12	So reporting back at the next meeting is
13	going to be an issue. I guess my question would be is
14	there some recommendation that the committee could
15	make to us to fix the problem.
16	MEMBER WILLIAMSON: Yes.
17	CHAIRMAN MALMUD: We will give Dr.
18	Williamson an opportunity as soon as we hear from Dr.
19	Howe.
20	MEMBER WILLIAMSON: I would recommend
21	(Laughter.)
22	CHAIRMAN MALMUD: Dr. Williamson is
23	recommending we hear from Dr. Howe first.
24	DR. HOWE: I just wanted to make a comment
25	as to the fact that the NRC had this same predicament

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 when we brought in the authorized medical physicist, 2 and one of the things that happened when we did that 3 we already had -- and I don't know if the was 4 agreement states do it -- we already had physicists 5 listed for teletherapy physicists, and because we line itemed remote after-loaders, we had physicists listed 6 7 for authorization for HDR units and physicists listed for authorization for gamma knife units, and those 8 physicists that were listed on licenses or recognized 9 by broad scopes as being physicists for HDR and 10 11 physicists for knife considered qamma were 12 grandfathered, and the teletherapy physicists were certainly considered grandfathered. 13 14 So that gave us a small, but an existing 15 basis for having authorized medical physicist precept. 16 CHAIRMAN MALMUD: Thank you, Dr. Howe. Dr. Williamson. 17 Well, I think this 18 MEMBER WILLIAMSON: 19 sounds like I'm sure it was everybody's intention that 20 the rule work this way, but the language is stated in 21 such a specific way that it may not. So, you know, I 22 think my proposal would be that you amend the license 23 the rule -change the or excuse me \_ \_ and 24 grandfathering procedure to basically mean just what 25 Dr. Howe said, that individuals who are now authorized

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

166

	167
1	to serve as physicists for high dose rate
2	brachytherapy, Cobalt 60 teletherapy and gamma
3	stereotactic by whatever mechanism in the agreement
4	states or in NRC states be grandfathered as authorized
5	medical physicists in those respective modalities and
6	avoid the language, the unduly restrictive language
7	listed on a license, you know, and come up with some
8	substitute language that captures the population.
9	Because my understanding would be even in
10	California, fuel cycle 86-4, which came out in 1992,
11	was an edict that basically said, created through
12	underground regulation or whatever you call it an
13	entity called HDR Physicists that had to be Board
14	certified, had to attend treatments.
15	And so I would presume the agreement
16	states, you know, essentially had some mechanism for
17	promulgating those rules. No?
18	CHAIRMAN MALMUD: You've made a
19	recommendation on discussion. Can you just make the
20	recommendation, a brief recommendation to the
21	MEMBER WILLIAMSON: I will restate my
22	recommendation. My recommendation is that 3557 be
23	modified to read as follows: that physicists who have
0.4	been authorized to serve the function of authorized
24	been authorized to serve the runction of authorized

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

	168
1	gamma stereotactic radiosurgery and Cobalt 60
2	teletherapy be grandfathered to be allowed to serve
3	as authorized medical physicists for those respective
4	modalities.
5	CHAIRMAN MALMUD: Is there a second to
6	that motion? And then we'll open it for discussion.
7	MEMBER LIETO: Second.
8	CHAIRMAN MALMUD: It's been moved and
9	seconded, now open for discussion.
10	MEMBER BAILEY: Our biggest pool of
11	medical physicists are not in those areas. They
12	really are accelerator physicists, and I'm not sure
13	why I would exclude one of them from being named.
14	CHAIRMAN MALMUD: Dr. Williamson, do you
15	care to respond?
16	MEMBER WILLIAMSON: I'll try because I
17	think the intent of the new regulations is to require
18	the authorized medical physicist to have specific
19	experience, clinical experience essentially with the
20	modality in which they are allowed to precept in. So
21	that a physicist who has never supervised a high dose
22	rate brachytherapy procedure before and only does
23	external beam therapy would not be considered a
24	suitable preceptor, but someone who is currently
25	and I'm sure California is full of high dose rate

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	169
1	brachytherapy units would be, you know, a suitable
2	individual for serving as this preceptor.
3	CHAIRMAN MALMUD: Mr. Lieto?
4	MEMBER LIETO: I think Dr. Williamson
5	would maybe agree with this change to his motion and
6	it answered Mr. Bailey's concern if he replaced the
7	word "Cobalt 60" with "teletherapy," and that would,
8	I think, meet the intent of both groups.
9	MEMBER WILLIAMSON: Okay, yeah. Okay.
10	CHAIRMAN MALMUD: Are you willing to?
11	MEMBER WILLIAMSON: Oh, sure.
12	CHAIRMAN MALMUD: So your motion is
13	amended to replace Cobalt 60 with teletherapy. Does
14	the second remain intact?
15	MEMBER LIETO: So seconded.
16	CHAIRMAN MALMUD: All right. It has been
17	moved and seconded. Any further discussion of that
18	item?
19	Dr. Broseus.
20	DR. BROSEUS: I'd just like to clarify
21	because you brought up the point, and that is as
22	recommended by ACMUI for an authorized medical
23	physicist to qualify as an ANP, an individual has to
24	have training for the types of use which authorization
25	is sought, and that includes hands-on device

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	170
1	operations.
2	And so I'm not sure if I hear your I'm
3	not sure if I'm clear about where your motion is, and
4	that is: would your motion allow all of those types
5	of medical physicists?
6	MEMBER WILLIAMSON: No. It would not be
7	
8	DR. BROSEUS: Or would it be specific to
9	use?
10	MEMBER WILLIAMSON: It would be specific
11	to use. All I'm trying to do is suggest a more
12	general formulation of the grandfathering language
13	that, you know, gets around, you know, substitutes
14	listed on the license for some more general concept of
15	authorized currently by their license or licensee or
16	agency, whatever it is, to perform the functions
17	listed in 35.600. That's the concept, is that there
18	is a pool of working physicists within the agreement
19	state organization, within the agreement states that
20	one way or another have been authorized to perform the
21	required function sin 35.600, and those are the people
22	that logically need to be grandfathered, and we have
23	to alter the language.
24	CHAIRMAN MALMUD: Any further discussion
25	of the motion? Do you want to call the motion?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	171
1	MEMBER LIETO: I was just going to say the
2	bottom line, I think, here, Roger, is that in the
3	predecisional draft, it states that the NRC does not
4	believe that it is appropriate to grandfather medical
5	physicists to allow them to serve as AMPs, and what
6	we're saying is that that cannot be. We need this
7	initial pool of AMPs to be grandfathered, existing AMP
8	medical physicists to be grandfathered as AMPs, both
9	from the standpoint of continuing care and, two, to
10	serve as the pool for preceptors for shall we say the
11	second wave of AMPs?
12	CHAIRMAN MALMUD: Thank you.
13	Do you want to call the motion? All in
14	favor?
15	(Show of hands.)
16	CHAIRMAN MALMUD: Any opposed?
17	(No response.)
18	CHAIRMAN MALMUD: Any abstentions?
19	(No response.)
20	CHAIRMAN MALMUD: It carries unanimously.
21	Are there other items under this topic?
22	May we move on or shall we take a break
23	for lunch? How are you all feeling? Dr. Miller.
24	MR. MILLER: At the risk of having
25	everyone in this room shoot me

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	172
1	CHAIRMAN MALMUD: We're not armed.
2	MR. MILLER: I take it that our goal
3	from this meeting obviously our original intent was
4	not obtained. However, I'd like to be able to walk
5	out of this meeting if possible and tell me if it's
6	not possible with the knowledge that, with the
7	exception of the issues that have been raised and
8	voted upon, which we will take under advisement with
9	regard to change, that other aspects of the rule
10	are
11	CHAIRMAN MALMUD: Acceptable?
12	MR. MILLER: acceptable and we can go
13	forward.
14	You know, what I'd like to be able to do
15	is to be able to say, you know, when we go forward
16	with the rule, "Here's the recommendations that ACMUI
17	made to us with regard to what you see before you,
18	Commission, and here's how we dealt with those."
19	And absent those specific items, because
20	the Commission will ask us this, is ACMUI okay with
21	the rule as it's being proposed?
22	CHAIRMAN MALMUD: My feeling is that the
23	answer to your question is affirmative, but let me ask
24	the members of the committee.
25	With the exception of those items which

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	173
1	we've brought to the attention of staff, do we approve
2	of that which we've reviewed to move forward?
3	Sally?
4	MS. SCHWARZ: I would like specifically to
5	state rather than just generally; I would like to
6	state for nuclear pharmacy since we really haven't
7	mentioned this at all in the discussion. I mean, it's
8	really the only specialty that's not been discussed;
9	that we do agree with the regulations that are written
10	for the training and experience for nuclear pharmacy.
11	We have no problems with it as it is written.
12	CHAIRMAN MALMUD: Thank you.
13	Shall we entertain a motion to move
14	forward with all of the items except those which have
15	been brought to the attention of staff?
16	MEMBER EGGLI: So moved.
17	CHAIRMAN MALMUD: Dr. Eggli. A second to
18	that?
19	MS. SCHWARZ: Second.
20	CHAIRMAN MALMUD: Ms. Schwarz.
21	All in favor?
22	(Show of hands.)
23	CHAIRMAN MALMUD: Any opposed?
24	(No response.)
25	CHAIRMAN MALMUD: Any abstentions?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	174
1	(No response.)
2	CHAIRMAN MALMUD: It carries unanimously.
3	You have achieved your goal.
4	MR. MILLER: Thank you.
5	(Laughter.)
6	CHAIRMAN MALMUD: Now, is there a reward
7	for that?
8	MR. MILLER: Let's go to lunch.
9	CHAIRMAN MALMUD: We'll reconvene at one
10	o'clock promptly.
11	(Whereupon, at 12:12 p.m., the meeting was
12	recessed for lunch, to reconvene at 1:00 p.m., the
13	same day.)

1       AFTERNOON SESSION         2       (1:03 p.m.)         3       CHAIRMAN MALMUD: We are now back for the         4       afternoon session, which begins with the second half         5       of the morning session, and the item on the agenda now         6       will be introduced by I lost my place.         7       PARTICIPANT: This is the proposed change         8       on the AO criteria.         9       CHAIRMAN MALMUD: And this will A. Jones         10       of the NRC.         11       PARTICIPANT: Andrea Jones.         12       MS. JONES: Yes.         13       CHAIRMAN MALMUD: Andrea Jones. I'm         14       sorry. Is it Dr. or Ms. Jones or Ms. Jones?         15       MS. JONES: Ms.         16       CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,         17       and what is your role with the NRC so we may         18       introduced you properly?         19       MS. JONES: Health physicist.         20       CHAIRMAN MALMUD: This is Andrea Jones,         21       health physicist with the NRC, and the project is         22       entitled "Proposed Changes to AO Criteria."         23       Thank you.         24       MS. JONES: Okay. Thank you. <th></th> <th>175</th>		175
<ul> <li>CHAIRMAN MALMUD: We are now back for the</li> <li>afternoon session, which begins with the second half</li> <li>of the morning session, and the item on the agenda now</li> <li>will be introduced by I lost my place.</li> <li>PARTICIPANT: This is the proposed change</li> <li>on the AO criteria.</li> <li>CHAIRMAN MALMUD: And this will A. Jones</li> <li>of the NRC.</li> <li>PARTICIPANT: Andrea Jones.</li> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	1	AFTERNOON SESSION
<ul> <li>afternoon session, which begins with the second half</li> <li>of the morning session, and the item on the agenda now</li> <li>will be introduced by I lost my place.</li> <li>PARTICIPANT: This is the proposed change</li> <li>on the AO criteria.</li> <li>CHAIRMAN MALMUD: And this will A. Jones</li> <li>of the NRC.</li> <li>PARTICIPANT: Andrea Jones.</li> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	2	(1:03 p.m.)
5       of the morning session, and the item on the agenda now         6       will be introduced by I lost my place.         7       PARTICIPANT: This is the proposed change         8       on the AO criteria.         9       CHAIRMAN MALMUD: And this will A. Jones         10       of the NRC.         11       PARTICIPANT: Andrea Jones.         12       MS. JONES: Yes.         13       CHAIRMAN MALMUD: Andrea Jones. I'm         14       sorry. Is it Dr. or Ms. Jones or Ms. Jones?         15       MS. JONES: Ms.         16       CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,         17       and what is your role with the NRC so we may         18       introduced you properly?         19       MS. JONES: Health physicist.         20       CHAIRMAN MALMUD: This is Andrea Jones,         18       introduced you properly?         19       MS. JONES: Health physicist.         20       CHAIRMAN MALMUD: This is Andrea Jones,         21       health physicist with the NRC, and the project is         22       Thank you.	3	CHAIRMAN MALMUD: We are now back for the
<ul> <li>will be introduced by I lost my place.</li> <li>PARTICIPANT: This is the proposed change</li> <li>on the AO criteria.</li> <li>CHAIRMAN MALMUD: And this will A. Jones</li> <li>of the NRC.</li> <li>PARTICIPANT: Andrea Jones.</li> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	4	afternoon session, which begins with the second half
<ul> <li>PARTICIPANT: This is the proposed change</li> <li>on the AO criteria.</li> <li>CHAIRMAN MALMUD: And this will A. Jones</li> <li>of the NRC.</li> <li>PARTICIPANT: Andrea Jones.</li> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	5	of the morning session, and the item on the agenda now
8       on the AO criteria.         9       CHAIRMAN MALMUD: And this will A. Jones         10       of the NRC.         11       PARTICIPANT: Andrea Jones.         12       MS. JONES: Yes.         13       CHAIRMAN MALMUD: Andrea Jones. I'm         14       sorry. Is it Dr. or Ms. Jones or Ms. Jones?         15       MS. JONES: Ms.         16       CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,         17       and what is your role with the NRC so we may         18       introduced you properly?         19       MS. JONES: Health physicist.         20       CHAIRMAN MALMUD: This is Andrea Jones,         21       health physicist with the NRC, and the project is         22       entitled "Proposed Changes to AO Criteria."         23       Thank you.	6	will be introduced by I lost my place.
9CHAIRMAN MALMUD: And this will A. Jones10of the NRC.11PARTICIPANT: Andrea Jones.12MS. JONES: Yes.13CHAIRMAN MALMUD: Andrea Jones. I'm14sorry. Is it Dr. or Ms. Jones or Ms. Jones?15MS. JONES: Ms.16CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,17and what is your role with the NRC so we may18introduced you properly?19MS. JONES: Health physicist.20CHAIRMAN MALMUD: This is Andrea Jones,21health physicist with the NRC, and the project is22Thank you.	7	PARTICIPANT: This is the proposed change
<ul> <li>of the NRC.</li> <li>PARTICIPANT: Andrea Jones.</li> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	8	on the AO criteria.
11PARTICIPANT: Andrea Jones.12MS. JONES: Yes.13CHAIRMAN MALMUD: Andrea Jones. I'm14sorry. Is it Dr. or Ms. Jones or Ms. Jones?15MS. JONES: Ms.16CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,17and what is your role with the NRC so we may18introduced you properly?19MS. JONES: Health physicist.20CHAIRMAN MALMUD: This is Andrea Jones,21health physicist with the NRC, and the project is22entitled "Proposed Changes to AO Criteria."23Thank you.	9	CHAIRMAN MALMUD: And this will A. Jones
<ul> <li>MS. JONES: Yes.</li> <li>CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>MS. JONES: Ms.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	10	of the NRC.
<ul> <li>13 CHAIRMAN MALMUD: Andrea Jones. I'm</li> <li>14 sorry. Is it Dr. or Ms. Jones or Ms. Jones?</li> <li>15 MS. JONES: Ms.</li> <li>16 CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>17 and what is your role with the NRC so we may</li> <li>18 introduced you properly?</li> <li>19 MS. JONES: Health physicist.</li> <li>20 CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>21 health physicist with the NRC, and the project is</li> <li>22 entitled "Proposed Changes to AO Criteria."</li> <li>23 Thank you.</li> </ul>	11	PARTICIPANT: Andrea Jones.
14 sorry. Is it Dr. or Ms. Jones or Ms. Jones? 15 MS. JONES: Ms. 16 CHAIRMAN MALMUD: Ms. Jones. Ms. Jones, 17 and what is your role with the NRC so we may 18 introduced you properly? 19 MS. JONES: Health physicist. 20 CHAIRMAN MALMUD: This is Andrea Jones, 11 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	12	MS. JONES: Yes.
<ul> <li>MS. JONES: MS.</li> <li>CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,</li> <li>and what is your role with the NRC so we may</li> <li>introduced you properly?</li> <li>MS. JONES: Health physicist.</li> <li>CHAIRMAN MALMUD: This is Andrea Jones,</li> <li>health physicist with the NRC, and the project is</li> <li>entitled "Proposed Changes to AO Criteria."</li> <li>Thank you.</li> </ul>	13	CHAIRMAN MALMUD: Andrea Jones. I'm
16 CHAIRMAN MALMUD: Ms. Jones. Ms. Jones, 17 and what is your role with the NRC so we may 18 introduced you properly? 19 MS. JONES: Health physicist. 20 CHAIRMAN MALMUD: This is Andrea Jones, 14 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	14	sorry. Is it Dr. or Ms. Jones or Ms. Jones?
17 and what is your role with the NRC so we may 18 introduced you properly? 19 MS. JONES: Health physicist. 20 CHAIRMAN MALMUD: This is Andrea Jones, 21 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	15	MS. JONES: Ms.
<pre>18 introduced you properly? 19 MS. JONES: Health physicist. 20 CHAIRMAN MALMUD: This is Andrea Jones, 21 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.</pre>	16	CHAIRMAN MALMUD: Ms. Jones. Ms. Jones,
19 MS. JONES: Health physicist. 20 CHAIRMAN MALMUD: This is Andrea Jones, 21 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	17	and what is your role with the NRC so we may
CHAIRMAN MALMUD: This is Andrea Jones, health physicist with the NRC, and the project is entitled "Proposed Changes to AO Criteria." Thank you.	18	introduced you properly?
21 health physicist with the NRC, and the project is 22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	19	MS. JONES: Health physicist.
22 entitled "Proposed Changes to AO Criteria." 23 Thank you.	20	CHAIRMAN MALMUD: This is Andrea Jones,
23 Thank you.	21	health physicist with the NRC, and the project is
	22	entitled "Proposed Changes to AO Criteria."
24 MS. JONES: Okay. Thank you.	23	Thank you.
	24	MS. JONES: Okay. Thank you.
25 Today I'm going to present new language	25	Today I'm going to present new language

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

```
(202) 234-4433
```

	176
1	that, if approved by the Commission, will change the
2	way the NRC classifies and reports to Congress medical
3	events that we call abnormal occurrences.
4	Okay. What is an AO? The NRC defines an
5	abnormal occurrence as an unscheduled incident or
6	event determined to be significant from the standpoint
7	of public health or safety.
8	An AO can occur at a nuclear power plant,
9	a fuel facility, a radiography fill site, but in the
10	majority of the cases that we get reported to us, they
11	occur at hospitals or medical facilities.
12	Okay. Why should we revise the AO
13	criteria? To appropriately classify and report to
14	Congress only those events that the Commission
15	considers to have safety and security significance; to
16	reduce potential misunderstanding by the public of
17	actual health or safety significance from medical
18	event occurrences; and to acknowledge the introduction
19	of evolving therapeutic treatment procedures
20	delivering high radiation doses to portions of an
21	organ or tissue.
22	Let me give you just a couple of examples
23	to support a revisement of the AO criteria. In 2003,
24	one of the cases that we included in the AO report
25	involved an event where a patient received four

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

millicuries of Thallium 201 instead of the prescribed dose of four millicuries of Iodine 131.

What's the safety significance involved in 3 4 this case? Well, the oncologist evaluating the case 5 reported that no adverse health effects would occur. During an intervascular 6 Another case. 7 brachytherapy treatment procedure, 2,300 rads was given to an area approximately one and a half inches 8 away from the intended prescribed treatment site. If 9 a member of the public were to read this write-up, 10 11 they may think a high dose of 2,300 rads is really, 12 really a bad thing, but the doctor evaluating the case reported that the threshold delivered to this artery 13 14 was well below the threshold where adverse effect

15 would occur.

1

2

Okay. This slide just gives the current wording for medical licensees. A medical event will be considered an AO if it results in a dose that is equal or greater than 100 rads to the bone marrow, lens of the eye of the gonads, or equal to or greater than 1,000 rads to any other organ.

And a dose that is at least 50 percent greater than that prescribed or the wrong radiopharmaceutical or is delivered to the wrong treatment site by the wrong treatment mode or wrong

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	178
1	route of administration. That's the current wording.
2	The proposed new language. I'm not going
3	to read all of the different sections, but in summary,
4	what we did was and when I say "we," meaning the AO
5	working group we would add a new section which
6	would be recognized as Section A, adding the phrase
7	"unintended permanent functional damage by a
8	physician."
9	The term "tissue" would also be added to
10	"organ" to aid in classifying those areas where dose
11	was delivered to an area that's not called and
12	ordered.
13	B. The second change would be to increase
14	the dose threshold for the gonads from 100 rads to 250
15	rads. The term "tissue" is also added.
16	MEMBER NAG: Excuse me. Do you have this
17	in the handout? I'm trying to look for the handout.
18	Under what section?
19	MR. ESSIG: It's called "Proposed AO
20	Change."
21	MEMBER NAG: No handout?
22	MEMBER SULEIMAN: We have lots of no
23	copies actually.
24	MR. ESSIG: Do you have one?
25	CHAIRMAN MALMUD: I have one. He has one.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	179
1	A select member has one.
2	MS. JONES: I'm sorry. I thought that
3	CHAIRMAN MALMUD: I have one because I
4	have the distinct advantage of having left my book at
5	home and received the book as I arrived here. So I
6	didn't realize I had an advantage until now.
7	MR. MILLER: Trish, are there copies
8	there?
9	DR. HOLAHAN: Yes.
10	MR. MILLER: Trish will circulate copies.
11	We have an instant solution to this problem.
12	CHAIRMAN MALMUD: And may I ask a question
13	while we're waiting for the copies to be distributed?
14	MS. JONES: Yes.
15	CHAIRMAN MALMUD: The wording that you
16	have indicated has already been added in the second
17	slide on page 2; is that right, where you said that
18	the word "tissue" was added to "organ"?
19	MS. JONES: Yes.
20	CHAIRMAN MALMUD: Under B(3).
21	MS. JONES: Yes.
22	CHAIRMAN MALMUD: Very good. I have been
23	following you.
24	MS. JONES: Okay. That's your question?
25	Okay.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1MEMBER SULEIMAN:Why are you using2absorbed dose and not dose equivalent?3MS. JONES: That's the way the current4criteria is classified, is stated. That's the current5terminology that we use.6MEMBER SULEIMAN: So if it's an alpha or7a beta source?8MEMBER NAG: Now, the word "medical event"9and "abnormal occurrence" are two different entities10or are they going to be used interchangeably?11MS. JONES: No. A medical event is the12new wording for the previous term "medical13administration." And "abnormal occurrence" is a14different thing. It's at a higher threshold.15MEMBER SULEIMAN: Can I ask my question16again? I'm questioning why you're not using dose17equivalent rather than absorbed dose. Why not18sieverts or REM?19If you're using an alpha or beta course20technically the dose equivalent would be higher.21MS. JONES: Okay.22MS. JONES: Okay.23MR. ESSIG: We're talking about acute24events here, I think, in which case absorbed dose is25probably more accurate.		180
3       MS. JONES: That's the way the current         4       criteria is classified, is stated. That's the current         5       terminology that we use.         6       MEMBER SULEIMAN: So if it's an alpha or         7       a beta source?         8       MEMBER NAG: Now, the word "medical event"         9       and "abnormal occurrence" are two different entities         10       or are they going to be used interchangeably?         11       MS. JONES: No. A medical event is the         12       new wording for the previous term "medical         13       administration." And "abnormal occurrence" is a         14       different thing. It's at a higher threshold.         15       MEMBER SULEIMAN: Can I ask my question         16       again? I'm questioning why you're not using dose         17       equivalent rather than absorbed dose. Why not         18       sieverts or REM?         19       If you're using an alpha or beta course         20       technically the dose would be a factor ten times less         21       MS. JONES: Okay.         22       MS. JONES: Okay.         23       MR. ESSIG: We're talking about acute         24       events here, I think, in which case absorbed dose is	1	MEMBER SULEIMAN: Why are you using
4       criteria is classified, is stated. That's the current         5       terminology that we use.         6       MEMBER SULEIMAN: So if it's an alpha or         7       a beta source?         8       MEMBER NAG: Now, the word "medical event"         9       and "abnormal occurrence" are two different entities         10       or are they going to be used interchangeably?         11       MS. JONES: No. A medical event is the         12       new wording for the previous term "medical         13       administration." And "abnormal occurrence" is a         14       different thing. It's at a higher threshold.         15       MEMBER SULEIMAN: Can I ask my question         16       again? I'm questioning why you're not using dose         17       equivalent rather than absorbed dose. Why not         18       sieverts or REM?         19       If you're using an alpha or beta course         20       kechnically the dose would be a factor ten times less         21       MS. JONES: Okay.         22       MS. JONES: Okay.         23       MR. ESSIG: We're talking about acute         24       events here, I think, in which case absorbed dose is	2	absorbed dose and not dose equivalent?
5terminology that we use.6MEMBER SULEIMAN: So if it's an alpha or7a beta source?8MEMBER NAG: Now, the word "medical event"9and "abnormal occurrence" are two different entities10or are they going to be used interchangeably?11MS. JONES: No. A medical event is the12new wording for the previous term "medical13administration." And "abnormal occurrence" is a14different thing. It's at a higher threshold.15MEMBER SULEIMAN: Can I ask my question16again? I'm questioning why you're not using dose17equivalent rather than absorbed dose. Why not18sieverts or REM?19If you're using an alpha or beta course20when, in fact, the dose equivalent would be higher.21MS. JONES: Okay.23MR. ESSIG: We're talking about acute24events here, I think, in which case absorbed dose is	3	MS. JONES: That's the way the current
6       MEMBER SULEIMAN: So if it's an alpha or         7       a beta source?         8       MEMBER NAG: Now, the word "medical event"         9       and "abnormal occurrence" are two different entities         10       or are they going to be used interchangeably?         11       MS. JONES: No. A medical event is the         12       new wording for the previous term "medical         13       administration." And "abnormal occurrence" is a         14       different thing. It's at a higher threshold.         15       MEMBER SULEIMAN: Can I ask my question         16       again? I'm questioning why you're not using dose         17       equivalent rather than absorbed dose. Why not         18       sieverts or REM?         19       If you're using an alpha or beta course         20       technically the dose would be a factor ten times less         21       MS. JONES: Okay.         22       MS. JONES: Okay.         23       MR. ESSIG: We're talking about acute         24       events here, I think, in which case absorbed dose is	4	criteria is classified, is stated. That's the current
7       a beta source?         8       MEMBER NAG: Now, the word "medical event"         9       and "abnormal occurrence" are two different entities         10       or are they going to be used interchangeably?         11       MS. JONES: No. A medical event is the         12       new wording for the previous term "medical         13       administration." And "abnormal occurrence" is a         14       different thing. It's at a higher threshold.         15       MEMBER SULEIMAN: Can I ask my question         16       again? I'm questioning why you're not using dose         17       equivalent rather than absorbed dose. Why not         18       sieverts or REM?         19       If you're using an alpha or beta course         20       technically the dose would be a factor ten times less         21       MS. JONES: Okay.         22       MS. JONES: Okay.         23       MR. ESSIG: We're talking about acute         24       events here, I think, in which case absorbed dose is	5	terminology that we use.
8       MEMBER NAG: Now, the word "medical event"         9       and "abnormal occurrence" are two different entities         10       or are they going to be used interchangeably?         11       MS. JONES: No. A medical event is the         12       new wording for the previous term "medical         13       administration." And "abnormal occurrence" is a         14       different thing. It's at a higher threshold.         15       MEMBER SULEIMAN: Can I ask my question         16       again? I'm questioning why you're not using dose         17       equivalent rather than absorbed dose. Why not         18       sieverts or REM?         19       If you're using an alpha or beta course         20       technically the dose would be a factor ten times less         21       MS. JONES: Okay.         22       MS. JONES: Okay.         23       MR. ESSIG: We're talking about acute         24       events here, I think, in which case absorbed dose is	6	MEMBER SULEIMAN: So if it's an alpha or
9and "abnormal occurrence" are two different entities10or are they going to be used interchangeably?11MS. JONES: No. A medical event is the12new wording for the previous term "medical13administration." And "abnormal occurrence" is a14different thing. It's at a higher threshold.15MEMBER SULEIMAN: Can I ask my question16again? I'm questioning why you're not using dose17equivalent rather than absorbed dose. Why not18sieverts or REM?19If you're using an alpha or beta course20technically the dose would be a factor ten times less21MS. JONES: Okay.22MR. ESSIG: We're talking about acute24events here, I think, in which case absorbed dose is	7	a beta source?
<ul> <li>10 or are they going to be used interchangeably?</li> <li>11 MS. JONES: No. A medical event is the</li> <li>12 new wording for the previous term "medical</li> <li>13 administration." And "abnormal occurrence" is a</li> <li>14 different thing. It's at a higher threshold.</li> <li>15 MEMBER SULEIMAN: Can I ask my question</li> <li>16 again? I'm questioning why you're not using dose</li> <li>17 equivalent rather than absorbed dose. Why not</li> <li>18 sieverts or REM?</li> <li>19 If you're using an alpha or beta course</li> <li>20 technically the dose would be a factor ten times less</li> <li>21 when, in fact, the dose equivalent would be higher.</li> <li>22 MS. JONES: Okay.</li> <li>23 MR. ESSIG: We're talking about acute</li> <li>24 events here, I think, in which case absorbed dose is</li> </ul>	8	MEMBER NAG: Now, the word "medical event"
<ul> <li>MS. JONES: No. A medical event is the</li> <li>new wording for the previous term "medical</li> <li>administration." And "abnormal occurrence" is a</li> <li>different thing. It's at a higher threshold.</li> <li>MEMBER SULEIMAN: Can I ask my question</li> <li>again? I'm questioning why you're not using dose</li> <li>equivalent rather than absorbed dose. Why not</li> <li>sieverts or REM?</li> <li>If you're using an alpha or beta course</li> <li>technically the dose would be a factor ten times less</li> <li>when, in fact, the dose equivalent would be higher.</li> <li>MS. JONES: Okay.</li> <li>MR. ESSIG: We're talking about acute</li> <li>events here, I think, in which case absorbed dose is</li> </ul>	9	and "abnormal occurrence" are two different entities
12 new wording for the previous term "medical administration." And "abnormal occurrence" is a different thing. It's at a higher threshold. 15 MEMBER SULEIMAN: Can I ask my question again? I'm questioning why you're not using dose equivalent rather than absorbed dose. Why not sieverts or REM? 19 If you're using an alpha or beta course technically the dose would be a factor ten times less when, in fact, the dose equivalent would be higher. 20 MS. JONES: Okay. 21 MR. ESSIG: We're talking about acute events here, I think, in which case absorbed dose is	10	or are they going to be used interchangeably?
13administration." And "abnormal occurrence" is a14different thing. It's at a higher threshold.15MEMBER SULEIMAN: Can I ask my question16again? I'm questioning why you're not using dose17equivalent rather than absorbed dose. Why not18sieverts or REM?19If you're using an alpha or beta course20technically the dose would be a factor ten times less21when, in fact, the dose equivalent would be higher.22MS. JONES: Okay.23MR. ESSIG: We're talking about acute24events here, I think, in which case absorbed dose is	11	MS. JONES: No. A medical event is the
<ul> <li>14 different thing. It's at a higher threshold.</li> <li>15 MEMBER SULEIMAN: Can I ask my question</li> <li>16 again? I'm questioning why you're not using dose</li> <li>17 equivalent rather than absorbed dose. Why not</li> <li>18 sieverts or REM?</li> <li>19 If you're using an alpha or beta course</li> <li>20 technically the dose would be a factor ten times less</li> <li>21 when, in fact, the dose equivalent would be higher.</li> <li>22 MS. JONES: Okay.</li> <li>23 MR. ESSIG: We're talking about acute</li> <li>24 events here, I think, in which case absorbed dose is</li> </ul>	12	new wording for the previous term "medical
MEMBER SULEIMAN: Can I ask my question again? I'm questioning why you're not using dose equivalent rather than absorbed dose. Why not sieverts or REM? If you're using an alpha or beta course technically the dose would be a factor ten times less when, in fact, the dose equivalent would be higher. MS. JONES: Okay. MR. ESSIG: We're talking about acute events here, I think, in which case absorbed dose is	13	administration." And "abnormal occurrence" is a
16 again? I'm questioning why you're not using dose equivalent rather than absorbed dose. Why not sieverts or REM? 19 If you're using an alpha or beta course technically the dose would be a factor ten times less when, in fact, the dose equivalent would be higher. 20 MS. JONES: Okay. 23 MR. ESSIG: We're talking about acute events here, I think, in which case absorbed dose is	14	different thing. It's at a higher threshold.
<pre>17 equivalent rather than absorbed dose. Why not 18 sieverts or REM? 19 If you're using an alpha or beta course 20 technically the dose would be a factor ten times less 21 when, in fact, the dose equivalent would be higher. 22 MS. JONES: Okay. 23 MR. ESSIG: We're talking about acute 24 events here, I think, in which case absorbed dose is</pre>	15	MEMBER SULEIMAN: Can I ask my question
<pre>18 sieverts or REM? 19 If you're using an alpha or beta course 20 technically the dose would be a factor ten times less 21 when, in fact, the dose equivalent would be higher. 22 MS. JONES: Okay. 23 MR. ESSIG: We're talking about acute 24 events here, I think, in which case absorbed dose is</pre>	16	again? I'm questioning why you're not using dose
19If you're using an alpha or beta course20technically the dose would be a factor ten times less21when, in fact, the dose equivalent would be higher.22MS. JONES: Okay.23MR. ESSIG: We're talking about acute24events here, I think, in which case absorbed dose is	17	equivalent rather than absorbed dose. Why not
<pre>20 technically the dose would be a factor ten times less 21 when, in fact, the dose equivalent would be higher. 22 MS. JONES: Okay. 23 MR. ESSIG: We're talking about acute 24 events here, I think, in which case absorbed dose is</pre>	18	sieverts or REM?
21 when, in fact, the dose equivalent would be higher. 22 MS. JONES: Okay. 23 MR. ESSIG: We're talking about acute 24 events here, I think, in which case absorbed dose is	19	If you're using an alpha or beta course
<ul> <li>MS. JONES: Okay.</li> <li>MR. ESSIG: We're talking about acute</li> <li>events here, I think, in which case absorbed dose is</li> </ul>	20	technically the dose would be a factor ten times less
23 MR. ESSIG: We're talking about acute 24 events here, I think, in which case absorbed dose is	21	when, in fact, the dose equivalent would be higher.
24 events here, I think, in which case absorbed dose is	22	MS. JONES: Okay.
	23	MR. ESSIG: We're talking about acute
25 probably more accurate.	24	events here, I think, in which case absorbed dose is
	25	probably more accurate.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	181
1	MEMBER SULEIMAN: No. Let's say it's an
2	alpha source. It's in contact or beta, and so you
3	know, if you're delivering 1,000 rads beta, it's maybe
4	a wrong example. Let's say it is an alpha emitter.
5	MR. ESSIG: For a medical event?
6	MEMBER SULEIMAN: Well, I'm trying, but
7	the dose would be ten times higher. In other words,
8	1,000 rads of an alpha source would be 10,000 rem, and
9	so the actual equivalent would be ten times higher.
10	So there's a risk that would be greater.
11	Nominally for gamma or X-ray, they're
12	equivalent, but in those situations like a
13	brachytherapy, don't you take that into consideration
14	when you do your dose calculations?
15	MEMBER SULEIMAN: Do we have any alpha
16	PARTICIPANTS: No.
17	MR. ESSIG: Betas are I mean, most of
18	the time they're going to be equivalent, but I'm
19	thinking of the situation where you have a
20	contribution from some
21	MEMBER SULEIMAN: It would only be alphas.
22	The quality factor for betas is one.
23	MEMBER NAG: If I may as, (a), I guess
24	it's quite clear the result is unintended permanent
25	functional damage. The first thing is under B, the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

problems which are created by radioactive implants 2 that are closed to the eye because many times the eye 3 just by having the sources a few millimeters away 4 could increase the dose to the lens just quickly. A 5 radioactive implant for parietal melanomas in the eye, that very easily can give, you know, more than that 6 7 dose to the lens of the eye. Secondly, for the gonad, if you are having 8 9 an implant in the upper prostate, a gonad just by 10 having the implant a few millimeters one way or the other can easily give a dose greater than what you are 11 saying the gonads show. 12 We have to see how we are going to word 13 14 this. 15 Subir, this isn't "and" MEMBER EGGLI: You must meet A first before you even 16 condition. 17 begin to apply B. This is an "and" condition so that the threshold is unintended damage. 18 19 DR. HOLAHAN: And also it has to meet the criteria for medical event. 20 21 MEMBER NAG: Okay, but I think A itself, 22 if you are having a permanent damage even if it did not have any of the B, it would be a problem. 23 24 MEMBER VETTER: But if you prescribed this, then it's not a medical event. If it all was

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

1

(202) 234-4433

182

	183
1	administered in accordance with your prescription,
2	then it doesn't matter whether the eye got 100 rads or
3	1,000 rads. If that was your prescription, it's not
4	a medical event.
5	MEMBER WILLIAMSON: What if the GYN
6	patient had a fistula, for example? That happens,
7	say, two percent of the time. It's a complication,
8	you know, at a frequency level with a properly
9	administered treatment you would accept. You don't
10	want this to count.
11	MEMBER VETTER: These abnormal
12	occurrences, first of all, it's a medical event which
13	means didn't go the way you planned, and it's a high
14	level medical event.
15	MS. JONES: Right.
16	MEMBER NAG: Okay.
17	MR. ESSIG: And correct me if I'm wrong,
18	but if I can make another clarification here, I
19	believe that the B(1) is the same as is currently.
20	Even though it's proposed wording, B(1), the 100 rads
21	to major portion of bone marrow lens to the eye is the
22	same as it now.
23	MS. JONES: Right.
24	MR. ESSIG: The only thing that was
25	changed is that the gonads had previously been

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	184
1	included under that 100 rad statement.
2	MS. JONES: Correct.
3	MR. ESSIG: We have now moved them to the
4	250 rad, and so it's
5	MEMBER NAG: My misunderstanding was the
6	end because without the end, if it was either A or B,
7	then it would have been a problem.
8	CHAIRMAN MALMUD: Dr. Miller.
9	MR. MILLER: Quickly,I think what Andrea
10	is trying to do here is walk the committee through
11	some proposed changes to the O criteria, and if I
12	could ask for your patience, if she could walk through
13	all of the criteria, then I think what we would like
14	to do is to get your views on the new proposed
15	criteria that the staff has developed, but I think it
16	would be beneficial to hear the whole presentation
17	because I think when we keep jumping in in the middle,
18	it kind of discombobulates the
19	CHAIRMAN MALMUD: Thank you.
20	Now that everyone has a copy of the slide,
21	would you please continue?
22	MS. JONES: Okay. The proposed new
23	language which is denoted in bold with a new element
24	recognized as Section A, so NRC will consider a
25	misadministration a medical event that results in

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

unintended permanent functional damage to any organ or tissue as determined by a physician and which results in a dose that is equal to or greater than 100 rads to a major portion of the bone marrow or the lens of the eye or equal to or greater than 250 rads to the gonads or equal to or greater than 1,000 rads to any other -and I left the T out. I'm sorry -- to any other organ or tissue.

9 And there's a C: and represents either a 10 dose or a dosage that is 50 percent greater than that 11 prescribed in the written directive or a dose or a 12 dosage administered in the absence of a written 13 directive or a written directive was needed, but the 14 dose was given in mistake. It wasn't an intended 15 dosage.

And also we add the term "unsealed by product material" to three.

So really the proposed new wording, the major things that we're doing is we're adding A. The event has to result in some type of unintended permanent functional damage to an organ, and we add the word "tissue" because previously sometimes we get cases where there's not -- the area exposed isn't defined as an organ.

So you have to get A, first of all, in

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

25

1

2

3

4

5

6

7

8

186 1 order to even begin to meet the criteria for being 2 classified as an AO. So B, what's the change in B, 3 which was the previous A? We raised the dose to the 4 gonads to 250 rads, and we added the word "tissue" for 5 the same reasons that we added it in A. Okay? C, what we really did here, we tried to 6 7 capture those events that were given in error where 8 the doctor, because of the quantities or the 9 treatment, the doctor didn't even prepare a written directive because the facilities' procedures didn't 10 11 But there was permanent functional require one. 12 damage and the dose threshold was exceeded, and it follows the regular criteria. 13 14 MEMBER WILLIAMSON: Just a question of 15 clarification. For any of these, A, B, or C, to be 16 invoked, it already has to be a medical event per the definition in Part 35. So we're starting out with the 17 18 assumption --19 MS. JONES: Yes. MEMBER WILLIAMSON: -- that this already 20 21 meets the criteria. 22 MS. JONES: It reached the medical event. 23 MEMBER WILLIAMSON: Okay. 24 MEMBER LIETO: So is C just a repeat or 25 what the definition is of a medical event?

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	187
1	MS. JONES: No, C adds. It adds a new
2	"or" where there was you know, if you were where
3	there was an administration given and a written
4	directive wasn't prepared. So maybe the technologist
5	didn't know that she was supposed to give five
6	microcuries and she gave 500 millicuries. She didn't
7	I mean, there wasn't a written directive prepared.
8	So she didn't have the prescriptive directions in
9	front of her.
10	MS. McINTOSH: Pardon me. May I make a
11	comment right here? I'm on the working group with
12	Andrea to propose these changes.
13	For that language right there that's
14	highlighted, the purpose of that language is to
15	capture events whereby the dose administered was at a
16	level where a written directive was required, but
17	because the intended dose didn't require a written
18	directive, one was not prepared.
19	So stated differently, the doctor may have
20	intended to give the patient a diagnostic level dose,
21	but what wound up being administered was a therapeutic
22	level dose.
23	Well, in that case, a written directive
24	would not have been prepared because what was intended
25	was a dose that didn't require a written directive.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	188
1	So we want to capture events whereby the dose that was
2	administered, there should have been a written
3	directive prepared, and currently we're not capturing
4	those events because of the technicality that we don't
5	have that language in there. Yet a mistake, a
6	significant mistake was made.
7	So that's the purpose of adding that
8	proposed language there.
9	My name is Angela McIntosh, for the
10	record.
11	CHAIRMAN MALMUD: Thank you, Angela.
12	May we continue with your
13	MS. McINTOSH: Dr. Malmud, I believe Dr.
14	Howe.
15	CHAIRMAN MALMUD: Oh, all right. Because
16	we were going to okay, all right.
17	MS. SCHWARZ: This pertains to the
18	statements, Dr. Howe. I think in this case the
19	medical event that's at the top of the slide is not
20	the definition of a medical event that's in Part 35.
21	It is just the plain language medical event. It's
22	really an event in a medical use licensee's site
23	because of this additional part where we've had people
24	receive therapeutic doses when they were only supposed
25	to get diagnostic, and we want to capture those that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	189
1	have permanent functional damage.
2	And OGC has interpreted the reporting
3	requirements in Part 35 not to capture the case in
4	which there wasn't a written directive because one was
5	not intended, to start out with, and a therapeutic
6	dose is given.
7	So this is to help capture those.
8	CHAIRMAN MALMUD: Thank you.
9	Dr. Vetter.
10	MEMBER VETTER: Just quickly, if these
11	don't meet the definition of a medical event as
12	described in Part 35, they shouldn't be called medical
13	events.
14	MEMBER WILLIAMSON: Here, here.
15	MEMBER VETTER: We should use some other
16	term.
17	MS. JONES: Well, we call them abnormal
18	occurrences.
19	MEMBER VETTER: No, I mean in the
20	definition of this particular abnormal occurrence
21	we're seeing, first of all, these are medical events.
22	If these do not meet the definition of medical event
23	as per Part 35, they should not be called medical
24	events.
25	MS. JONES: Okay.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	190
1	MEMBER WILLIAMSON: It should say "an
2	administration of byproduct material that."
3	MS. JONES: I understand.
4	MEMBER WILLIAMSON: Good comment.
5	MS. JONES: Yeah.
6	CHAIRMAN MALMUD: Please go on.
7	MS. JONES: Okay. In conclusion, if
8	approved by the Commission, the revised medical
9	criterion will insure that and I'm just going to
10	say "medical events" for the purpose of the slides
11	already prepared insure that the medical events
12	reported to Congress have resulted in permanent
13	functional damage to a specified target organ or
14	surrounding tissue as determined by a physician; will
15	capture the current recommendations of ICRP 60;
16	include medical events where the dose was administered
17	in error and a written directive was not required for
18	the intended administration; and include unsealed
19	byproduct material commensurate with Part 35.
20	So I'm open to any questions or comments
21	that you may have right now. However, I am
22	requesting, you know, written comments to be submitted
23	to Angela by the end of this month.
24	CHAIRMAN MALMUD: Thank you, Ms. Jones.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	191
1	CHAIRMAN MALMUD: Are there any questions
2	or comments for Ms. Jones?
3	MEMBER NAG: Yes.
4	CHAIRMAN MALMUD: Dr. Nag.
5	MEMBER NAG: Now that I'm practicing all
6	of the "ands" and "ors" and so on, if you have a place
7	that this is no longer a medical event, you know, even
8	just the administration of a routine radioactive
9	material, you have now an unintended functional damage
10	and at the same time there was, for example, if this
11	was an implant in the eye, the lens would
12	automatically or most likely have received more than
13	100 Gray; almost any event that is having some
14	unintended functional damage in the eye will
15	automatically be in there.
16	MS. JONES: Oh.
17	MEMBER NAG: Yes.
18	MEMBER WILLIAMSON: Not if you intended to
19	damage the eye. If you did a treatment, say, of the
20	organ of the right eye and you accepted knowingly and
21	consented the patient and told them, you know, "Your
22	lens is going to get this dose and you're going to
23	have to have a lends transplant most likely," I think
24	that Phrase A because of the word "unintended" in
25	there would exclude this.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

Now, if you treated the wrong eye by 2 mistake, if the therapist made a mistake and treated the wrong eye, and that lens got a dose of 2.5 Gray 3 4 and the patient had a cataract or some other damage, then I think it would be an abnormal occurrence, 6 right?

7 MS. JONES: That's exactly right. This is not intended to capture therapy. This is intended to 8 9 capture mistakes, and that's the reason why the word "unintended" has been included. Something happened 10 11 that was not intended. So damage occurred to the 12 patient.

MEMBER NAG: And in that I think it may be 13 14 a good idea to have at the beginning that it had to be 15 medical event although, you know, you are saying а that doesn't really mean medical event. Perhaps it 16 17 would be better if the entry would be that it had to be a medical event in the first place. 18

MEMBER WILLIAMSON: But then they couldn't 19 20 capture all of the events they want to because if one 21 gives a diagnostic dose of radionuclide and, you know, 22 makes a mistake and gives 100 times too much 23 activity --

24 MEMBER NAG: That itself would be a 25 medical event.

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1

5

193
MEMBER WILLIAMSON: No, it is not. They
just told us that the definition of medical event
fails to capture that. So that's why they need to put
some more neutral language like "an administration of
byproduct material that."
MEMBER NAG: Yeah, you can put that.
Administration of the byproduct material that forces
a medical event, number one, and results in permanent
damage. That I think will solve that problem.
MEMBER WILLIAMSON: It will exclude, you
know, the bullet on her last slide insured where is
it? "Include medical events where the dose was
administered in error and a written directive was not
required," because the medical event definition in
Part 35 does not apply to cases where a written
directive was not required. Am I right?
MEMBER VETTER: No, you can still have
medical events.
MEMBER WILLIAMSON: You can have a medical
event where
MS. JONES: Yeah.
MEMBER VETTER: If there's 50 rads to an
organ or more than five rads to the whole body and

it's more than --

MEMBER WILLIAMSON: I thought someone just

**NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	194
1	I thought that Dr. Howe just said that the Office
2	of General Counsel had ruled that a misadministration
3	of a diagnostic dose that caused injury could not be
4	a medical event per Part 35. Is that not correct?
5	DR. ZELAC: Dr. Malmud.
6	CHAIRMAN MALMUD: Dr. Zelac.
7	DR. ZELAC: What was excluded from her
8	statement apparently is the condition relating to dose
9	that results from this. If you, in fact, administered
10	a dosage that exceeded on a percentage basis or was
11	outside of the range that was intended, that by itself
12	would not qualify as a medical event if we're talking
13	about a diagnostic dosage.
14	However, if the variation from the
15	intended dosage was sufficiently great that the
16	resultant dose to an organ exceeded the 50 rad limit,
17	then, in fact, it becomes a medical event.
18	So it's two conditions that are required.
19	MEMBER WILLIAMSON: All right. Then maybe
20	Dr. Nag's point is a good point, that it seems
21	unlikely you're what kind of a major complication
22	are you going to have without the diagnostic
23	administration satisfying the medical event criteria
24	in Part 35?
25	MS. JONES: Probably none.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	195
1	DR. HOWE: Dr. Malmud, may I make a
2	comment?
3	CHAIRMAN MALMUD: Please, Dr. Howe.
4	DR. HOWE: We've actually had people that
5	have given the wrong administration of the therapy,
6	but they haven't had a written directive either, and
7	this would capture those events also.
8	MEMBER NAG: That would automatically be
9	a medical event.
10	DR. HOWE: No, it would not because our
11	Office of the General Counsel reviewed these cases
12	with us, and they said, no, the prescribed does didn't
13	exist. So it can't be greater than the prescribed
14	does because there was no written directive.
15	And it's a problem we need to come back
16	and probably look at the rule language for again, but
17	that's what this is trying to capture, is the fact
18	that there are a few cases, and we've tried to set the
19	bar very high in other words, there's permanent
20	functional organ or tissue damage that will
21	capture these cases for which for one reason or
22	another there was no written directive, and so it
23	doesn't meet the criteria for a medical event, but it
24	certainly is a serious occurrence.
25	MEMBER NAG: Life threatening. If you

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	196
1	don't have a medical directive, that automatically
2	becomes a medical event. A medical event is an
3	occurrence where a written directive is not there,
4	when a written directive is required.
5	DR. HOWE: Dr. Nag, there's clearly a
6	violation of the regulations where to deliver a
7	therapeutic dose you should have had a written
8	directive. However, our Office of the General Counsel
9	has determined that when you go to the definition of
10	a medical event, it has to be a dose or dosage that
11	differs from the prescribed, and the prescribed is
12	that which is written in the written directive.
13	So if there is nothing written in the
14	written directive, then you don't have a prescribed
15	and you don't have a recording requirement because you
16	didn't have a medical event.
17	You can have a violation of the
18	regulations, but those cases would not be captured for
19	the abnormal occurrence in severe incidences because
20	they technically didn't meet medical event.
21	CHAIRMAN MALMUD: Dr. Eggli.
22	MEMBER EGGLI: Now, it strikes me that if
23	you don't have a written directive that you have to
24	have a standard dose by policy or procedure, and
25	wouldn't that be covered if you exceeded your standard

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	197
1	policy or procedure dose?
2	DR. HOWE: In the cases that we've had,
3	no, there hasn't been a standard.
4	MEMBER EGGLI: Because you can't just give
5	anything for a diagnostic study. I mean either you
6	have to have a prescribed dose or you have to have a
7	policy that says for a bone scan we give 20
8	millicuries. I mean, you can't just willy-nilly give
9	100 millicuries and say that's okay.
10	DR. HOWE: This case also captures those
11	therapeutic procedures that are given without a
12	written directive.
13	MEMBER NAG: I know that the therapeutic
14	procedure for which there is no written directive
15	required. Could you tell me I'll give you an
16	example. All the implants I do require a
17	DR. HOWE: Dr. Nag, the point isn't
18	whether you were supposed to have a written directive.
19	The point is there wasn't one. You were supposed to
20	have it, but it wasn't there.
21	MEMBER NAG: Yeah, but the definition of
22	medical event includes having a procedure where a
23	medical directive is not there. That automatically
24	becomes
25	MEMBER WILLIAMSON: That's what they're

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	198
1	telling you. That's not true.
2	MEMBER NAG: But there is. Why wouldn't
3	you include that?
4	DR. HOWE: That's our problem. It's not
5	there, Dr. Nag.
6	CHAIRMAN MALMUD: May I try and bring some
7	clarity to this? The circumstance that you're
8	describing, Dr. Howe, is one in which the physician
9	should have written a directive, did not do so. The
10	wrong dose was given. Since the current definition of
11	a medical event includes not abiding by the written
12	directive, it's not currently considered a medical
13	event because there was no breach of the written
14	directive which didn't exist.
15	DR. HOWE: That's correct.
16	CHAIRMAN MALMUD: All right. I understand
17	the problem. This does address that problem, does it
18	not?
19	DR. HOWE: Yes, it does.
20	CHAIRMAN MALMUD: Is there anyone who
21	feels that this does not address that problem? Dr.
22	Lieto.
23	MEMBER LIETO: I don't think it fixes it
24	because what you should do is change the definition of
25	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	199
1	that doesn't seem to be in here.
2	CHAIRMAN MALMUD: Was that given
3	consideration to changing the definition of a medical
4	event?
5	DR. HOWE: We currently have a user need
6	memo that we're in the process of finalizing going to
7	rulemaking that would change the rule text, but in the
8	meantime we would not have these severe events
9	reported when they are a severe event and they should
10	be reported under the abnormal occurrence.
11	So it's going to take us years to get rule
12	language changed, and the priority for going in and
13	opening Part 35, I believe, at this particular point
14	is very low.
15	CHAIRMAN MALMUD: All right. So now we
16	understand that the presentation by Ms. Jones is for
17	a specific instance which is not covered by the
18	current regulations adequately and that this would
19	cover it until the definition of a medical event can
20	be redefined. Is that a fair statement?
21	DR. HOWE: I believe that's clear.
22	MR. MILLER: Almost.
23	CHAIRMAN MALMUD: Almost. What did I
24	leave out?
25	MR. MILLER: I think the distinction that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	200
1	you have to make is the purpose for which it's used.
2	What we're offering here is we have a definition
3	currently of abnormal occurrence, you know. We're
4	focusing on the medical abnormal occurrence at this
5	point in time.
6	CHAIRMAN MALMUD: Yes.
7	MR. MILLER: We have a requirement to
8	report to Congress the number of abnormal occurrences
9	every year and what they are. What we're proposing to
10	do here is to change the definition of abnormal
11	occurrence as it relates to the medical area so that
12	what we report to Congress truly captures all that we
13	would intend to report and fix the problem for the
14	definition of abnormal occurrence.
15	It doesn't fix the problem at this point
16	in time of the definition of a medical event, and I
17	think Dr. Williamson has offered a way around that for
18	the purposes of the definition of abnormal occurrences
19	as to, you know, not call it a medical event. I
20	think you used the term "administration of byproduct
21	material." Dr. Vetter identified the fact that you
22	couldn't call it a medical event if it didn't meet the
23	strict definition.
24	So the distinction is it's for different
25	purposes. You know, it's not to replace the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	201
1	definition of medical event.
2	CHAIRMAN MALMUD: We understand.
3	MR. MILLER: It's to fix the abnormal
4	occurrence definition to more accurately report to
5	Congress those things that are really of concern to us
6	that meet the threshold.
7	CHAIRMAN MALMUD: Pretty straightforward.
8	Mr. Lieto.
9	MEMBER LIETO: Well, I'm going to take the
10	devil's advocate side here. I have an event that does
11	not have to be reported. In other words, I give ten
12	millicuries to a patient of 131 that was only supposed
13	to get 100 mics. I don't write a written directive.
14	I don't have to report it
15	MS. JONES: Right.
16	MEMBER LIETO: according to this
17	because it doesn't meet a medical event.
18	MS. JONES: Right.
19	MEMBER LIETO: So how do you capture
20	something that doesn't have to be reported?
21	MEMBER VETTER: Excuse me. You said
22	you're going to give ten millicuries instead of
23	MEMBER LIETO: No, I gave ten millicuries
24	and I was supposed to give 100 mics.
25	MEMBER VETTER: That is a medical event

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	202
1	because ten millicuries of I-131 to the thyroid is not
2	insignificant.
3	MEMBER LIETO: No, I didn't write the
4	written directive.
5	MEMBER WILLIAMSON: But it gives a dose of
6	more than 50 centigrade to some organ, right?
7	MS. JONES: Well, it would have to result
8	under the new wording.
9	MEMBER LIETO: See, what I'm saying is
10	that you need to change what we're doing is we're
11	putting a Bandaid in the wrong spot. Okay? We're not
12	fixing what needs to be fixed because if I don't have
13	to report it because I didn't have a written
14	directive, what's
15	DR. HOWE: This is Dr. Howe.
16	Just because you don't have to report it
17	doesn't mean that NRC may not become aware of it
18	because it is a violation of the regulations and we
19	may become aware of it during inspection or at some
20	other point at which the information comes forward.
21	So it's a violation of the regulations and is a
22	regulatory concern.
23	But you're right. It's not reportable
24	under the medical event reporting requirements.
25	CHAIRMAN MALMUD: Dr. Suleiman.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	203
1	MEMBER SULEIMAN: What if you give a 50
2	rad dose without a written directive and that's what
3	you intended? So you deliver the dose you intended,
4	but there was no written directive. So what would
5	that be?
6	MS. JONES: If there was no permanent
7	functional damage, then it wouldn't be an AO.
8	CHAIRMAN MALMUD: It wouldn't be
9	reportable, but it would still be something which the
10	radiation safety officer
11	MS. JONES: Yes.
12	CHAIRMAN MALMUD: within the
13	institution would monitor and point out was an error.
14	MS. JONES: Right.
15	MEMBER WILLIAMSON: And if they found it
16	during an inspection, you could be cited for a
17	violation.
18	MS. JONES: Right.
19	PARTICIPANT: I also understand the legal
20	argument in that you have never specifically
21	prescribed the dose, how can you know that you are
22	exceeding it by a certain quantity since there's no
23	reference value to compare it against.
24	So that's dangerous, but I can sometimes
25	understand their perspective.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	204
1	MEMBER LIETO: I mean, I see what Andrea
2	and Angela and the group is trying to do, but you
3	know, I guess why can't you just I mean, we all
4	recognize that this just simply needs to have that one
5	line item in the definition of a medical event.
6	You're doing all of these changes to Part
7	35 right now. Why don't you just slip it in there?
8	(Laughter.)
9	MEMBER LIETO: It's not a significant
10	change.
11	CHAIRMAN MALMUD: Well, I think
12	experience, which Dr. Howe has reinforced by reminding
13	us, indicates that it would take a long time to get
14	that done, and here is a potential solution to a
15	current problem which Andrea Jones has given us a
16	solution to.
17	MR. MILLER: I think, again, what Ralph
18	has offered is exactly on target with regard to a
19	problem that we have to separate into two separate
20	issues here because the definition of medical event
21	needed to be changed, and I think we agree that it
22	should be, and that will go through its due course in
23	order to get changed.
24	What we're trying to focus on here is
25	getting current and accurate wording for what an

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	205
1	abnormal occurrence should be so that the annual
2	reporting of that to Congress reflects our current
3	thinking on what an abnormal occurred should be,
4	regardless of whether or not it's reportable to the
5	NRC.
6	As we've pointed out, we may learn a
7	matter by some other means even though it might not be
8	reported.
9	CHAIRMAN MALMUD: Ralph, you wanted to say
10	something?
11	MEMBER LIETO: Well, I was just going to
12	say in the last occurrence report, I mean, you still
13	have captured those events and reported them. I mean,
14	it's not like this definition is not prevented the NRC
15	from capturing these events and reporting them to
16	Congress in line with this new proposed definition,
17	and I don't have an objection there.
18	I guess, you know, the issues of getting
19	the real problem fixed, which as Charlie pointed out
20	is a separate issue.
21	CHAIRMAN MALMUD: Mr. Essig was next, I
22	believe.
23	MR. ESSIG: Just to quickly add on, I
24	don't know that we've clarified or made the point yet
25	that the language you're looking at here is not for a

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	206
1	rule. It's for management directive, which is an
2	internal NRC document. So a rulemaking would be a
3	totally separate issue. This is just language and
4	management directive which is much easier to change.
5	CHAIRMAN MALMUD: Thank you.
6	Dr. Holahan.
7	DR. HOLAHAN: Yes. The other thing, and
8	I haven't talked to the working group yet, but the
9	criteria for AOs also includes for our licensees human
10	expose to radiation from licensed material. If the
11	committee believes it's important to keep it to
12	medical events, maybe we could put it in that
13	criteria, the things that are not technically a
14	medical event.
15	CHAIRMAN MALMUD: Thank you.
16	Dr. Essig.
17	MR. ESSIG: I think that this is good,
18	particularly with the addition of Part A and the
19	changing of the threshold to resulting in functional
20	damage. I think this is real good, and I think we
21	should endorse it.
22	You know, some of the wording may be
23	convoluted. We may be trying to fix a problem
24	incompletely fixed, but I think just the addition of
25	Part A itself justifies our endorsing it.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	207
1	CHAIRMAN MALMUD: Is there a second to
2	that motion?
3	MEMBER WILLIAMSON: Second.
4	CHAIRMAN MALMUD: Any further discussion?
5	(No response.)
6	CHAIRMAN MALMUD: All in favor?
7	(Chorus of ayes.)
8	CHAIRMAN MALMUD: Any negatives?
9	(No response.)
10	CHAIRMAN MALMUD: Any abstentions?
11	(No response.)
12	CHAIRMAN MALMUD: You have carried it
13	unanimously. Thank you.
14	MS. JONES: Thank you.
15	CHAIRMAN MALMUD: The next item on the
16	agenda, national source tracking.
17	MR. ESSIG: We were pulling that off the
18	agenda because of time.
19	CHAIRMAN MALMUD: And then we're going to
20	go to the ICRP recommendations.
21	MR. ESSIG: Yes, and I wanted to make a
22	word or two of introduction.
23	CHAIRMAN MALMUD: Mr. Essig is going to
24	introduce Dr. Vetter and the issue that is before us,
25	and there is a handout which you all should have, and

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	208
1	we're passing around something else relevant to this
2	discussion.
3	MR. ESSIG: And while that's being passed
4	around, I should
5	CHAIRMAN MALMUD: So there are two
6	handouts to this; is that correct?
7	MR. ESSIG: No, not this one. It's in
8	your packet.
9	CHAIRMAN MALMUD: It's in the book.
10	MR. ESSIG: Or it was given to you.
11	CHAIRMAN MALMUD: Or it was given to you,
12	one of the two.
13	MR. ESSIG: I should just add that I
14	really wasn't going to introduce Dr. Vetter since he
15	needs no introduction. I was just going to introduce
16	the topic.
17	The topic is next week you have one of
18	your handouts, notes that the Advisory Committee on
19	Nuclear Waste will be meeting, and they have a working
20	group which will be reporting to them on Tuesday, the
21	19th regarding their comments on the proposed ICRP
22	2005 recommendations.
23	They've pulled together a large number of
24	speakers, some NRC people, an NIH expert on biological
25	aspects of radiation protection, and Dr. Keith

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	209
1	Eckerman from Oak Ridge National Laboratory, a number
2	of very well known people in the community.
3	And you will notice on the agenda, page 2,
4	at two o'clock your own Edgar Bailey, representing
5	CRCPD, will be presenting, and then followed by him
6	will be Dr. Vetter.
7	And the purpose of today was for Dr.
8	Vetter to give an overview of the recommendations and
9	some of his insights, and then entertain any comments
10	from the committee that he should carry to the meeting
11	next Tuesday representing really, although it says
12	Mayo Clinic, he's really representing the ACMUI. That
13	was asked for. They wanted a representative of the
14	ACMUI.
15	So I believe we'll be asking you to
16	empower Dr. Vetter to carry forward any comments that
17	you may have or if you have no comments, to accept the
18	comments that he has prepared.
19	CHAIRMAN MALMUD: Thank you, Mr. Essig.
20	Dr. Vetter.
21	MEMBER VETTER: Thank you.
22	I'm going to forego the formal slides
23	projecting them on the screen. We'll just take a look
24	at the handout because most of this I'll skip through
25	rather quickly.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

ICRP's fundamental aim hasn't changed much or basically not at all. The intended use might be worth emphasizing that their intention is to influence regulatory agencies, management bodies, and so forth. Oh, by the way, these slides, potential impact of ICRP 2005, they were provided for you. Okay. You have them.

So the intended use, ICRP intends for 8 regulatory 9 their recommendations influence to 10 agencies. They're not in large measure directing 11 these at us as individual practitioners, but there are 12 certain aspects of it that do affect us individually. They do define safety culture. They have 13 14 some principles of protection which there are a couple 15 of things that are worth mentioning. One of them is that they now more clearly spell out a restriction on 16 dose from certain activities, and they call this a 17 constraint. 18

And I must say, if you have the same reactions I do, you have to read through some of this several times before you really begin to understand what they mean by "constraint," but I'll try to point that out to you as we go.

24 So they do have some restrictions on dose 25 called a constraint. This is not a dose limit for an

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

	211
1	individual, but it's a constraint, dose constraint on
2	particular activities. They want us to understand
3	that their position is that achieving a constraint is
4	an obligation. So it almost becomes a limit, a dose
5	limit or it does become a regulatory limit of sorts.
6	And they also make it very clear that if
7	a program does not maintain a constraint, then it is
8	failing. The program is failing in that regard.
9	The scope of the recommendations, they do
10	clearly define what they mean by various sources. A
11	source is a cause of an exposure, not a particular
12	radiation source.
13	I'm not going to read through most of
14	these. Practice judgment. Judgment it's worth
15	pointing out, I think. They're saying that the
16	responsibility for justification falls on governments
17	or government agencies, except for medical.
18	In other words, if the public is going to
19	be exposed to a source of radiation through some
20	proved activity, that is up to the government to
21	justify that. For medical it's different. For
22	medical they're saying that justification has more to
23	do with not causing harm to patients, doing more good
24	to patients than harm. They're saying that the
25	practice must be justified, and the justification lies

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 more with the profession than the government. 2 So justification for implementation of 3 computerized tomography, for example, or PET or a new 4 byproduct material, introduction of a new source of 5 radiation to a practice must be justified by the profession, but justification of the procedure, so 6 7 applying that to a particular patient or in a practice must be justified by the practitioners. 8 9 Classes of exposure, the classified exposure by various groups of people and how they can 10 11 be exposed. Occupational, pretty straightforward, 12 occurs at work principally as the result of work, that being the responsibility of management. Medical, 13 14 exposure of persons as part of their diagnosis or 15 treatment, and there are no constraints for that particular class of exposure. 16 There they clearly 17 point out and emphasize that those exposures must be justified. 18 finally, public, 19 And then all other 20 That's a class of exposure. exposures. 21 Now to the point of dose constraints. 22 the definition or the purpose Just of а dose

23 constraint. А dose constraint is provide to 24 protection for the, underscore, exposed most 25 individual; so the individual who would get the

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

212

highest dose within a class of exposure. That would be occupational, medical or the public, whichever individual gets the highest dose within one of those classes, from a single source.

5 Now, it falls out of the purview of the NRC, but I will mention because some of you in this 6 7 room would be very familiar with this issue. There is a very contentious issue in the radiation protection 8 9 community right now that falls right square in this ballpark, and that is the design of diagnostic X-ray 10 11 facilities to prevent the public from receiving a 12 certain does, and the NCRP has recently approved a report that will allow a hospital to design a shield 13 14 that could result in the highest dose to an individual 15 member of the public of 100 millirem.

Now, that is the public 16 limit, 100 17 millirem. Most states have adopted that, but the NCRP also has buried in one of its recommendations, we 18 19 don't call it a constraint in this country, but it's 20 sort of a sublimit; that if a member of the public 21 could be exposed to more than one source of radiation, 22 then each of those sources should be a fraction of 23 that 100 millirem limit.

And so now the argument is, well, members of the public who sit in a waiting room, if they could

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

	214
1	receive 100 millirem at this hospital, what if they're
2	living over here and they're receiving 25 millirem
3	from this source of air from a reactor or whatever it
4	might be? I know they don't get that much, but it's
5	a philosophical issue.
б	So this is a big deal. This constraint
7	thing is a big deal, and I think we need to just be
8	aware of that.
9	So relative to our own activities as it
10	applies to public exposure, we need to keep in mind
11	that a constraint means that the individual member of
12	the public could be exposed. If the member of the
13	public could be exposed to more than one source of
14	radiation, then each of those sources can't expose the
15	member of the public to the limit. The limit is a
16	combination of all those sources, and each one of them
17	must be constrained. That's the recommendation.
18	And that's where it gets confusing,
19	because in the next table you'll see that the dose
20	constraint, the maximum value of the dose constraint
21	is the value listed. So, for example, for societal
22	benefit, that would be a member of the public,
23	societal benefit meaning people are not being
24	informed; they're not being trained; there's no
25	individual assessment as to what their exposure is.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	215
1	The constraint is one millisievert or 100 millirem.
2	That's the maximum constraint.
3	The next table shows you the limit, and
4	you'll see the limit for a member of the public is
5	also one millisievert or 100 millirem. That's the
6	limit. So if the member of the public is being
7	exposed to more than one source of radiation, then
8	each of those must be constrained so that the member
9	of the public doesn't get 100 millirem.
10	Do you see what I'm saying?
11	And that will be problematic in terms of
12	agreeing philosophically with that. It really comes
13	down to a very difficult problem on application. Does
14	that mean that every hospital has to assure that a
15	member of the public doesn't get one-tenth if they
16	could go to ten different hospitals? I mean, where do
17	you draw the line here?
18	This is going to require some significant
19	discussion.
20	Now, just to point out again, as Tom
21	mentioned, the purpose of my presentation here is to
22	take your views to next week's meeting. So I don't
23	know that we want to spend a whole lot of time
24	discussing this because this is simply a
25	recommendation at this point, but if you perceive that

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	216
1	this could be a significant problem, I want to take
2	that to next week's meeting.
3	Dr. Miller, did you have a question?
4	MR. MILLER: I have a question out of
5	ignorance. Would by that definition X-rays be
6	included?
7	MEMBER VETTER: These recommendations
8	apply to everyone.
9	MR. MILLER: So if someone went to get a
10	dental X-ray or a medical X-ray
11	MEMBER VETTER: Oh, I'm sorry. They don't
12	apply to the procedure itself, to the patient's dose.
13	They apply to the visitor waiting for the patient, the
14	visitor in the waiting room.
15	MR. MILLER: Okay. So if you were the
16	patient you wouldn't have
17	MEMBER VETTER: There's no constraint on
18	patient dose.
19	MR. MILLER: Okay.
20	MEMBER VETTER: An there's no limit on
21	patient dose.
22	MR. MILLER: Okay.
23	MEMBER VETTER: This is a member of the
24	public who would be waiting for the patient in the
25	waiting room.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	217
1	MR. MILLER: I understand, but if they by
2	some means were to get some dose from that source,
3	that would be counted?
4	MEMBER VETTER: If who? Oh, you mean the
5	patient while they were in the waiting room?
6	MR. MILLER: Yeah, if I was in the waiting
7	room.
8	MEMBER VETTER: Absolutely, yes.
9	MR. MILLER: Not that it's practical, I
10	mean, but if by some means they did.
11	MEMBER VETTER: Right. Anyone sitting in
12	the waiting room basically.
13	MR. MILLER: I guess from I'm sorry I'm
14	interrupting.
15	MEMBER VETTER: No, that's okay.
16	MR. MILLER: But the thought that I have
17	is how are you going to accumulate this. How are you
18	going to account for this? People are going to have
19	to walk around with dosimetry on?
20	MEMBER VETTER: No, I think
21	MR. MILLER: From a practical perspective,
22	how would you accumulate the fact that you have
23	exceeded the hundred by all of those means?
24	MEMBER VETTER: No, that's a very good
25	question, a very good question, and the medical

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

community, medical physics community is almost in an 2 uproar over this because you can't. You can't 3 possibly measure. You have to calculate it, and so 4 the constraint is something that has to be -- it's almost an artificial thing. You have to design your facility so that the maximally exposed individual 6 would not get more than the constraint.

8 MR. MILLER: The radiation safetv 9 community has been practicing this for decades. It's 10 just that now they're trying to come up with some 11 guidance and come up with some new numbers, but the 12 fact is we're dealing with some very, very low numbers, and so it's not a completely new practice. 13 14 It's just that the numbers are going to be downsized 15 somewhat, and that's caused the anxiety.

Well, 16 MEMBER VETTER: what's really 17 different about it is there's very little data to support -- well, the data that has been collected 18 19 suggests that anyone sitting in a waiting room is 20 going to get almost an immeasurable dose, but when the waiting room is designed, when you determine the 21 22 thickness of the shield on the wall, what criteria do 23 you use for that? 24 One of them is what's the permissible dose

25 that person sitting in the waiting room, and to

> **NEAL R. GROSS** COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

5

7

	219
1	historically the medical physics community has used
2	the public dose limit as the maximum dose to any
3	person sitting in the waiting room.
4	The constraint would suggest that you must
5	use a lower number because that member of the public
6	might be exposed to more than one source of radiation.
7	In other words, they might got to Hopkins and then
8	they go to Georgetown and so forth. So each one of
9	them would need to design their facility so that the
10	member of the public would receive some fraction of
11	the maximum permissible dose, not the maximum
12	permissible dose.
13	MEMBER WILLIAMSON: I think there can be
14	I'm sorry.
15	MR. MILLER: I'm sorry. I didn't mean to
16	interrupt you.
17	CHAIRMAN MALMUD: That's the purpose of
18	this.
19	MEMBER WILLIAMSON: Yeah. Well, I think
20	an analogy can be made between this and prostate
21	brachytherapy. In prostate brachytherapy, if you
22	placed the regulatory limit at something, a minimum or
23	maximum dose, that's a single point. The result will
24	be notoriously unreliable and of no clinical
25	significance.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	220
1	So I think the problem with the system is
2	the fact that it doesn't deal with a stochastic model
3	of the patient population, but tries to base the whole
4	idea on the concept that no single individual
5	exceeding the maximum dose with 100 percent
6	probability, which is, you know, a clogged procedure.
7	So I think that the fundamental suggestion
8	one could make to inform this process better is to go
9	to some sort of a probability based model where the
10	likelihood of individuals being in three successive
11	waiting rooms at Hopkins, Mass. General Hospital,
12	wherever, is taken into account.
13	CHAIRMAN MALMUD: Dr. Miller.
14	MR. MILLER: Dr. Vetter, I'm sorry if I
15	missed the innuendo, but this would be for more than
16	just medical; is that correct, as you're defining it?
17	MEMBER VETTER: Yes, right. The ICFP 2005
18	applies to when they say the dose to the public, it
19	cold be from any source.
20	MR. MILLER: So if I were a member of the
21	public who was visiting a nuclear power plant, then
22	the dose I received for that would have to be added to
23	this by that. Okay?
24	If I had some business and I happened to
25	be adjacent to an industrial radiography facility,

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	221
1	that would have to be added.
2	MEMBER VETTER: Yes, all of those are
3	added.
4	MR. MILLER: I think that that begins to
5	show the difficulty.
6	MEMBER VETTER: Well, the point they would
7	make, Dr. Miller, the point they would make is it
8	isn't right to expose that person to 100 millirem per
9	year in each case. That's the point that ICRP would
10	make.
11	MR. MILLER: Is it only from regulated
12	activities as opposed to natural sources of radiation
13	or is that
14	MEMBER EGGLI: What if I live in a brick
15	house?
16	MEMBER VETTER: Cosmic are excluded.
17	Radon is not.
18	MEMBER EGGLI: So what about natural
19	radiation in brick?
20	PARTICIPANT: That's background. So
21	that's excluded.
22	MR. MILLER: Radon is not.
23	MEMBER VETTER: No, that would be
24	MEMBER EGGLI: A brick house is going to
25	give me

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	222
1	MEMBER VETTER: That does not
2	MEMBER EGGLI: in a year.
3	MEMBER VETTER: They don't specifically
4	address brick. What they do is they address any
5	activity that could increase your dose, and so they
6	would probably say the brick should be included.
7	MR. MILLER: How about a flight, if I took
8	an airplane?
9	MEMBER VETTER: A flight would be
10	included, yeah, anything that what they're saying
11	is their recommendations apply to anything, any new
12	exposure or anything where you manipulate something
13	and increase the dose. The example they use in that
14	regard is radon.
15	DR. HOLAHAN: I'm going to ask Vince
16	Holahan to speak to that because he's shaking his
17	head.
18	DR. VINE HOLAHAN: Yes, good afternoon.
19	Vice Holahan. I'm from Research.
20	The key point here is controllable
21	sources. If it's not a controllable source, it
22	doesn't come under the jurisdiction of the scope of
23	these recommendations. A case in point, Dr. Miller
	bed montioned on simplene flight Whatle not
24	had mentioned an airplane flight. That's not

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	223
1	You'll also find that when we talk about
2	radon, it generally tends to be the industrial
3	applications, and they say if you fall below a certain
4	level and they articulated what the maximum level
5	should be, then that's considered now a
6	noncontrollable source. So they've got some breaks in
7	there.
8	MS. SCHWARZ: I have a question. Have
9	they made any recommendations of how many sources in
10	a year, I mean, or that there should be a limit to
11	each occurrence?
12	MEMBER VETTER: No. My understanding is
13	they are recommending to governments that each source
14	of radiation, controllable source of radiation, should
15	have a constraint, and the maximum constraint it one
16	millisievert per year for a member of the public, 20
17	for occupational and so forth.
18	So each government would have to decide on
19	how many constraints would be appropriate.
20	CHAIRMAN MALMUD: Thank you.
21	Please go on.
22	MEMBER VETTER: Did Ralph do you?
23	MEMBER LIETO: No, I was going to wait
24	until you finished.
25	MEMBER VETTER: Okay. That's constraints.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1 relative to dose limits, Now, the 2 occupational limit, they are simply reemphasizing 3 that, 20 millisieverts per year or that's two rem, 4 averaged over five years with a maximum of 50 5 millisieverts or five rem in any one year. I don't different, 6 believe that's but they're simply 7 reemphasizing that. Now, relative to medical, I know Vince 8 Holahan has taken a look at some doses from other 9 sources where the NRC is able to track those doses, 10 11 but relative to occupational doses in medicine, we 12 have --MEMBER VAN DECKER: No national database 13 14 to track those. 15 MEMBER VETTER: People don't do a whole lot of publishing on what the doses are within their 16 17 facility, except to say that our doses in cardiology were such-and-so, and we took the following action, 18 19 and so now they're such-and-so. So they're lower. So 20 this action was a good thing to do. So they're very specific relative to 21 22 cardiac lab dose or nuclear medicine personnel in the 23 hot lab, that sort of thing. 24 We don't have a good idea of what average doses are in medicine, what maximum doses are in 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

medicine. I took a look at my own facility, and we would be able to live with this. The only people that get badge doses that exceed five rem in any one year are people such as interventional cardiologists who are wearing an apron, and when you factor in the apron, the effective dose is a couple hundred millirem a year.

8 In nuclear medicine, our technologists, 9 the highest doses they get are a few hundred millirem 10 per year. The imaging techs would get less than that. 11 Those that work in the hot lab would be a few hundred 12 millirem a year.

Their hand doses can get pretty high if you don't watch them, but nothing that -- so this is just looking at one facility, but I don't have a good handle on average doses -- I don't mean average dose -- on a distribution of doses among workers in medical facilities in this country, and I don't know if anybody does.

20 MEMBER VAN DECKER: Well, there have been 21 some published studies, occupational for RTs, 22 radiological technologists, and whatever, and the 23 results are relatively --

24 MEMBER VETTER: They're all within these 25 limits.

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

1MEMBER VAN DECKER: Yeah, yeah.2CHAIRMAN MALMUD: Ralph?3MEMBER LIETO: I was just going to make4the comment that medical exposures probably provide5the largest group of individuals that are exposed6ionizing radiation, but there's no requirement or any7resource that keeps any type of a national either8database or even just like the NRC requires, I think,9for a fuel cycle and nuclear power and waste and so10forth. They have to provide these what do you call11it? not necessarily the individual exposures, but1213DR. HOLAHAN: Yes, but it's a rare14database and they have to provide statistical data.15MEMBER LIETO: Right. I mean, there's16nothing like that for medical. So, you know, there's17really don't have a good handle onto what that19actually is when you start to look at, you know, the20fluoroscopy exposures and so forth.		226
MEMBER LIETO: I was just going to make the comment that medical exposures probably provide the largest group of individuals that are exposed ionizing radiation, but there's no requirement or any resource that keeps any type of a national either database or even just like the NRC requires, I think, for a fuel cycle and nuclear power and waste and so forth. They have to provide these what do you call it? not necessarily the individual exposures, but  DR. HOLAHAN: Yes, but it's a rare database and they have to provide statistical data. MEMBER LIETO: Right. I mean, there's nothing like that for medical. So, you know, there's really no central location that that's kept so we really don't have a good handle onto what that actually is when you start to look at, you know, the	1	MEMBER VAN DECKER: Yeah, yeah.
4 the comment that medical exposures probably provide 5 the largest group of individuals that are exposed 6 ionizing radiation, but there's no requirement or any 7 resource that keeps any type of a national either 8 database or even just like the NRC requires, I think, 9 for a fuel cycle and nuclear power and waste and so 10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	2	CHAIRMAN MALMUD: Ralph?
5 the largest group of individuals that are exposed 6 ionizing radiation, but there's no requirement or any 7 resource that keeps any type of a national either 8 database or even just like the NRC requires, I think, 9 for a fuel cycle and nuclear power and waste and so 10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	3	MEMBER LIETO: I was just going to make
6 ionizing radiation, but there's no requirement or any 7 resource that keeps any type of a national either 8 database or even just like the NRC requires, I think, 9 for a fuel cycle and nuclear power and waste and so 10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	4	the comment that medical exposures probably provide
7 resource that keeps any type of a national either 8 database or even just like the NRC requires, I think, 9 for a fuel cycle and nuclear power and waste and so 10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	5	the largest group of individuals that are exposed
8database or even just like the NRC requires, I think,9for a fuel cycle and nuclear power and waste and so10forth. They have to provide these what do you call11it? not necessarily the individual exposures, but1213DR. HOLAHAN: Yes, but it's a rare14database and they have to provide statistical data.15MEMBER LIETO: Right. I mean, there's16nothing like that for medical. So, you know, there's17really no central location that that's kept so we18really don't have a good handle onto what that19actually is when you start to look at, you know, the	б	ionizing radiation, but there's no requirement or any
9 for a fuel cycle and nuclear power and waste and so 10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	7	resource that keeps any type of a national either
<pre>10 forth. They have to provide these what do you call 11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the</pre>	8	database or even just like the NRC requires, I think,
<pre>11 it? not necessarily the individual exposures, but 12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the</pre>	9	for a fuel cycle and nuclear power and waste and so
12 13 DR. HOLAHAN: Yes, but it's a rare 14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	10	forth. They have to provide these what do you call
13DR. HOLAHAN:Yes, but it's a rare14database and they have to provide statistical data.15MEMBER LIETO:Right. I mean, there's16nothing like that for medical.So, you know, there's17really no central location that that's kept so we18really don't have a good handle onto what that19actually is when you start to look at, you know, the	11	it? not necessarily the individual exposures, but
14 database and they have to provide statistical data. 15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	12	
15 MEMBER LIETO: Right. I mean, there's 16 nothing like that for medical. So, you know, there's 17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	13	DR. HOLAHAN: Yes, but it's a rare
nothing like that for medical. So, you know, there's really no central location that that's kept so we really don't have a good handle onto what that actually is when you start to look at, you know, the	14	database and they have to provide statistical data.
17 really no central location that that's kept so we 18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	15	MEMBER LIETO: Right. I mean, there's
18 really don't have a good handle onto what that 19 actually is when you start to look at, you know, the	16	nothing like that for medical. So, you know, there's
19 actually is when you start to look at, you know, the	17	really no central location that that's kept so we
	18	really don't have a good handle onto what that
20 fluoroscopy exposures and so forth.	19	actually is when you start to look at, you know, the
	20	fluoroscopy exposures and so forth.
21 MEMBER VETTER: So based on the feedback	21	MEMBER VETTER: So based on the feedback
22 or our knowledge in this room, we should be able to	22	or our knowledge in this room, we should be able to
23 live with this occupational limit of 20 millisieverts	23	live with this occupational limit of 20 millisieverts
24 per year averaged over five years.	24	per year averaged over five years.
25 DR. HOLAHAN: I have a question to that.	25	DR. HOLAHAN: I have a question to that.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	227
1	Are you sure that the interventional cardiologist can
2	live with that? Because we were under the impression
3	that they had troubles meeting the five rem.
4	MEMBER EGGLI: Yeah, they do. So do
5	conventional radiologists.
6	MEMBER VETTER: To the bad, you mean.
7	MEMBER EGGLI: No, adjusted dose. There
8	are a lot of procedures that are very high.
9	CHAIRMAN MALMUD: Dr. Van Decker, the
10	question is are you familiar at all with the exposures
11	of interventional cardiologists, your colleagues, with
12	respect to annual dose?
13	MEMBER VAN DECKER: I would preface it by
14	saying I'm not an interventionalist myself, but having
15	been on enough radiation safety committees, I would
16	say that most of them to badge break this number but
17	on calculated effect of doses usually are much less,
18	and so don't break the limits at that point.
19	CHAIRMAN MALMUD: Thank you.
20	I think we had some additional comments.
21	Dr. Suleiman.
22	MEMBER SULEIMAN: Yes and no because I'm
23	going back and forth with the medical exposure and
24	the
25	CHAIRMAN MALMUD: Oh, I'm sorry. I

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	228
1	thought you had your hand up.
2	MEMBER SULEIMAN: And I didn't. I was
3	vacillating between whether I should say something or
4	not, but the effective dose with the whole body dose
5	and the organ doses there when you're dealing with the
6	specific organ doses, you're introducing a factor of
7	ten or so greater safety, you know, but I don't think
8	this is as I said earlier, I think we can live with
9	these numbers. I think it's just more of what we've
10	been doing in the past.
11	The two rem per year, I think you can
12	allow five rem in a given year. They just don't want
13	you to exceed an average of two rem over a ten-year
14	period of time.
15	So it's an effort to sort of impose more
16	constraint, but it's not, like you said, a limit. So
17	the interventionalist, I agree that you hear stories
18	about them approaching the limits, but you also hear
19	about some stories where good radiation safety
20	practice can get those doses lower.
21	So aside from the academic debate about
22	how you calculate the doses and what it's doing, I
23	think those numbers are pretty realistic.
24	MEMBER VETTER: So it may be fair to say
25	that anecdotally these numbers are realistic, but we

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	229
1	really don't know whether or not or what the impact
2	this would have on individual practices.
3	CHAIRMAN MALMUD: Dr. Williamson.
4	MEMBER WILLIAMSON: Well, I guess there's
5	two other categories of workers. I'd ask the question
6	whether this means we're going to leave the two rem
7	limit, and that would be cyclotron workers, especially
8	from positron emitting radionuclides where it's high
9	energy and aprons aren't going to make any difference,
10	and I think the other group where there may be some
11	concern might be source handlers and manufacturers
12	where I hear anecdotally workers do get pushed.
13	DR. HOLAHAN: Manufacturers and
14	distributors are already required to input into the
15	REARS (phonetic) database, and I don't know.
16	PARTICIPANT: I don't know what those
17	doses are.
18	DR. HOLAHAN: But I think they're below
19	the limits, but I don't know if they're below two rem.
20	CHAIRMAN MALMUD: Thank you.
21	MS. SCHWARZ: I would say for PET workers,
22	not even the cyclotron operators, I mean, for the
23	technologists, that would run about 200 millirem a
24	month. So over a year, 200 millirem a month. I mean,
25	that's not all workers, and probably if you look at

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

230 1 averages you'll be all right, but individual workers 2 may have some problems. 3 MEMBER LIETO: I was just going to say 4 that I think the two rem is going to create some 5 difficulties, and I think people need to recognize that, you know, basically that's the dose. 6 Even 7 though it's constraint on one page, it's a limit on the other, and Dick's presentation here, and I think 8 9 that it gets to the question what is wrong now with the current limits. 10 You know, we are for the most part living 11 12 below the five rem and probably very close to below the two rem for even our worst case situations. What 13 14 is the necessity; what is the driving force for 15 ratcheting these down even further? Okay? Because it's just going to, I think, require I think the 16 economic factors and so forth. 17 People are going to say, well, the limit 18 19 You know, if I'm going to implement is two rem. 20 ALARA, does that mean now the new ALARA levels should 21 be 200 millirem? 22 You know, I just think this is really, 23 really not a good thing. 24 DR. HOLAHAN: And I just want to note that 25 this was the same thing that was in ICRP 60 that we

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	231
1	didn't adopt.
2	CHAIRMAN MALMUD: Dr. Eggli.
3	MEMBER EGGLI: Also, what is this going to
4	do to the cost of construction of medical facilities
5	when you have to increase the shielding to meet these
6	new guidelines? Right now we have a new CT scan, and
7	we're not going to install because the cost of adding
8	the shielding to the space where we want to install it
9	is equal to the price of the instrument. So it's not
10	going to happen.
11	I mean, this could have problems as you
12	ratchet down the public exposures. The cost of
13	shielding medical devices is going to make a
14	significant impact on the cost of health care.
15	MR. BAKER: I think that's a good point.
16	In their recommendations ICRP does not address quality
17	of life or any of those issues. They don't try to
18	quantify benefit in any way. There's simply their
19	mission. They have blinders on, and their idea is to
20	try to keep doses as low as possible, you know,
21	justify and so forth.
22	I think they tried to be reasonable, but
23	they're very firm believers in the linear, no
24	threshold dose response curve, and they're driving the
25	doses down, and they don't look at these other side

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	232
1	issues.
2	MS. SCHWARZ: And another issue: have
3	they quantified any risks? I mean, is there reason
4	because they have determined the risks from ionizing
5	radiation?
6	MEMBER VETTER: Well, they've indicated
7	that they have examined the biological literature and
8	so forth, and first of all, these numbers, as Trish
9	mentioned, the two rem average over five years, that's
10	not a change. They're simply underscoring.
11	MS. SCHWARZ: No, I understand.
12	MEMBER VETTER: Yeah.
13	MS. SCHWARZ: I understand.
14	MEMBER VETTER: No, they believe that
15	that's what they have selected as an acceptable risk.
16	CHAIRMAN MALMUD: Dr. Williamson.
17	MEMBER WILLIAMSON: Yeah, I think
18	especially given that this two rem has been instituted
19	in their literature for some time, the area of most
20	concern would be paring back the 100 MR limit for
21	members of the general public, and I think that this
22	is an opportunity to try to how shall I say it?
23	at least delay their program to ratchet down dose
24	limits in an ever more irrational way to zero, no
25	matter what the cost to anybody.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	233
1	So I'm wondering what your opinion would
2	be, Dick, about what would be sort of tactically the
3	most appropriate and how could I say? useful
4	objections to bring up at this event that would make
5	sense to them and resonate, would actually have some
6	impact in modifying this, slowing down the approval of
7	this effective lower limit for the members of the
8	general public.
9	MEMBER VETTER: Well, this isn't new
10	either. They've had a constraint for members of the
11	public prior. So this isn't new either.
12	I think it might be a little different.
13	Do you know, Vince? It's .3 millisieverts per year.
14	What was the old one?
15	DR. VINCE HOLAHAN: Well, right now we
16	already have constraints. We use constraints in our
17	rulemaking, and an example of that is the
18	decommissioning rule, and we're fighting with EPA as
19	a constraint for decommissioning. The unrestricted
20	release of those sizes should be 15 millirem or 25
21	millirem.
22	We have water standards that are four
23	millirem. So these are already being used in this
24	country, and we essentially call them constraints. So
25	this is not a new issue.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1 One issue I would like to raise is there's 2 another class of worker you've got to consider, and 3 this is one of the few changes they have in their 4 limits, even though they say there are no changes in 5 the limits. That's to the fetus. The fetal exposure would not be 100 millirem. 6 7 So my question would be: what is the impact on the declared pregnant worker? 8 9 MEMBER VETTER: Yeah, that's in one of my 10 later slides, but we can talk about it now. 11 DR. VINCE HOLAHAN: And right now in the 12 United States, the fetal exposure for the declared pregnant worker is 500 millirem during the remainder 13 14 of the course of the pregnancy. 15 Part 60, ICRP 60, which was published in 1991, is 200 millirem to the surface of the abdomen. 16 17 Now these recommendations would say 100 millirem, and I would ask what impact would this have on some of 18 19 your declared workers that might be, in particular, 20 medicine and things like that. 21 Ralph. CHAIRMAN MALMUD: 22 I'll tell you right now MEMBER LIETO: 23 they wouldn't be able to work. All right? Period. 24 Because I have to assure that, and for me to say that 25 a nurse, nuke med tech or whatever, I have not ever

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	235
1	had anybody in the decades that I've been responsible
2	for this had a pregnant worker exceed 500, but I've
3	had a few over 100. Okay?
4	Now, the fact that I know that it can
5	occur means, one, that they would not be able to
6	declare pregnancies, okay, if they wanted to continue
7	on working, is basically what it gets to because if we
8	have to meet this 100 millirem, you can't have
9	declared pregnancies because they're going to be
10	mutually exclusive in the training or practice of
11	using ionizing radiation.
12	And I think it's catastrophic.
13	CHAIRMAN MALMUD: Dr. Eggli.
14	MEMBER EGGLI: I think along that line I
15	agree with Ralph on a far broader basis. I think an
16	interventional physician who is getting exposed to
17	somewhere near the limit is going to be inclined to
18	take their badge off and put it in a drawer and going
19	to continue to work because if you damage my
20	livelihood and tell me I can't work for the next five
21	years because I've hit my limit, that ain't going to
22	fly.
23	So I think that you have to look at what's
24	the benefit, you know. I understand that if you
25	believe in the linear nonthreshold model, then you can

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	236
1	calculate a mathematical benefit, but you have to look
2	at the cost of that benefit, and the cost of that
3	benefit, I think, as we ratchet these things down to
4	ever lower levels becomes economically for society as
5	a whole and for individuals within that society
6	becomes prohibitive.
7	CHAIRMAN MALMUD: Thank you.
8	Another comment? Let's see. Dr. Suleiman
9	and then Dr. Lieto.
10	MEMBER SULEIMAN: At FDA actually we're
11	dealing with some ethical issues regarding young
12	pediatric, the fetus, and the radiation risks, I've
13	had that responsibility lately, but there's a whole
14	other issue that has an element of what's probably
15	driving this very thing. So my perspective on this is
16	that I think I can live with the two rem, five rem
17	because I think in reality it's obtainable.
18	But I am concerned when you're getting
19	down to what we would consider background levels, when
20	you're talking about a millisievert and you're going
21	to pick up three during the course of a year and
22	you're further restraining or constraining the fetus
23	at an almost ridiculously low level for an
24	occupational worker, I think that's probably if you're

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	237
1	where you ought to focus on it rather than the
2	occupational limits.
3	CHAIRMAN MALMUD: Thank you.
4	Ralph.
5	MEMBER LIETO: Well, I was going to just
6	say like Orhan had said that we're looking at
7	fractions of background that they want to have these
8	limits put at, which really makes it very difficult to
9	understand the credibility for this, other than
10	simply lower is better, and I wanted to go back to a
11	point that I think Dr. Miller might have asked about
12	with the shielding.
13	We've run into this already on the
14	diagnostic X-ray side in my state, and what you have
15	to also look at is not only future facilities,
16	existing facilities that have already been designed in
17	existence, especially in urban areas.
18	What you're now saying is that I think
19	they're using a constraint of one-third in the ICRP.
20	Putting the exact same machine in there with the exact
21	same work load, everything else identical, you now
22	have to put three times the shielding in to meet this
23	constraint level. Okay? Just simply because they
24	want to lower it to these newer values, and I think
25	that what it basically is going to prevent, renovation

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	238
1	and reuse of existing therapy rooms. It will prevent
2	facilities in urban areas from expanding because
3	there's no place to go to. Okay? They have to
4	basically use those areas that currently exist.
5	And, again, it gets to this what is the
6	benefit that we are trying to achieve, and I just see
7	it as being a blank answer as far as what the benefit
8	is.
9	CHAIRMAN MALMUD: Thank you.
10	Dr. Eggli.
11	MEMBER EGGLI: And to speak to the benefit
12	question, if you look at the incidences of cancers in
13	occupational workers, they're, in fact, lower than the
14	general population. So what are we trying to achieve
15	here?
16	I think that we have achieved with
17	radiation safety for both the public and for
18	occupational workers, we've achieved a very high
19	standard already. What better can we do than making
20	occupational workers have a lower incidence of cancer
21	than the general population? What are we trying to
22	get to?
23	MEMBER VETTER: If you use that argument,
24	they'll throw the healthy worker effect at you.
25	You're looking at a subpopulation whose health is

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	239
1	better than the general public.
2	MS. SCHWARZ: I would like to make a
3	comment about the pregnant female.
4	CHAIRMAN MALMUD: Dr. Schwarz.
5	MS. SCHWARZ: I'm concerned about just to
6	add to the already stated facts. I think it's
7	definitely going to be problematic in that if a woman
8	does declare pregnancy, essentially will have to be
9	taken out of the work area, I mean, and not be allowed
10	to work. So this will essentially, though maybe not
11	on paper, could discourage women from being hired.
12	I mean, there could be an element that
13	could affect that, I'm sure.
14	MEMBER VETTER: Just in that regard
15	there's the Johnston Controls case which prohibits us
16	from doing that.
17	CHAIRMAN MALMUD: Prohibits who from doing
18	that?
19	MEMBER VETTER: It would prohibit us from
20	doing something that would affect the welfare of that
21	pregnant worker. In other words, we could transfer
22	her to another job temporarily that gave her the same
23	amount of money and so forth, but we can't do anything
24	to discriminate. We must protect that person so that
25	that person has the same opportunity as a male who

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

240 1 can't get pregnant. 2 So, I mean, the Supreme Court did that We can't discriminate. We can't not hire a 3 one. 4 pregnant woman because she's pregnant. 5 MS. SCHWARZ: No, I understand that, but what I am saying --6 7 MEMBER VETTER: Or prevent her from doing nuclear medicine or whatever. 8 MS. SCHWARZ: You could discourage her 9 10 from being hired in general, not in writing, not in 11 terms of policy. 12 MEMBER VETTER: Right. MS. SCHWARZ: But in terms of the mental 13 14 review of management. 15 MEMBER VETTER: I see what you're saying. Understanding that if 16 MS. SCHWARZ: 17 they're dealing with a young female population, that it could discourage them from being the choice between 18 19 two equal candidates. That's 20 CHAIRMAN MALMUD: valid а 21 observation. 22 We do have a comment from the public which 23 I'd like to entertain now if the committee will 24 permit. DR. WHITE: Gerald White. I'm here for 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	241
1	the AAPM, but speaking just personally.
2	I can't help but hang crepe on many of
3	these issues about experiences of community hospitals.
4	One issue about pregnant women that hasn't really been
5	stated explicitly is that of pregnant radiologists and
6	pregnant cardiologists.
7	If in my community hospital I go to a
8	pregnant cardiologist and say, "You cannot do your
9	patients in our hospital because we can't keep you
10	below 100 MR," that woman and all of her patients will
11	be at the hospital across town before you know it.
12	The pressures to ignore that rule or to
13	find some way around that rule will be enormous. In
14	order to encourage respect for the science of
15	radiation protection, the rules have to be reasonable
16	and enforceable, and if they're not, not to pick on
17	physicians, but physicians will be the first ones to
18	find a way around them and the hardest to control.
19	And these are the people in the hospital
20	we look to for leadership, for sensibility, and we're
21	going to lose that. It's going to be a net
22	degradation in the radiation protection program in
23	hospitals.
24	CHAIRMAN MALMUD: Thank you.
25	Would you like to go on, Dr. Vetter?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	242
1	MEMBER VETTER: Sure. Okay. Anything
2	more on dose limits?
3	CHAIRMAN MALMUD: No.
4	MEMBER VETTER: For physicists, the
5	weighting factors for certain types of radiation will
6	change a little, but I don't think that has a major
7	impact on any of us. For protons, it goes from five
8	to two, the weighting factor, and for neutrons, it's
9	roughly the same. It's just they determine the
10	weighting factor a little bit differently.
11	The tissue weighting factor has changed
12	somewhat. I don't perceive that that would have much
13	of an effect on how we calculate occupational dose.
14	In fact, most of our doses are simply measured with
15	badge. We don't have many up ticks or intakes. So
16	we're not very often calculating internal dose.
17	If we do, ICRP would say we calculated a
18	little bit differently the effective dose from prior
19	because some of the tissues have been changed a little
20	bit. I don't think it's significant enough to go into.
21	Do you want to flip to the last page, page
22	4? Application of dose constraints. This is where I
23	perceive we've already talked about this. I perceive
24	some of these areas to be problematic.
25	Occupational workers in controlled areas

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	243
1	are well informed and especially trained so that
2	constraints are fairly easy to administer if we choose
3	to appoint some constraints in our areas.
4	It should be pointed out that
5	administrative and support staff should be treated as
6	members of the public. There have been some who have
7	suggested that relative to this issue of designing
8	shields in diagnostic X-ray departments that a
9	receptionist who is going to be sitting right outside
10	the shield perhaps should be classified as an
11	occupational worker, a worker for purposes of
12	occupational dose.
13	The recommendations of ICRP are clearly
14	counter to that.
15	Let's see. We've just talked about the
16	working conditions should make it unlikely that a dose
17	to the fetus would exceed one millisievert, and
18	finally, relative to medical exposure, my second to
19	last slide, no limitation of dose to the individual
20	patient because it may actually reduce effectiveness
21	of diagnosis or treatment. So that clearly falls
22	under the arena of justification.
23	But related to medical exposure,
24	constraints should apply to workers and the public,
25	and this one, this is an area that we should probably

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	244
1	spend a minute on.
2	Some exposure may occur in patient care
3	and support by members of the public, such as family,
4	members of families who are caring for a radioiodine
5	patient, and they're saying that a constraint of a few
6	millisievert they don't get very quantitative about
7	that a few millisievert is reasonable, but should
8	not be used rigidly. For example, higher doses are
9	reasonable for parents of a sick child.
10	Now, this came up yesterday in
11	conversation, and I think the feeling of the advisory
12	committee is that we should look toward NCRP
13	commentary 11, which I think is dated what, about
14	1995?
15	PARTICIPANT: Yes.
16	MEMBER VETTER: So it's a few years old,
17	but I don't think if you ask NCRP, I don't think the
18	thinking would be much different from what they
19	recommended back then, and they recommended that and
20	the NCRP instituted a rule, in fact, that patients who
21	are administered therapeutic radionuclides could be
22	released to the public under the conditions that a
23	member of the public would not receive more than 500
24	millirem.
25	NCRP also said that for members of the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

public who are family members of the patient, that a higher dose would be justified in the care of that patient, and they said it could be as high as five rem, provided you instructed them appropriately in how to keep dose down and monitored them.

1

2

3

4

5

The NRC didn't adopt that condition, but 6 7 the ICRP is suggesting without giving any numbers, 8 they're suggesting that that is, in fact, justified. 9 You can justify a higher dose to the parents of a sick 10 child, for example. So there are a couple of 11 constraints here that are saying that certain very 12 small groups, members of the public can get a higher dose than the limit; that it is, in fact, justified, 13 14 for example, in this case, and you would establish 15 that maximum dose by some sort of a constraint.

And they're saying for a member of the public the constraint is a few millisieverts or maybe it's five. That would be the same as -- is that what they're saying now, two?

20DR. VINCE HOLAHAN:It's a maximum21constraint.22MEMBER VETTER:23DR. VINCE HOLAHAN:24constraint for a caregiver is two millisieverts.

MEMBER VETTER: I didn't see that.

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

25

	246
1	DR. VINCE HOLAHAN: Twenty millisieverts.
2	I'm sorry.
3	If you look at the table where they have
4	the maximum constraints
5	MEMBER VETTER: Two rem, yes. That's two
6	rem.
7	DR. VINCE HOLAHAN: That's correct.
8	MEMBER VETTER: Not 500 millirem, yeah.
9	So that would be the maximum, two rem.
10	DR. VINCE HOLAHAN: That's the maximum
11	constraint per caregiver.
12	MEMBER VETTER: Right. Oh, yes, I do
13	remember seeing that, yeah. the maximum constraint
14	for a caregiver would be two rem.
15	Now, current NRC rule is that the maximum
16	limit is 500 millirem. I'm sorry. That's not quite
17	the right way to put it. You base your release of the
18	patients on assuming that no one would get more than
19	500 millirem.
20	DR. HOWE: Dr. Vetter, is it clear that
21	it's for a whole year or is it per patient?
22	MEMBER VETTER: In this case it's per
23	episode.
24	DR. HOWE: Okay.
25	MEMBER VETTER: For caring of patients

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	247
1	it's per episode. Now, you would normally anticipate
2	that to be once in a number of years.
3	DR. HOWE: And for your other discussion
4	that you had, it was clear that the radiation to the
5	patient for the procedure the patient is receiving is
б	not included. What about the dose from the patient to
7	other people?
8	MEMBER VETTER: Yeah, they address that in
9	two different ways. One is for patients who are
10	sitting like in a nuclear medicine waiting room, that
11	the dose to other people in the waiting room is
12	they don't use the word "inconsequential," but it's
13	low and it doesn't need to be worried about, and the
14	same thing for transport of radioiodine patients on
15	the way home, that those doses are low enough not to
16	worry about.
17	But then the other group that they talk
18	about is caregivers, from dose from patients. It's
19	caregivers and they're saying a few millisieverts. It
20	would be two rem in our case would be the maximum to
21	caregivers, and possibly higher for parents of a sick
22	child.
23	CHAIRMAN MALMUD: Thank you.
24	Dr. Vetter, you've heard a number of
25	comments from the committee. What is it that you were

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	248
1	seeking in presenting this to the committee as an end
2	result?
3	MEMBER VETTER: What I'm interested in
4	hearing from the committee are their interpretations
5	of when these recommendations could be problematic for
6	the medical community.
7	CHAIRMAN MALMUD: And you've heard that?
8	MEMBER VETTER: I've heard that. I've
9	heard some very good feedback, and that's what I would
10	take to the meeting next week.
11	Now, the meeting next week is the Advisory
12	Committee on Nuclear Waste who is simply trying to get
13	educated on this issue, and they're interested in our
14	perspective.
15	CHAIRMAN MALMUD: And what we've heard is
16	that there's no evidence statistically that radiation
17	workers, despite the fact that they're classified as
18	perhaps a healthier group than the population at
19	large, has a higher incidence of cancer or mutations
20	that result in deformed fetuses than does the
21	population as a whole. Therefore, we are not
22	encouraging reducing the safe limits in a theoretical
23	pursuit rather than a practical one; that, in fact,
24	there may be unintended consequences in reducing those
25	limits, such as the inability of someone to maintain

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	249
1	gainful employment in the course of a pregnancy.
2	And, therefore, we are supporting your
3	transmitting the message that we don't see the need to
4	reduce these limits. Is that a fair summary?
5	Thank you.
6	MEMBER VETTER: We don't see a need to
7	reduce the limits that are currently
8	CHAIRMAN MALMUD: Currently established.
9	MEMBER VETTER: Right.
10	CHAIRMAN MALMUD: If that's a fair
11	summary, we will accept that. If someone will make
12	that motion other than the Chair, and that will be the
13	message that Dr. Vetter would deliver on behalf of the
14	ACMUI.
15	MEMBER EGGLI: So moved.
16	CHAIRMAN MALMUD: Moved? Did you second
17	it?
18	MEMBER LIETO: I would second it.
19	CHAIRMAN MALMUD: Moved and seconded. Dr.
20	Eggli moved it, seconded by (pause)
21	MEMBER LIETO: Mr. Lieto.
22	(Laughter.)
23	CHAIRMAN MALMUD: Mr. Lieto.
24	Is there any further discussion?
25	MEMBER LIETO: I have a couple of quick

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	250
1	comments. One thing that I think also this does is
2	convey a very negative aspect about radiation. If
3	you're above this constraint level, you know, a few
4	millirems, tens of millirems, it conveys the sense
5	that you failed to meet good radiation safety
6	standards and you're exposing people to harmful
7	amounts of radiation that are within the normal range
8	of variance of background itself, and I think that's
9	a negative connotation that would be relayed by this.
10	Another point is that in looking over this
11	document, we've always talked about dose equivalent
12	and equivalent dose. Well, in their infinite wisdom,
13	ICRP is saying, "Okay. We've not going to use that
14	because it's too confusing. We're going to establish
15	a new term." Okay?
16	So now we're on this merry-go-round of new
17	terminology, and I agree about the confusion with dose
18	equivalent or equivalent dose, but it has got to stop
19	someplace. I mean we need to say this is the
20	terminology and let's stick with it for more than five
21	years.
22	And they 've come up with another term, and
23	that's another thing I think is going to, I think,
24	related to a lot of confusion. I think a major change
25	in a lot of the rules the way they're defined and

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

regulations the way they're written to adopt this new terminology, and again, I just think there's absolutely no benefit being derived from all of these changes. I think it's just a bad piece of -- well, I shouldn't say that, not overall.

I can understand the weighting figures, 6 7 the factors, and some of these lower limits being established for natural sources, but you know, I think 8 that some of these other things are just not very 9 beneficial because I think they determine -- I guess 10 11 de minimis is not the right term -- but a level at 12 which you don't need to concern yourself, which is like one millirem. What is that? I quess you could 13 14 climb up to the eighth story and get more than that. 15 I just think it's an absolutely ridiculous number.

16 CHAIRMAN MALMUD: Any other comments with 17 regard to the recommendation that Dr. Vetter will 18 carry with him?

If not -- oh, yes.

20 DR. VINCE HOLAHAN: If I could just make 21 one quick clarification, the limits that we're talking 22 about in this draft document for all intents and 23 purposes are not different than ICRP 60. So to go 24 back to the main Commission and say 20 millisieverts 25 for an occupational exposure is unreasonable, well,

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

19

	252
1	they don't care. That's already on the table.
2	What will be important is several years
3	from now, will the NRC adopt these recommendations,
4	and that's the issue to be addressed with the
5	Commission.
б	CHAIRMAN MALMUD: Thank you.
7	And that's your understanding, Dr. Vetter?
8	MEMBER VETTER: Yes.
9	CHAIRMAN MALMUD: Mr. Lieto.
10	MEMBER LIETO: The point is well taken,
11	and the only thing that's new about this is if you
12	don't adopt these or I shouldn't say doses above
13	these constraints are considered failures now by the
14	ICRP, which is not the type of terminology that they
15	used before.
16	So I find that very, very negative and,
17	you know, really is sort of almost I don't want to say
18	a strong arming, but sort of a way of trying to coerce
19	national bodies and agencies to adopt their values,
20	which, you know, many countries have not, including
21	ours.
22	CHAIRMAN MALMUD: Thank you.
23	So we are encouraging of not tightening
24	things, in addition to for the ICRP to look at the
25	unintended consequences of some of their actions.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	253
1	We still haven't given you a nod of
2	approval for what you would like to take with you.
3	All in favor?
4	(Show of hands.)
5	CHAIRMAN MALMUD: Any opposed?
б	(Show of hands.)
7	CHAIRMAN MALMUD: Any abstentions?
8	(No response.)
9	CHAIRMAN MALMUD: It carries the majority.
10	MEMBER VETTER: Just one comment relative
11	to the impact of these, what they really mean.
12	Historically I think the NRC and regulators in this
13	country had looked to the NCRP for guidance as opposed
14	to the ICRP.
15	Now, in large measure they're the same,
16	except that these dose limits have been different
17	since ICRP 60. So in that regard I did ask NCRP when
18	do they plan on taking another look at their
19	recommendations. They are waiting for BEERS-7 to be
20	published, and then they will ask them. Then they'll
21	kind of ask themselves: are the limits that ICRP is
22	proposing here appropriate or do they want to maintain
23	the limits they have in NCRP 116 or whatever?
24	But I just wanted to throw that out for
25	your information.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1MEMBER SULEIMAN: When is BEERS-7 supposed2to be published?3MEMBER VETTER: That's a good question.4MEMBER SULEIMAN: I mean a year, five5years, ten years?6DR. VINCE HOLAHAN: The final chapters of7BEERS-7 are being finalized now. The project8director, Mr. Rick Jostice (phonetic) or Dr. Jostice,9is hoping to put that out to peer review in the10National Academies this fall. I would say it's11possible to be released as early as the April time12frame of next year. I'd feel a little bit better13saying maybe June of next year.14CHAIRMAN MALMUD: To be precise, Dr.15Suleiman, it's in the future.16Thank you.17May we move on to the next item on the18agenda?19MR. ESSIG: Yes. The next item on the20cHAIRMAN MALMUD: Before you introduce21the agenda.22CHAIRMAN MALMUD: May up once again thank Dr. Vetter for		254
3       MEMBER VETTER: That's a good question.         4       MEMBER SULEIMAN: I mean a year, five         5       years, ten years?         6       DR. VINCE HOLAHAN: The final chapters of         7       BEERS-7 are being finalized now. The project         8       director, Mr. Rick Jostice (phonetic) or Dr. Jostice,         9       is hoping to put that out to peer review in the         10       National Academies this fall. I would say it's         11       possible to be released as early as the April time         12       frame of next year. I'd feel a little bit better         13       saying maybe June of next year.         14       CHAIRMAN MALMUD: To be precise, Dr.         15       Suleiman, it's in the future.         16       Thank you.         17       May we move on to the next item on the         18       agenda?         19       MR. ESSIG: Yes. The next item on the         20       agenda, if I may introduce it, is the final item on         21       CHAIRMAN MALMUD: Before you introduce	1	MEMBER SULEIMAN: When is BEERS-7 supposed
4MEMBER SULEIMAN: I mean a year, five5years, ten years?6DR. VINCE HOLAHAN: The final chapters of7BEERS-7 are being finalized now. The project8director, Mr. Rick Jostice (phonetic) or Dr. Jostice,9is hoping to put that out to peer review in the10National Academies this fall. I would say it's11possible to be released as early as the April time12frame of next year. I'd feel a little bit better13saying maybe June of next year.14CHAIRMAN MALMUD: To be precise, Dr.15Suleiman, it's in the future.16Thank you.17May we move on to the next item on the18agenda?19MR. ESSIG: Yes. The next item on the20agenda, if I may introduce it, is the final item on21CHAIRMAN MALMUD: Before you introduce	2	to be published?
5       years, ten years?         6       DR. VINCE HOLAHAN: The final chapters of         7       BEERS-7 are being finalized now. The project         8       director, Mr. Rick Jostice (phonetic) or Dr. Jostice,         9       is hoping to put that out to peer review in the         10       National Academies this fall. I would say it's         11       possible to be released as early as the April time         12       frame of next year. I'd feel a little bit better         13       saying maybe June of next year.         14       CHAIRMAN MALMUD: To be precise, Dr.         15       Suleiman, it's in the future.         16       Thank you.         17       May we move on to the next item on the         18       agenda?         19       MR. ESSIG: Yes. The next item on the         20       agenda, if I may introduce it, is the final item on         21       CHAIRMAN MALMUD: Before you introduce	3	MEMBER VETTER: That's a good question.
6       DR. VINCE HOLAHAN: The final chapters of         7       BEERS-7 are being finalized now. The project         8       director, Mr. Rick Jostice (phonetic) or Dr. Jostice,         9       is hoping to put that out to peer review in the         10       National Academies this fall. I would say it's         11       possible to be released as early as the April time         12       frame of next year. I'd feel a little bit better         13       saying maybe June of next year.         14       CHAIRMAN MALMUD: To be precise, Dr.         15       Suleiman, it's in the future.         16       Thank you.         17       May we move on to the next item on the         18       agenda?         19       MR. ESSIG: Yes. The next item on the         20       cHAIRMAN MALMUD: Before you introduce	4	MEMBER SULEIMAN: I mean a year, five
7       BEERS-7 are being finalized now. The project         8       director, Mr. Rick Jostice (phonetic) or Dr. Jostice,         9       is hoping to put that out to peer review in the         10       National Academies this fall. I would say it's         11       possible to be released as early as the April time         12       frame of next year. I'd feel a little bit better         13       saying maybe June of next year.         14       CHAIRMAN MALMUD: To be precise, Dr.         15       Suleiman, it's in the future.         16       Thank you.         17       May we move on to the next item on the         18       agenda?         19       MR. ESSIG: Yes. The next item on the         20       agenda.         21       CHAIRMAN MALMUD: Before you introduce	5	years, ten years?
8       director, Mr. Rick Jostice (phonetic) or Dr. Jostice,         9       is hoping to put that out to peer review in the         10       National Academies this fall. I would say it's         11       possible to be released as early as the April time         12       frame of next year. I'd feel a little bit better         13       saying maybe June of next year.         14       CHAIRMAN MALMUD: To be precise, Dr.         15       Suleiman, it's in the future.         16       Thank you.         17       May we move on to the next item on the         18       agenda?         19       MR. ESSIG: Yes. The next item on the         20       agenda.         21       CHAIRMAN MALMUD: Before you introduce	6	DR. VINCE HOLAHAN: The final chapters of
<ul> <li>9 is hoping to put that out to peer review in the</li> <li>10 National Academies this fall. I would say it's</li> <li>11 possible to be released as early as the April time</li> <li>12 frame of next year. I'd feel a little bit better</li> <li>13 saying maybe June of next year.</li> <li>14 CHAIRMAN MALMUD: To be precise, Dr.</li> <li>15 Suleiman, it's in the future.</li> <li>16 Thank you.</li> <li>17 May we move on to the next item on the</li> <li>18 agenda?</li> <li>19 MR. ESSIG: Yes. The next item on the</li> <li>20 agenda, if I may introduce it, is the final item on</li> <li>21 the agenda.</li> <li>22 CHAIRMAN MALMUD: Before you introduce</li> </ul>	7	BEERS-7 are being finalized now. The project
<ul> <li>National Academies this fall. I would say it's</li> <li>possible to be released as early as the April time</li> <li>frame of next year. I'd feel a little bit better</li> <li>saying maybe June of next year.</li> <li>CHAIRMAN MALMUD: To be precise, Dr.</li> <li>Suleiman, it's in the future.</li> <li>Thank you.</li> <li>May we move on to the next item on the</li> <li>agenda?</li> <li>MR. ESSIG: Yes. The next item on the</li> <li>agenda, if I may introduce it, is the final item on</li> <li>the agenda.</li> <li>CHAIRMAN MALMUD: Before you introduce</li> </ul>	8	director, Mr. Rick Jostice (phonetic) or Dr. Jostice,
<ul> <li>possible to be released as early as the April time</li> <li>frame of next year. I'd feel a little bit better</li> <li>saying maybe June of next year.</li> <li>CHAIRMAN MALMUD: To be precise, Dr.</li> <li>Suleiman, it's in the future.</li> <li>Thank you.</li> <li>May we move on to the next item on the</li> <li>agenda?</li> <li>MR. ESSIG: Yes. The next item on the</li> <li>agenda, if I may introduce it, is the final item on</li> <li>the agenda.</li> <li>CHAIRMAN MALMUD: Before you introduce</li> </ul>	9	is hoping to put that out to peer review in the
12 frame of next year. I'd feel a little bit better 13 saying maybe June of next year. 14 CHAIRMAN MALMUD: To be precise, Dr. 15 Suleiman, it's in the future. 16 Thank you. 17 May we move on to the next item on the 18 agenda? 19 MR. ESSIG: Yes. The next item on the 20 agenda, if I may introduce it, is the final item on 21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce	10	National Academies this fall. I would say it's
<ul> <li>13 saying maybe June of next year.</li> <li>14 CHAIRMAN MALMUD: To be precise, Dr.</li> <li>15 Suleiman, it's in the future.</li> <li>16 Thank you.</li> <li>17 May we move on to the next item on the</li> <li>18 agenda?</li> <li>19 MR. ESSIG: Yes. The next item on the</li> <li>20 agenda, if I may introduce it, is the final item on</li> <li>21 the agenda.</li> <li>22 CHAIRMAN MALMUD: Before you introduce</li> </ul>	11	possible to be released as early as the April time
14CHAIRMAN MALMUD: To be precise, Dr.15Suleiman, it's in the future.16Thank you.17May we move on to the next item on the18agenda?19MR. ESSIG: Yes. The next item on the20agenda, if I may introduce it, is the final item on21the agenda.22CHAIRMAN MALMUD: Before you introduce	12	frame of next year. I'd feel a little bit better
15 Suleiman, it's in the future. 16 Thank you. 17 May we move on to the next item on the 18 agenda? 19 MR. ESSIG: Yes. The next item on the agenda, if I may introduce it, is the final item on 21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce	13	saying maybe June of next year.
16 Thank you. 17 May we move on to the next item on the 18 agenda? 19 MR. ESSIG: Yes. The next item on the 20 agenda, if I may introduce it, is the final item on 21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce	14	CHAIRMAN MALMUD: To be precise, Dr.
17May we move on to the next item on the18agenda?19MR. ESSIG: Yes. The next item on the20agenda, if I may introduce it, is the final item on21the agenda.22CHAIRMAN MALMUD: Before you introduce	15	Suleiman, it's in the future.
<pre>18 agenda? 19 MR. ESSIG: Yes. The next item on the 20 agenda, if I may introduce it, is the final item on 21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce</pre>	16	Thank you.
19 MR. ESSIG: Yes. The next item on the 20 agenda, if I may introduce it, is the final item on 21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce	17	May we move on to the next item on the
<ul> <li>20 agenda, if I may introduce it, is the final item on</li> <li>21 the agenda.</li> <li>22 CHAIRMAN MALMUD: Before you introduce</li> </ul>	18	agenda?
21 the agenda. 22 CHAIRMAN MALMUD: Before you introduce	19	MR. ESSIG: Yes. The next item on the
22 CHAIRMAN MALMUD: Before you introduce	20	agenda, if I may introduce it, is the final item on
	21	the agenda.
23 the final item, may I once again thank Dr. Vetter for	22	CHAIRMAN MALMUD: Before you introduce
	23	the final item, may I once again thank Dr. Vetter for
all of the effort he went to thus far and will go so	24	all of the effort he went to thus far and will go so
again next week on behalf of the ACMUI.	25	again next week on behalf of the ACMUI.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

MR. ESSIG: Okay. The final item on the agenda, we had wanted to go over if possible the action items arising from the meeting which based on the way we've captured them, it's going to take a more detailed review, and so we don't think trying to reach agreement on action items here more or less in real time would not be fruitful.

So we're not going to propose to you right 8 9 now that we go over the action items. What we would go over is the recommendations that arose and that 10 11 were in the form of a motion that was acted upon. We 12 will summarize those. Angela will, and then the second order of business then prior to declaring the 13 14 meeting adjourned is to discuss the meeting dates for 15 the spring 2005 meeting, which hopefully those who have to leave left a vote sheet with somebody. 16 Dr. Diamond or Mr. Bailey, I'm hoping that they left their 17 preference behind somewhere, but maybe they didn't. 18

Because I think the preferred approach on the 2005 meeting was to either circle the dates that each member preferred or to cross out those that appeared to be unworkable.

MEMBER NAG: Tom.

MR. ESSIG: Yes.

MEMBER NAG: I thought the dates of the

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1

2

3

4

5

6

7

23

24

25

	256
1	26th and 27th of April was the main one and we wanted
2	to see how many are not able to attend that because
3	there are so many. We'll never come to consensus. It
4	might be better off saying how many cannot make that
5	April 26th-27th, and then go from there.
6	If a lot of people cannot make that, then
7	we look for an alternative. Otherwise, I will be here
8	for certain dates, and you will never have a consensus
9	doing it that way.
10	MR. ESSIG: Okay. We can certainly do
11	that, and we just more or less picked those dates
12	because they didn't appear to conflict with our
13	knowledge of the major society meetings at that time.
14	Now, we have to review our own schedule in
15	house, which we haven't done, against those dates for
16	Dr. Miller and Dr. Holahan's availability. So they're
17	a little bit tentative in that sense.
18	But at least what we know is that the
19	auditorium is available on those two days and we've
20	preliminarily locked it in. So maybe next door to
21	business then would be to discuss the recommendations
22	that arose, and Angela will do that.
23	MS. McINTOSH: Bear with me a little.
24	This is a matter of combing through some very rough
25	information to capture what we believe are the motions

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	257
1	that arose from the committee meeting yesterday and
2	today.
3	The first motion that the committee made
4	was regarding the seeds electron guidance, and that
5	motion basically stated that the seeds electron is
6	appropriately codified in 10 CFR 35.1000, but that the
7	staff should use the regulatory framework in Section
8	35.400 as a model for creating guidance for the seeds
9	electron, adding only those elements of Section 35.600
10	as needed.
11	Looks like everyone is in agreement with
12	that one.
13	The second one, the second motion, the
14	committee motioned to have the 200 hours' worth of
15	training and experience in Part 35.390 reduced to 80
16	hours.
17	CHAIRMAN MALMUD: That is correct.
18	MS. McINTOSH: Another motion that the
19	committee made, it's almost general in nature, but the
20	committee motioned that except for all of those issues
21	identified regarding the draft 10 CFR 35, except for
22	those issues that the committee identified as
23	problematic, the committee motioned to move forward
24	with the draft final rule.
25	CHAIRMAN MALMUD: That is correct.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	258
1	MS. McINTOSH: And regarding the abnormal
2	occurrence criteria
3	MEMBER WILLIAMSON: You forgot the one on
4	grandfathering. I think a motion was made on
5	grandfathering of AMPs. There was some suggested
6	rephrasing of the grandfathering text that would allow
7	I can't remember exactly what was said.
8	MS. McINTOSH: Okay.
9	MEMBER WILLIAMSON: But that was one of
10	the two problems that was identified with the 35.
11	MS. WASTLER: Let me try it.
12	MS. McINTOSH: We're working from meeting
13	notes. So we don't have the the transcript will
14	have the specific. Do you have that?
15	MS. WASTLER: If I can decipher my
16	scribbled handwriting here, I think
17	CHAIRMAN MALMUD: This is Sandra Wastler.
18	MS. WASTLER: Thank you. Sorry.
19	that the recommendation was that
20	physicists authorized to serve as AMPs for HDR, gamma
21	knife I messed up the appropriate title gamma
22	stereotactic surgery
23	(Simultaneous conversation.)
24	MS. WASTLER: All right and
25	teletherapy be grandfathered as AMP I've got as AMP

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	259
1	modalities. I don't think that's the exact right
2	words for AMP modalities.
3	MEMBER WILLIAMSON: That's AMPs in the
4	area in which they are practicing, which they are
5	currently authorized to practice, I think.
6	MS. SCHWARZ: Jeff, was there something
7	also mentioned about being preceptors for those AMPs?
8	CHAIRMAN MALMUD: It says they can
9	supervise trainees.
10	MEMBER WILLIAMSON: They become preceptors
11	automatically, yeah.
12	MS. McINTOSH: And then the last motion
13	that we've been able to identify quickly was the
14	motion regarding the proposed changes to the abnormal
15	occurrence criteria, and the committee basically
16	agreed to move forward with those proposed changes.
17	CHAIRMAN MALMUD: And we just did one for
18	Dr. Vetter.
19	MS. MCINTOSH: Okay, and that was a motion
20	for
21	CHAIRMAN MALMUD: Yes.
22	MS. McINTOSH: Okay.
23	CHAIRMAN MALMUD: And I think that's
24	complete.
25	MS. WASTLER: Doctor.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

Í	260
1	CHAIRMAN MALMUD: Do you recall another
2	one?
3	MS. WASTLER: Yes. It seems to me that
4	there was a recommendation that you be provided, the
5	committee be provided the research protocol for the I-
б	25 users' markers to allow you to further evaluate
7	that procedure. This was
8	CHAIRMAN MALMUD: Yesterday.
9	MS. WASTLER: Robert Gallagher's
10	presentation.
11	CHAIRMAN MALMUD: That's correct. The
12	committee did request more information bout the use of
13	I-125 seeds as markers for the specific indication
14	that was reviewed was for localization of breast
15	masses and breast surgery. And we would appreciate
16	seeing more information regarding the use.
17	MS. McINTOSH: Okay. Can anyone think of
18	anything else that the committee proposed or a motion
19	that the committee made?
20	CHAIRMAN MALMUD: That's all that we
21	recall at this moment.
22	MS. McINTOSH: Okay. And the other
23	administrative item is the setting of the meeting
24	dates for the spring 2005 meeting.
25	CHAIRMAN MALMUD: And we were given a

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	261
1	number of options based upon the availability of this
2	conference room.
3	MR. ESSIG: The auditorium. Correction.
4	CHAIRMAN MALMUD: The auditorium. Excuse
5	me.
6	MS. McINTOSH: Yes. I have since learned
7	that the auditorium is actually not going to be
8	available on one of those dates in April. So we would
9	still have to go back and set a date for the
10	auditorium.
11	MEMBER NAG: Was that the 26th?
12	MS. McINTOSH: We proposed the 26th
13	through the 27th.
14	MEMBER NAG: And that is available or not
15	available?
16	MS. McINTOSH: It's not available on the
17	27th.
18	MS. WASTLER: Excuse me. Can I just
19	point out, I believe this is Sandra Wastler
20	again that Dr. Miller pointed out, and I think we
21	all agreed, that what we need to do is set a date we
22	can all live with. The place we will deal with. All
23	right?
24	CHAIRMAN MALMUD: Is that your point, Dr.
25	Miller?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	262
1	MR. MILLER: My point was that, yes, I
2	asked my staff let's focus on setting a date for the
3	meeting. Once that's agreed upon my staff will find
4	a venue where we can hold the meeting, and let's not
5	be restrictive; based upon what I heard yesterday,
6	let's not be so restrictive as to be concerned whether
7	it's in this room or the auditorium or some other
8	suitable venue that's nearby. It's more important to
9	find a date where we can get maximum participation.
10	CHAIRMAN MALMUD: Ralph?
11	MEMBER LIETO: A question for staff. Not
12	knowing the days of the weeks that these are, is
13	Monday-Tuesday better for individuals as opposed to a
14	Tuesday-Wednesday?
15	MS. McINTOSH: Can I? The dates that are
16	proposed are Tuesday-Wednesday or Wednesday-Thursday.
17	MEMBER WILLIAMSON: It can't be Thursday-
18	Friday?
19	MS. McINTOSH: Well, it can. It's just
20	that most of the committee members prefer to have it
21	between Tuesday and Thursday because most people don't
22	want to travel on Mondays or Fridays.
23	MEMBER WILLIAMSON: Teaching Monday and
24	Wednesday.
25	MS. McINTOSH: Okay. Well, traditionally

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1that's been those days of the week that the committee2has been amenable to having the meeting on.3MEMBER NAG: Since we had that 26-274April, can we just maybe just have a show of hands5whether anybody is not available on those dates,6rather than saying when you're available and then7you'll have people overlap?8MEMBER EGGLI: My concern with that,9Subir, is that you've got two members that aren't10here.11MS. McINTOSH: Well, actually Dr. Diamond12did leave me his input, and his input was he's13available for everything, for every date except for14March 15th through the 17th.15MR. MILLER: I know I'm not available as16it stands now. I think I have to go to IAEA that17week; is that correct, Trish, based upon the18information we have now?19DR. HOLAHAN: Twenty-fifth to 28th.20MS. McINTOSH: So, I mean, we can go in21NS. McINTOSH: So, I mean, we can go in23several March dates, 1 through 2, 2 through 3, 824storal dates, 1 through 2, 2 through 3, 825through 9 or 9 through 10.		263
3       MEMBER NAG: Since we had that 26-27         4       April, can we just maybe just have a show of hands         5       whether anybody is not available on those dates,         6       rather than saying when you're available and then         7       you'll have people overlap?         8       MEMBER EGGLI: My concern with that,         9       Subir, is that you've got two members that aren't         10       here.         11       MS. MCINTOSH: Well, actually Dr. Diamond         12       did leave me his input, and his input was he's         13       available for everything, for every date except for         14       March 15th through the 17th.         15       MR. MILLER: I know I'm not available as         16       it stands now. I think I have to go to IAEA that         17       week; is that correct, Trish, based upon the         18       information we have now?         19       DR. HOLAHAN: Twenty-fifth to 28th.         20       MEMBER WILLIAMSON: In theory, yes, I am         21       not available on April 27th.         22       MS. MCINTOSH: So, I mean, we can go in         23       March if March is a little bit better. There's         24       several March dates, 1 through 2, 2 through 3, 8	1	that's been those days of the week that the committee
4April, can we just maybe just have a show of hands5whether anybody is not available on those dates,6rather than saying when you're available and then7you'll have people overlap?8MEMBER EGGLI: My concern with that,9Subir, is that you've got two members that aren't10here.11MS. McINTOSH: Well, actually Dr. Diamond12did leave me his input, and his input was he's13available for everything, for every date except for14March 15th through the 17th.15MR. MILLER: I know I'm not available as16it stands now. I think I have to go to IAEA that17week; is that correct, Trish, based upon the18information we have now?19DR. HOLAHAN: Twenty-fifth to 28th.20MS. McINTOSH: So, I mean, we can go in21March if March is a little bit better. There's24several March dates, 1 through 2, 2 through 3, 8	2	has been amenable to having the meeting on.
whether anybody is not available on those dates, rather than saying when you're available and then you'll have people overlap? MEMBER EGGLI: My concern with that, Subir, is that you've got two members that aren't here. MEMBER EGGLI: My concern with that, Subir, is that you've got two members that aren't here. MS. MCINTOSH: Well, actually Dr. Diamond did leave me his input, and his input was he's available for everything, for every date except for March 15th through the 17th. MR. MILLER: I know I'm not available as it stands now. I think I have to go to IAEA that week; is that correct, Trish, based upon the information we have now? DR. HOLAHAN: Twenty-fifth to 28th. MEMBER WILLIAMSON: In theory, yes, I am not available on April 27th. March if March is a little bit better. There's several March dates, 1 through 2, 2 through 3, 8	3	MEMBER NAG: Since we had that 26-27
<ul> <li>rather than saying when you're available and then you'll have people overlap?</li> <li>MEMBER EGGLI: My concern with that,</li> <li>Subir, is that you've got two members that aren't here.</li> <li>MS. McINTOSH: Well, actually Dr. Diamond did leave me his input, and his input was he's available for everything, for every date except for March 15th through the 17th.</li> <li>MR. MILLER: I know I'm not available as it stands now. I think I have to go to IAEA that week; is that correct, Trish, based upon the information we have now?</li> <li>DR. HOLAHAN: Twenty-fifth to 28th.</li> <li>MEMBER WILLIAMSON: In theory, yes, I am not available on April 27th.</li> <li>MS. McINTOSH: So, I mean, we can go in March if March is a little bit better. There's several March dates, 1 through 2, 2 through 3, 8</li> </ul>	4	April, can we just maybe just have a show of hands
7you'll have people overlap?8MEMBER EGGLI: My concern with that,9Subir, is that you've got two members that aren't10here.11MS. McINTOSH: Well, actually Dr. Diamond12did leave me his input, and his input was he's13available for everything, for every date except for14March 15th through the 17th.15MR. MILLER: I know I'm not available as16it stands now. I think I have to go to IAEA that17week; is that correct, Trish, based upon the18information we have now?19DR. HOLAHAN: Twenty-fifth to 28th.20MEMBER WILLIAMSON: In theory, yes, I am21not available on April 27th.22MS. McINTOSH: So, I mean, we can go in23March if March is a little bit better. There's24several March dates, 1 through 2, 2 through 3, 8	5	whether anybody is not available on those dates,
8       MEMBER EGGLI: My concern with that,         9       Subir, is that you've got two members that aren't         10       here.         11       MS. McINTOSH: Well, actually Dr. Diamond         12       did leave me his input, and his input was he's         13       available for everything, for every date except for         14       March 15th through the 17th.         15       MR. MILLER: I know I'm not available as         16       it stands now. I think I have to go to IAEA that         17       week; is that correct, Trish, based upon the         18       information we have now?         19       DR. HOLAHAN: Twenty-fifth to 28th.         20       MEMBER WILLIAMSON: In theory, yes, I am         21       not available on April 27th.         22       MS. McINTOSH: So, I mean, we can go in         23       March if March is a little bit better. There's         24       several March dates, 1 through 2, 2 through 3, 8	6	rather than saying when you're available and then
9 Subir, is that you've got two members that aren't here. 11 MS. MCINTOSH: Well, actually Dr. Diamond did leave me his input, and his input was he's available for everything, for every date except for March 15th through the 17th. 15 MR. MILLER: I know I'm not available as it stands now. I think I have to go to IAEA that week; is that correct, Trish, based upon the information we have now? 19 DR. HOLAHAN: Twenty-fifth to 28th. 20 MR. MILLIAMSON: In theory, yes, I am not available on April 27th. 21 March if March is a little bit better. There's several March dates, 1 through 2, 2 through 3, 8	7	you'll have people overlap?
10 here. 11 MS. McINTOSH: Well, actually Dr. Diamond 12 did leave me his input, and his input was he's 13 available for everything, for every date except for 14 March 15th through the 17th. 15 MR. MILLER: I know I'm not available as 16 it stands now. I think I have to go to IAEA that 17 week; is that correct, Trish, based upon the 18 information we have now? 19 DR. HOLAHAN: Twenty-fifth to 28th. 20 MEMBER WILLIAMSON: In theory, yes, I am 21 not available on April 27th. 22 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8	8	MEMBER EGGLI: My concern with that,
<ul> <li>MS. MCINTOSH: Well, actually Dr. Diamond</li> <li>did leave me his input, and his input was he's</li> <li>available for everything, for every date except for</li> <li>March 15th through the 17th.</li> <li>MR. MILLER: I know I'm not available as</li> <li>it stands now. I think I have to go to IAEA that</li> <li>week; is that correct, Trish, based upon the</li> <li>information we have now?</li> <li>DR. HOLAHAN: Twenty-fifth to 28th.</li> <li>MEMBER WILLIAMSON: In theory, yes, I am</li> <li>not available on April 27th.</li> <li>MS. MCINTOSH: So, I mean, we can go in</li> <li>March if March is a little bit better. There's</li> <li>several March dates, 1 through 2, 2 through 3, 8</li> </ul>	9	Subir, is that you've got two members that aren't
did leave me his input, and his input was he's available for everything, for every date except for March 15th through the 17th. MR. MILLER: I know I'm not available as it stands now. I think I have to go to IAEA that week; is that correct, Trish, based upon the information we have now? DR. HOLAHAN: Twenty-fifth to 28th. MEMBER WILLIAMSON: In theory, yes, I am not available on April 27th. March if March is a little bit better. There's several March dates, 1 through 2, 2 through 3, 8	10	here.
13available for everything, for every date except for14March 15th through the 17th.15MR. MILLER: I know I'm not available as16it stands now. I think I have to go to IAEA that17week; is that correct, Trish, based upon the18information we have now?19DR. HOLAHAN: Twenty-fifth to 28th.20MEMBER WILLIAMSON: In theory, yes, I am21not available on April 27th.22MS. McINTOSH: So, I mean, we can go in23March if March is a little bit better. There's24several March dates, 1 through 2, 2 through 3, 8	11	MS. McINTOSH: Well, actually Dr. Diamond
<ul> <li>March 15th through the 17th.</li> <li>MR. MILLER: I know I'm not available as</li> <li>it stands now. I think I have to go to IAEA that</li> <li>week; is that correct, Trish, based upon the</li> <li>information we have now?</li> <li>DR. HOLAHAN: Twenty-fifth to 28th.</li> <li>MEMBER WILLIAMSON: In theory, yes, I am</li> <li>not available on April 27th.</li> <li>MS. MCINTOSH: So, I mean, we can go in</li> <li>March if March is a little bit better. There's</li> <li>several March dates, 1 through 2, 2 through 3, 8</li> </ul>	12	did leave me his input, and his input was he's
<ul> <li>MR. MILLER: I know I'm not available as</li> <li>it stands now. I think I have to go to IAEA that</li> <li>week; is that correct, Trish, based upon the</li> <li>information we have now?</li> <li>DR. HOLAHAN: Twenty-fifth to 28th.</li> <li>MEMBER WILLIAMSON: In theory, yes, I am</li> <li>not available on April 27th.</li> <li>MS. McINTOSH: So, I mean, we can go in</li> <li>March if March is a little bit better. There's</li> <li>several March dates, 1 through 2, 2 through 3, 8</li> </ul>	13	available for everything, for every date except for
<pre>16 it stands now. I think I have to go to IAEA that 17 week; is that correct, Trish, based upon the 18 information we have now? 19 DR. HOLAHAN: Twenty-fifth to 28th. 20 MEMBER WILLIAMSON: In theory, yes, I am 21 not available on April 27th. 22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8</pre>	14	March 15th through the 17th.
<pre>17 week; is that correct, Trish, based upon the 18 information we have now? 19 DR. HOLAHAN: Twenty-fifth to 28th. 20 MEMBER WILLIAMSON: In theory, yes, I am 21 not available on April 27th. 22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8</pre>	15	MR. MILLER: I know I'm not available as
<pre>18 information we have now? 19 DR. HOLAHAN: Twenty-fifth to 28th. 20 MEMBER WILLIAMSON: In theory, yes, I am 21 not available on April 27th. 22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8</pre>	16	it stands now. I think I have to go to IAEA that
19DR. HOLAHAN: Twenty-fifth to 28th.20MEMBER WILLIAMSON: In theory, yes, I am21not available on April 27th.22MS. McINTOSH: So, I mean, we can go in23March if March is a little bit better. There's24several March dates, 1 through 2, 2 through 3, 8	17	week; is that correct, Trish, based upon the
20 MEMBER WILLIAMSON: In theory, yes, I am 21 not available on April 27th. 22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8	18	information we have now?
<pre>21 not available on April 27th. 22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8</pre>	19	DR. HOLAHAN: Twenty-fifth to 28th.
22 MS. McINTOSH: So, I mean, we can go in 23 March if March is a little bit better. There's 24 several March dates, 1 through 2, 2 through 3, 8	20	MEMBER WILLIAMSON: In theory, yes, I am
<ul> <li>23 March if March is a little bit better. There's</li> <li>24 several March dates, 1 through 2, 2 through 3, 8</li> </ul>	21	not available on April 27th.
24 several March dates, 1 through 2, 2 through 3, 8	22	MS. McINTOSH: So, I mean, we can go in
	23	March if March is a little bit better. There's
25 through 9 or 9 through 10.	24	several March dates, 1 through 2, 2 through 3, 8
	25	through 9 or 9 through 10.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	264
1	MR. MILLER: There are earlier April
2	dates, too, aren't there?
3	MS. MCINTOSH: Well, 19th through 20th for
4	the April or 20th through the 21st of April.
5	MEMBER WILLIAMSON: So we have to do it
6	Wednesday-Thursday or Tuesday-Wednesday?
7	MR. MILLER: There's something that I need
8	to introduce to remind everybody of. I need Angela to
9	listen to this to make sure that I've got it correct.
10	Last year, while we talked yesterday,
11	while Tom articulated yesterday that there's no
12	requirement for the committee to meet with the
13	Commission, there are times where the Commission
14	desires to meet with the committee. And last year the
15	Commission dictated a date that they wanted to meet
16	with the committee, which dictated when which to a
17	degree dictated when we had the March meeting because
18	it allowed the committee to be in town one time rather
19	than twice.
20	My anticipation will be that the
21	Commission would probably want to meet with given
22	where Part 35 has been and is coming, I would
23	anticipate that the Commission would want to meet with
24	the committee again.
25	Have you done any checking on that?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	265
1	MS. McINTOSH: No, I haven't.
2	MR. MILLER: Because I wouldn't want to
3	set a date for the meeting and then find out that the
4	Commission wants to have a meeting with the committee,
5	and then there's the concern of or is that a
6	concern of the committee to come to town a third time
7	for a Commission meeting?
8	MEMBER NAG: I mean, at one time, you
9	know, we had to put this off until you had a tentative
10	date with the Commissioner, and what you can do to
11	speed up, you know, maybe us, not what you know,
12	which of these dates we are not available.
13	MR. MILLER: Right, and I think having
14	that information allows us to go to SECY and propose
15	these are dates that ACMUI could be in town for a
16	meeting. Do you want to have a Commission meeting
17	with them?
18	And I guess the question I would ask the
19	committee is: do you want to have a meeting with the
20	Commission on the annual basis? And if so, could you
21	arrange, could we arrange a Commission meeting that
22	suits around one of those dates?
23	CHAIRMAN MALMUD: Well, we still remain
24	Ralph?
25	MEMBER LIETO: I was just going to say I

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	266
1	personally don't have a problem with Thursday-Fridays.
2	So if that turns out to help out members and the
3	staff, I would be amenable to that just as an offering
4	or a suggestion and, you k now, it might be that
5	CHAIRMAN MALMUD: Which were the two days
6	that you were offering is first, Angela? April?
7	MS. McINTOSH: Initially we offered April
8	26th through 27th.
9	MEMBER NAG: But now that's out.
10	MEMBER WILLIAMSON: Assuming that's a good
11	date for any of you.
12	MEMBER NAG: And the other thing is I
13	wonder why even, you know, Monday-Tuesday cannot be.
14	I mean, there is really no reason why we can't have
15	that.
16	MEMBER EGGLI: There may be some people
17	who don't want to travel on the weekend day because
18	the people who have to come in from a distance have to
19	come in the day before. For me, you know, I just come
20	down the evening before, but maybe somebody doesn't
21	want to spend all day Sunday flying or something.
22	MR. ESSIG: Which Ed Bailey would have to
23	do coming from California. Coming from California, it
24	would take Ed a whole day, and Robert Schenter has to
25	come from Washington, the other Washington.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	267
1	CHAIRMAN MALMUD: Next choice after April?
2	MEMBER NAG: Well, I don't think we can
3	solve anything because we don't know when the
4	Commissioners are going to meet. So we have to shelve
5	that. So I think there is
6	CHAIRMAN MALMUD: I thought it was
7	necessary for us to set a date so that you could get
8	the room.
9	MR. MILLER: Yes, it is.
10	CHAIRMAN MALMUD: We can have this whole
11	thing by E-mail.
12	MR. MILLER: I think what is important is
13	knowing the dates. Angela has offered some windows of
14	opportunity here, and I guess the question becomes are
15	there some proposed dates that we can accommodate and
16	then we can take and see if the Commission is willing
17	to meet around those dates so that we can hold the
18	meeting and have the Commission meeting at the same
19	time.
20	MS. McINTOSH: What I was trying to learn
21	is if out of the proposed dates if there were
22	definitely dates where you knew that you would not be
23	able to be here. Then we could just eliminate those,
24	and we could have some options out of what was left
25	over.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1       MR. MILLER: Yes, I would encourage you         2       move expeditiously on this because there was a with         3       range of dates, and I can't lock all of those dates         4       my calendar.         5       MS. McINTOSH: Right, right. So we were         6       trying to get a feel of what we could walk away with         7       if possible right now, what we could walk away with         8       MEMBER NAG: I know like in March 18	de on ere ch, th.
<pre>3 range of dates, and I can't lock all of those dates 4 my calendar. 5 MS. McINTOSH: Right, right. So we we 6 trying to get a feel of what we could walk away wit 7 if possible right now, what we could walk away wi 8 MEMBER NAG: I know like in March 18</pre>	on ere ch, th.
4 my calendar. 5 MS. McINTOSH: Right, right. So we we 6 trying to get a feel of what we could walk away with 7 if possible right now, what we could walk away with 8 MEMBER NAG: I know like in March 18	ere ch, th.
5 MS. McINTOSH: Right, right. So we we 6 trying to get a feel of what we could walk away wit 7 if possible right now, what we could walk away wi 8 MEMBER NAG: I know like in March 18	th,
6 trying to get a feel of what we could walk away with 7 if possible right now, what we could walk away wi 8 MEMBER NAG: I know like in March 18	th,
7 if possible right now, what we could walk away wi 8 MEMBER NAG: I know like in March 18	th.
8 MEMBER NAG: I know like in March 18	
	}th
9 through 30 I'm not available.	
10 CHAIRMAN MALMUD: Those weren't in t	he
11 dates anyway.	
12 MS. McINTOSH: I handed out an E-mail,	if
13 everyone has a copy of it. It has the range	of
14 dates.	
15 CHAIRMAN MALMUD: How about April 12th a	and
16 13th? That's a Tuesday and Wednesday?	
17 MS. McINTOSH: Is that fine with everyor	ıe?
18 MR. ESSIG: That conflicts with ACR.	
19 CHAIRMAN MALMUD: That conflicts with t	he
20 American College of Radiology.	
21 MS. McINTOSH: It does.	
22 MEMBER EGGLI: Is anybody planning to	go
23 to ACR?	
24 PARTICIPANTS: No.	
25 MEMBER EGGLI: Again, physicists dor	ı't

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	269
1	usually go to ACR. Radiation oncologists usually go
2	to ASTRO rather than ACR.
3	CHAIRMAN MALMUD: The 12th and 13th is
4	okay for us?
5	MS. McINTOSH: Twelfth and 13th.
6	MEMBER NAG: Twelfth and 13th, Tuesday-
7	Wednesday. That's something I can live with.
8	CHAIRMAN MALMUD: Twelfth and 13th,
9	Tuesday-Wednesday.
10	PARTICIPANT: When you're actually doing
11	your taxes.
12	(Laughter.)
13	MS. McINTOSH: Would the committee like to
14	propose an alternate date so that we have two sets of
15	dates?
16	MEMBER WILLIAMSON: What about Thursday
17	and Friday the same week?
18	MR. MILLER: Why don't we take that based
19	upon the information that
20	PARTICIPANT: Well, actually Thursday and
21	Friday of that same week I'm unavailable.
22	MEMBER NAG: Question. For two days or
23	three days? Usually when we meet with the
24	Commissioners, three days.
25	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	270
1	we've been in the last number of sessions, we can't
2	even get through what's on the agenda in two full
3	days. If you're going to meet with the Commission,
4	you're going to want to have some time, I would think,
5	as a group before you go up and meet with them.
6	MEMBER WILLIAMSON: Yeah.
7	MR. MILLER: So three full days is
8	probably good for planning.
9	MS. SCHWARZ: So 12th, 13th, and 14th?
10	MR. MILLER: Or at least two and a half.
11	MEMBER NAG: Twelfth, 13th and 14th. The
12	last thing you probably want to make it a half day
13	anyway so that people can go home the same day.
14	MS. SCHWARZ: What about 11, 12, and 13,
15	Monday, Tuesday, Wednesday?
16	MEMBER WILLIAMSON: I would advise us,
17	even though at the moment maybe we don't have anything
18	urgent we would like to talk to the Commissioners
19	about, I would urge us to continue having the annual
20	contact with them. I think it's always important to
21	bring to the attention or your superiors the
22	activities you're working on and not turn down
23	opportunities to cultivate a relationship. I think
24	it's just bad politics to not, you know, continue this
25	tradition.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	271
1	I'm sure we can find something to talk
2	about.
3	CHAIRMAN MALMUD: It should be something
4	of substance.
5	MEMBER WILLIAMSON: Yes, but, I mean, we
6	deal with lots of substantive activities.
7	CHAIRMAN MALMUD: But do we have a firm
8	date for the Commission's meeting?
9	MR. MILLER: No, that's the dilemma. What
10	we're trying to do, what I was hoping to do, and I
11	can't promise that we can deliver on this is get out
12	ahead of what happened last year where the Commission
13	dictated a date, as I recall, and then we had to force
14	the ACMUI meeting to be coincident with that date so
15	that you would only have to come to town once.
16	If we can get some potential dates now
17	perhaps we could propose those to the Commission and
18	get something, if they accept that, that's more under
19	our control than their control.
20	MEMBER WILLIAMSON: Or you can work it the
21	other way around and examine the Commissioners'
22	schedules and come up with several.
23	MS. McINTOSH: I don't think it's out this
24	far ahead.
25	MEMBER WILLIAMSON: Do they meet in April?
I	

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	272
1	MR. MILLER: Pardon me?
2	CHAIRMAN MALMUD: Do they usually meet in
3	April?
4	MR. MILLER: Well, it's a question of a
5	number of things. It's not a question the
б	Commission meets whenever the Commission deems that
7	they need to meet, but they try to plan their meeting
8	schedule so that it doesn't interfere with their
9	individual travel activities or other obligations they
10	have. So they try to hold their meetings currently
11	there are three Commissioners they try to hold
12	their meetings when all three Commissioners are
13	available.
14	CHAIRMAN MALMUD: We will have to wait
15	until they set their meeting date.
16	MR. MILLER: And so what it might mean is
17	if we ask them to set a date, that will dictate when
18	the ACMUI meeting will be, which may interfere with
19	some of your availability. Understand that.
20	I mean, having I guess there was one
21	member absent this time. I guess there were two
22	counting Dr. Sukera (phonetic), but having maximum
23	membership at the meetings I find opts for a more
24	healthy, productive dialogue than if we have less
25	members present.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	273
1	CHAIRMAN MALMUD: Agreed. Ralph?
2	MEMBER LIETO: Would it be valuable, in
3	light of the fact that the Commissioners may not do
4	something or plan their schedule that far in advance,
5	as I think Angela was suggesting, having a primary
б	meeting time and maybe an alternate? In other words,
7	we come up with two groups of dates and then just kind
8	of maybe they can work from there with the
9	Commissioners.
10	MR. MILLER: We will try, nd you know, it
11	may or may not fit their schedules. They may come
12	back and dictate something anyway, you know.
13	MEMBER LIETO: That's fine.
14	MS. McINTOSH: But as far as April 12
15	through 13, I think I head the committee say 12
16	through the 14th and then someone said, well, no,
17	that's not going to work.
18	PARTICIPANT: I did. I'm unavailable on
19	the 14th.
20	MS. McINTOSH: Okay.
21	MS. SCHWARZ: What about the Monday, 11th,
22	12th, 13th?
23	MS. McINTOSH: There was concern about
24	Mondays because of travel, but we could. Should we go
25	with the 11 through the 13th as one proposal?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	274
1	MS. SCHWARZ: Yes.
2	MS. McINTOSH: Okay, and would there be an
3	alternate proposal perhaps in March?
4	MEMBER EGGLI: You had also the week of
5	the 21st of April.
6	MS. McINTOSH: Yes, I had proposed the
7	20th through the 21st.
8	MEMBER EGGLI: Are the important people,
9	the prerequisite people from NRC staff available that
10	week?
11	MR. MILLER: As far as I know, yes.
12	MR. ESSIG: Okay. So then three days
13	during that week, right?
14	MS. McINTOSH: I haven't heard. I haven't
15	heard one way or the other.
16	MR. ESSIG: You proposed two.
17	MS. McINTOSH: The second one, right.
18	MR. ESSIG: Two days.
19	MS. McINTOSH: The 11th through the 13th
20	is the first proposal.
21	DR. HOLAHAN: We're talking about the
22	second proposal.
23	MS. McINTOSH: Right.
24	MS. McINTOSH: I haven't heard one way or
25	the other if that's okay.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	275
1	Would the 20th through the 22nd
2	PARTICIPANT: Of April?
3	MS. McINTOSH: of April be okay?
4	CHAIRMAN MALMUD: Any objection to that,
5	20th through the 22nd of April?
6	MEMBER WILLIAMSON: No.
7	CHAIRMAN MALMUD: As an alternative. Dr.
8	Nag?
9	MEMBER NAG: Right now that looks okay
10	now.
11	MS. SCHWARZ: What was the date again?
12	CHAIRMAN MALMUD: The 20th through the
13	22nd.
14	MS. SCHWARZ: Of March?
15	CHAIRMAN MALMUD: April.
16	MS. McINTOSH: As the alternative.
17	PARTICIPANT: And what's the primary?
18	MS. McINTOSH: The primary would be the
19	11th through the 13th of April.
20	MR. MILLER: So why don't we take those
21	two proposals?
22	CHAIRMAN MALMUD: April 20th to 22nd?
23	MR. MILLER: Yeah.
24	CHAIRMAN MALMUD: I think that might be a
25	problem. We have to reappoint the new modality

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	276
1	subcommittee, by the way.
2	MR. ESSIG: Yes.
3	CHAIRMAN MALMUD: April 20th to 22nd,
4	what's our schedule look like?
5	MEMBER WILLIAMSON: I thought there were
6	two other action items we had. Something I'm supposed
7	to do with the medical event criteria.
8	MR. ESSIG: Jeffrey, are you speaking of
9	action items or motions? We didn't talk about action
10	items. We're going to dig those out.
11	MS. McINTOSH: Right.
12	MR. ESSIG: It was too much trouble to dig
13	those out of the transcript at this point.
14	MS. McINTOSH: Okay. So the 20th through
15	the 22nd.
16	CHAIRMAN MALMUD: Yes.
17	MS. McINTOSH: So the 20th through the
18	22nd is going to be the alternate proposed date for
19	the spring meeting.
20	MEMBER WILLIAMSON: What is the initial
21	date or primary date?
22	MS. McINTOSH: Eleventh through the 13th
23	of April.
24	MR. MILLER: What we will do is we will
25	check to see if we could arrange a Commission meeting

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

1at that time. If the Commissioners offer an2alternative date that they want to meet, well, then I3think we'll probably need to get back to you and see4if you can accommodate that.5It's always a challenge to do both.6CHAIRMAN MALMUD: Thank you.7The next item is the new modality8subcommittee, which needs to be reappointed. Its9chair has left the committee; is that not correct?10MS. SCHWARZ: Yes.11CHAIRMAN MALMUD: And who was on the12previous subcommittee on modalities? Dr. Nag, Dr.13Williamson, and Dr. Schwarz? Would one of you wish to14be the successor to chair the committee?15Dr. Schwarz has been nominated by Dr.16Williamson for that position.17MEMBER NAG: I second it.18(Laughter.)19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.25CHAIRMAN MALMUD: Why don't we nominate		277
3       think we'll probably need to get back to you and see         4       if you can accommodate that.         5       It's always a challenge to do both.         6       CHAIRMAN MALMUD: Thank you.         7       The next item is the new modality         8       subcommittee, which needs to be reappointed. Its         9       chair has left the committee; is that not correct?         10       MS. SCHWARZ: Yes.         11       CHAIRMAN MALMUD: And who was on the         12       previous subcommittee on modalities? Dr. Nag, Dr.         13       Williamson, and Dr. Schwarz? Would one of you wish to         14       be the successor to chair the committee?         15       Dr. Schwarz has been nominated by Dr.         16       Williamson for that position.         17       MEMBER NAG: I second it.         18       (Laughter.)         19       CHAIRMAN MALMUD: Dr. Nag seconds it. Do         20       we need one more member or is three adequate?         21       PARTICIPANT: It probably would help to         22       PARTICIPANT: It agreement state         23       MEMBER WILLIAMSON: The agreement state         24       person.	1	at that time. If the Commissioners offer an
<ul> <li>if you can accommodate that.</li> <li>It's always a challenge to do both.</li> <li>CHAIRMAN MALMUD: Thank you.</li> <li>The next item is the new modality</li> <li>subcommittee, which needs to be reappointed. Its</li> <li>chair has left the committee; is that not correct?</li> <li>MS. SCHWARZ: Yes.</li> <li>CHAIRMAN MALMUD: And who was on the</li> <li>previous subcommittee on modalities? Dr. Nag, Dr.</li> <li>Williamson, and Dr. Schwarz? Would one of you wish to</li> <li>be the successor to chair the committee?</li> <li>Dr. Schwarz has been nominated by Dr.</li> <li>Williamson for that position.</li> <li>MEMBER NAG: I second it.</li> <li>(Laughter.)</li> <li>CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>we need one more member or is three adequate?</li> <li>PARTICIPANT: It probably would help to</li> <li>have the agreement state person on.</li> <li>MEMBER WILLIAMSON: The agreement state</li> <li>person.</li> </ul>	2	alternative date that they want to meet, well, then I
5       It's always a challenge to do both.         6       CHAIRMAN MALMUD: Thank you.         7       The next item is the new modality         8       subcommittee, which needs to be reappointed. Its         9       chair has left the committee; is that not correct?         10       MS. SCHWARZ: Yes.         11       CHAIRMAN MALMUD: And who was on the         12       previous subcommittee on modalities? Dr. Nag, Dr.         13       Williamson, and Dr. Schwarz? Would one of you wish to         14       be the successor to chair the committee?         15       Dr. Schwarz has been nominated by Dr.         16       Williamson for that position.         17       MEMBER NAG: I second it.         18       (Laughter.)         19       CHAIRMAN MALMUD: Dr. Nag seconds it. Do         20       we need one more member or is three adequate?         21       PARTICIPANT: It probably would help to         22       have the agreement state person on.         23       MEMBER WILLIAMSON: The agreement state         24       person.	3	think we'll probably need to get back to you and see
<ul> <li>6 CHAIRMAN MALMUD: Thank you.</li> <li>7 The next item is the new modality</li> <li>8 subcommittee, which needs to be reappointed. Its</li> <li>9 chair has left the committee; is that not correct?</li> <li>10 MS. SCHWARZ: Yes.</li> <li>11 CHAIRMAN MALMUD: And who was on the</li> <li>12 previous subcommittee on modalities? Dr. Nag, Dr.</li> <li>13 Williamson, and Dr. Schwarz? Would one of you wish to</li> <li>14 be the successor to chair the committee?</li> <li>15 Dr. Schwarz has been nominated by Dr.</li> <li>16 Williamson for that position.</li> <li>17 MEMBER NAG: I second it.</li> <li>18 (Laughter.)</li> <li>19 CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>20 we need one more member or is three adequate?</li> <li>21 PARTICIPANT: It probably would help to</li> <li>22 have the agreement state person on.</li> <li>23 MEMBER WILLIAMSON: The agreement state</li> <li>24 person.</li> </ul>	4	if you can accommodate that.
7       The next item is the new modality         8       subcommittee, which needs to be reappointed. Its         9       chair has left the committee; is that not correct?         10       MS. SCHWARZ: Yes.         11       CHAIRMAN MALMUD: And who was on the         12       previous subcommittee on modalities? Dr. Nag, Dr.         13       Williamson, and Dr. Schwarz? Would one of you wish to         14       be the successor to chair the committee?         15       Dr. Schwarz has been nominated by Dr.         16       Williamson for that position.         17       MEMBER NAG: I second it.         18       (Laughter.)         19       CHAIRMAN MALMUD: Dr. Nag seconds it. Do         20       we need one more member or is three adequate?         21       PARTICIPANT: It probably would help to         22       MEMBER WILLIAMSON: The agreement state         23       MEMBER WILLIAMSON: The agreement state         24       person.	5	It's always a challenge to do both.
<ul> <li>subcommittee, which needs to be reappointed. Its</li> <li>chair has left the committee; is that not correct?</li> <li>MS. SCHWARZ: Yes.</li> <li>CHAIRMAN MALMUD: And who was on the</li> <li>previous subcommittee on modalities? Dr. Nag, Dr.</li> <li>Williamson, and Dr. Schwarz? Would one of you wish to</li> <li>be the successor to chair the committee?</li> <li>Dr. Schwarz has been nominated by Dr.</li> <li>Williamson for that position.</li> <li>MEMBER NAG: I second it.</li> <li>(Laughter.)</li> <li>CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>we need one more member or is three adequate?</li> <li>PARTICIPANT: It probably would help to</li> <li>have the agreement state person on.</li> <li>MEMBER WILLIAMSON: The agreement state</li> <li>person.</li> </ul>	6	CHAIRMAN MALMUD: Thank you.
<ul> <li>9 chair has left the committee; is that not correct?</li> <li>10 MS. SCHWARZ: Yes.</li> <li>11 CHAIRMAN MALMUD: And who was on the</li> <li>12 previous subcommittee on modalities? Dr. Nag, Dr.</li> <li>13 Williamson, and Dr. Schwarz? Would one of you wish to</li> <li>14 be the successor to chair the committee?</li> <li>15 Dr. Schwarz has been nominated by Dr.</li> <li>16 Williamson for that position.</li> <li>17 MEMBER NAG: I second it.</li> <li>18 (Laughter.)</li> <li>19 CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>20 we need one more member or is three adequate?</li> <li>21 PARTICIPANT: It probably would help to</li> <li>22 have the agreement state person on.</li> <li>23 MEMBER WILLIAMSON: The agreement state</li> <li>24 person.</li> </ul>	7	The next item is the new modality
10MS. SCHWARZ: Yes.11CHAIRMAN MALMUD: And who was on the12previous subcommittee on modalities? Dr. Nag, Dr.13Williamson, and Dr. Schwarz? Would one of you wish to14be the successor to chair the committee?15Dr. Schwarz has been nominated by Dr.16Williamson for that position.17MEMBER NAG: I second it.18(Laughter.)19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.	8	subcommittee, which needs to be reappointed. Its
11CHAIRMAN MALMUD: And who was on the12previous subcommittee on modalities? Dr. Nag, Dr.13Williamson, and Dr. Schwarz? Would one of you wish to14be the successor to chair the committee?15Dr. Schwarz has been nominated by Dr.16Williamson for that position.17MEMBER NAG: I second it.18(Laughter.)19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.	9	chair has left the committee; is that not correct?
12 previous subcommittee on modalities? Dr. Nag, Dr. 13 Williamson, and Dr. Schwarz? Would one of you wish to 14 be the successor to chair the committee? 15 Dr. Schwarz has been nominated by Dr. 16 Williamson for that position. 17 MEMBER NAG: I second it. 18 (Laughter.) 19 CHAIRMAN MALMUD: Dr. Nag seconds it. Do 20 we need one more member or is three adequate? 21 PARTICIPANT: It probably would help to 22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	10	MS. SCHWARZ: Yes.
<ul> <li>Williamson, and Dr. Schwarz? Would one of you wish to</li> <li>be the successor to chair the committee?</li> <li>Dr. Schwarz has been nominated by Dr.</li> <li>Williamson for that position.</li> <li>MEMBER NAG: I second it.</li> <li>(Laughter.)</li> <li>CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>we need one more member or is three adequate?</li> <li>PARTICIPANT: It probably would help to</li> <li>have the agreement state person on.</li> <li>MEMBER WILLIAMSON: The agreement state</li> <li>person.</li> </ul>	11	CHAIRMAN MALMUD: And who was on the
14be the successor to chair the committee?15Dr. Schwarz has been nominated by Dr.16Williamson for that position.17MEMBER NAG: I second it.18(Laughter.)19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.	12	previous subcommittee on modalities? Dr. Nag, Dr.
15Dr. Schwarz has been nominated by Dr.16Williamson for that position.17MEMBER NAG: I second it.18(Laughter.)19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.	13	Williamson, and Dr. Schwarz? Would one of you wish to
16 Williamson for that position. 17 MEMBER NAG: I second it. 18 (Laughter.) 19 CHAIRMAN MALMUD: Dr. Nag seconds it. Do 20 we need one more member or is three adequate? 21 PARTICIPANT: It probably would help to 22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	14	be the successor to chair the committee?
<ul> <li>MEMBER NAG: I second it.</li> <li>(Laughter.)</li> <li>CHAIRMAN MALMUD: Dr. Nag seconds it. Do</li> <li>we need one more member or is three adequate?</li> <li>PARTICIPANT: It probably would help to</li> <li>have the agreement state person on.</li> <li>MEMBER WILLIAMSON: The agreement state</li> <li>person.</li> </ul>	15	Dr. Schwarz has been nominated by Dr.
18 (Laughter.) 19 CHAIRMAN MALMUD: Dr. Nag seconds it. Do 20 we need one more member or is three adequate? 21 PARTICIPANT: It probably would help to 22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	16	Williamson for that position.
19CHAIRMAN MALMUD: Dr. Nag seconds it. Do20we need one more member or is three adequate?21PARTICIPANT: It probably would help to22have the agreement state person on.23MEMBER WILLIAMSON: The agreement state24person.	17	MEMBER NAG: I second it.
20 we need one more member or is three adequate? 21 PARTICIPANT: It probably would help to 22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	18	(Laughter.)
21 PARTICIPANT: It probably would help to 22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	19	CHAIRMAN MALMUD: Dr. Nag seconds it. Do
22 have the agreement state person on. 23 MEMBER WILLIAMSON: The agreement state 24 person.	20	we need one more member or is three adequate?
23 MEMBER WILLIAMSON: The agreement state 24 person.	21	PARTICIPANT: It probably would help to
24 person.	22	have the agreement state person on.
	23	MEMBER WILLIAMSON: The agreement state
25 CHAIRMAN MALMUD: Why don't we nominate	24	person.
	25	CHAIRMAN MALMUD: Why don't we nominate

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	278
1	Mr. Bailey in his absence and essentially agree?
2	Yes, Dr. Nag.
3	MEMBER NAG: I would like Dr. Diamond
4	taking out (unintelligible). I want to know if the
5	NRC has talked to the board and tried to appoint a new
6	Commissioner as part of this.
7	MR. MILLER: I think I can address that.
8	One of the things that I am working with my staff to
9	do is to address that issue. Of concern to me and I
10	think to everyone is not to wait until people are
11	rotating off in order to try to find a replacement.
12	Do that ahead of time.
13	Also, recognizing that in some years there
14	are multiple members that are rotating off, and that
15	can really impact the committee, I've asked my staff
16	to do thinking on how can we minimize that, and if
17	there are some innovative ways we could minimize that,
18	including coming up with proposals for extending
19	people's terms beyond two terms in order to get
20	through the initial dilemma that we found.
21	We're exploring all of that, and thirdly,
22	the nomination process itself. There are some steps
23	that we've looked at in the nomination process that we
24	think make it more torturous than it needs to be. In
25	other words, how many times we have to go to the

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	279
1	Commission during the process to seek approvals.
2	What we have to do is send a policy paper
3	up to the Commission and get their vote on any changes
4	to the process and to new nominations, and we're
5	actively working that. As Mr. Essig can tell you,
б	I've pushed to try to get that done.
7	So I hope to get that done in the very
8	near term.
9	PARTICIPANT: And just to add to that, I
10	know some of you had been approached probably a year
11	or so ago and asked if we received approval from the
12	Commission would you be willing to serve beyond your
13	two term limit, and several of you indicated that you
14	would be interested and available to do that.
15	We haven't forgotten about that. What
16	we're probably going to have to do is because that was
17	about a year ago, we would cast the net out once
18	again, make sure that your offer if you did offer to
19	serve beyond the two terms and we have Commission
20	approval of that conceptually, take that offer that
21	you still were willing to do that.
22	And so that will all be included in this
23	effort.
24	MEMBER WILLIAMSON: I was under the
25	impression that in my own case I was already beyond

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	280
1	the two term limit and I am now in my terminal years.
2	(Laughter.)
3	MEMBER WILLIAMSON: That this is now my
4	fourth year of my I believe. Am I wrong?
5	MS. McINTOSH: No, you're in your second
б	term.
7	MEMBER WILLIAMSON: I am? Oh, okay. I
8	stand correct.
9	MEMBER NAG: Because you took six months
10	off and you were reappointed. So you restarted on
11	your reappointment.
12	MEMBER WILLIAMSON: No, I understand that.
13	MEMBER NAG: The old one was off.
14	MEMBER WILLIAMSON: So when does my term
15	end?
16	MS. McINTOSH: In 2006.
17	MR. MILLER: So along those lines what
18	we're also trying to think through is rather than just
19	asking members who are rotating off if they're willing
20	to serve more, we may be looking at staggered terms
21	for reappointment so that we don't find ourselves in
22	a continuing dilemma of having five people rotating
23	off at the same time.
24	So we're trying to do some thinking in
25	that regard as to what's the most logical path forward

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	281
1	on that so that we get continued representation from
2	the various specialties that we have here and also
3	seek new people, get some fresh ideas to the table
4	that also are willing to serve and can work
5	productively in this environment.
6	CHAIRMAN MALMUD: To that end, you might
7	develop a matrix with the existing membership, their
8	specialties, and their terms and then begin the
9	preparation for exception.
10	MR. MILLER: And as we move forward and do
11	that, if it's okay with the committee, we will
12	probably have some initial discussions with your
13	chair, who he can then decide how he wants to share
14	those kinds of issues with the rest of the committee,
15	but it's kind of part of the role of the chair, I
16	think, to have some administrative discussions
17	concerning that.
18	CHAIRMAN MALMUD: Fine. Dr. Schwarz.
19	MS. SCHWARZ: One other item that we
20	appointed a group was for the best practice where we
21	were looking at the I-131 events and some others.
22	CHAIRMAN MALMUD: Yes.
23	MS. SCHWARZ: And Dr. Eggli was appointed
24	the chair and then Dr. Vetter, Malmud, and myself.
25	CHAIRMAN MALMUD: Correct.

(202) 234-4433 COURT REPORTERS AND TRANSCRIBERS WASHINGTON, D.C. 20005-3701

	282
1	MS. SCHWARZ: So that was
2	CHAIRMAN MALMUD: That's in the minutes.
3	I wasn't certain that the other one was, but I think
4	that they both are in the minutes.
5	Thank you for
6	MEMBER WILLIAMSON: It will take six weeks
7	to find all of that stuff.
8	CHAIRMAN MALMUD: Oh, it won't take that
9	long.
10	MS. SCHWARZ: It's due back in two months.
11	CHAIRMAN MALMUD: I have the minutes from
12	the meeting, our phone conversation of last week, a
13	week and a half ago, and they've already been
14	processed.
15	MR. MILLER: We were told we can get the
16	transcript in how many days? Three.
17	CHAIRMAN MALMUD: In how many days?
18	MS. McINTOSH: Three business days.
19	CHAIRMAN MALMUD: And Angela will get it
20	out to me, and welcome back.
21	MR. ESSIG: Just one additional point on
22	the committee appointments. What we have done in the
23	past is that since the appointments have been on a
24	fiscal year basis, the new appointments would take
25	effect October 1 of this year. For example, Dr. Van

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

283 1 Decker is now on the -- I mean, his appointment was 2 effective October 1st. Had Dr. Sukera been able to be 3 here, this would have been a transition meeting. Dr. 4 Sukera would have been able to do a mind meld or 5 something to that order with Dr. Van Decker, and likewise Mr. Bailey. This was to be his. 6 Had Ruth 7 McBurney been able to attend, but she couldn't because of other obligations, this would have been her ability 8 9 or opportune time to transfer her knowledge, and in the same way with the public advocate or patient 10 advocate representative. 11 12 Unfortunately neither one could be here, the new nor the old this time, but that we'd like to 13 14 have kind of the transition meeting, but as 15 unfortunately it didn't work as well this time. 16 Ι iust mention that for background information. 17 Well, if we get the 18 CHAIRMAN MALMUD: 19 matrix together, we can see whose terms might be 20 extended by an odd number of years, if possible, and 21 then create the transition, the smooth transition that 22 you're seeking. 23 MR. MILLER: Right, and also it's probably 24 time we do think about does the committee see any

25 specialties that aren't represented here that might be

NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

284 1 important to regulatory activities to be added to the 2 committee or replace the specialty if one is not being 3 utilized anymore. 4 So we're interested in your thoughts on 5 that. CHAIRMAN MALMUD: Yes. Dr. Eggli, are you 6 7 going to address that issue? The question is do 8 MEMBER EGGLI: Yes. 9 you have a statutory limit on the size of this committee, and if not --10 11 MR. MILLER: No. 12 MEMBER EGGLI: -- again, the other thing to look at --13 14 MR. ESSIG: Budgetary. 15 MEMBER EGGLI: Yes, but from the point of view of clinical practice, diagnostic radiologists are 16 a major number of practitioners of activity in both 17 Subpart 200 and Subpart 300, and it might be worth 18 19 considering having a member of the diagnostic 20 radiology community. Although I am also a Board certified 21 22 radiologist, in addition to being a Board certified 23 nuclear medicine physician, I think my attitudes more 24 represent the nuclear medicine community than the radiology community, although in the absence of a 25

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	285
1	radiologist member, I have been, in fact, quite
2	vociferously, I think, representing the interests of
3	the radiology committee or the radiology community.
4	But it might be useful to have that
5	community speak for itself.
6	MS. McINTOSH: Might I also add that your
7	self-evaluation is due in the spring, due next spring,
8	the spring of 2005. So if you have any issues or
9	suggestions about the composition of the committee,
10	you can always add those comments to your self-
11	evaluation that we forward to the Commission.
12	CHAIRMAN MALMUD: Thank you.
13	MR. ESSIG: And on that same topic, I know
14	recently we broached the subject of endocrinologists
15	and whether or not one was wanted, and I think the
16	consensus was or the comment I got back was that, no,
17	one was not.
18	CHAIRMAN MALMUD: We've heard nothing from
19	that community regarding wanting to be on the
20	committee, and they seem to be covered by the current
21	regs. well; and we've heard no requests for exemptions
22	or changes to practice.
23	I'm an inclusionary person, but I don't
23	
24	see the need for that at the moment.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

286 1 it's 3:20, and it would be astonishing an accomplishment to finish before the adjournment time 2 3 at 3:30. And we would like to thank all of those who 4 have remained here to the end, as well as to the 5 members of the NRC who are here: Dr. Miller, Mr. Essig, and staff, Angela and staff. 6 We very much 7 appreciate the opportunity to share and -- excuse me, 8 Dr. Howe and Zelac. 9 We really appreciate the opportunity to exchange all of these ideas and to try and reach 10 11 issues that difficult. consensus on are very 12 Representation of this committee, excluding the NRC staff, is very diverse with very different interests 13 14 and concerns. 15 At one extreme perhaps are the states' 16 representatives, who very concerned about are 17 prescriptive definitions, and on the other hand, there are those who are from the training programs which 18 19 feel that those kinds of standards are best 20 established by the boards. 21 So that reaching consensus isn't easy. 22 You've made it a constructive engagement for us, and we appreciate that, and in the breaks that we've had 23 24 at lunch and so on, the members of the committee of 25 the ACMUI have commented on the improved relationship,

> NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

(202) 234-4433

	287
1	if you will, between NRC and the committee by virtue
2	of the presence of the two of you, and we're very
3	appreciative of that and your leadership role.
4	MR. MILLER: Thank you.
5	CHAIRMAN MALMUD: And so thank you and
6	thank all of the members of the committee. And is
7	there a motion for adjournment?
8	MR. MILLER: Before you do
9	(Laughter.)
10	MR. MILLER: I'd like to reciprocate.
11	One of the things that we've been designed to do more
12	of is to get issues on the table that are important to
13	you so that we can move to have a dual dialogue as
14	opposed to the NRC staff puts issues on the table and
15	you just comment on it.
16	And I think having presentations this time
17	by Dr. Nag and Dr. Vetter moves the ball in that
18	direction. So I think from our perspective, we were
19	pleased with that, and we'd like to see continued
20	activity in that area in the future.
21	CHAIRMAN MALMUD: Thank you.
22	Is there a motion?
23	MEMBER SULEIMAN: I so move.
24	CHAIRMAN MALMUD: Dr. Suleiman. Second to
25	the motion?

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

	288
1	PARTICIPANTS: Second.
2	CHAIRMAN MALMUD: All in favor?
3	(Chorus of ayes.)
4	CHAIRMAN MALMUD: Thank you very much.
5	(Whereupon, at 3:20 p.m., the meeting was
6	concluded.)
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	